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Abstract 
The transfer of gene therapy from an academic exercIse to a clinical setting 
demands the development of an efficient, biocompatible gene delivery vector. Current 
non-viral systems suffer from toxicity, low transfection efficiency, and in vivo instability. 
In this work, a new class of polymers was designed to address these issues. Linear, 
polyamidine, ~-cyclodextrin (~CD)-containing polymers (~CDPs) are synthesized by 
polymerizing difunctionalized cyclodextrins with other difunctionalized comonomers. 
The inclusion of ~CD in the backbone of the polyamidine polymers decreases the IC50s 
by three orders of magnitude, resulting in a polymer with very low in vitro and in vivo 
toxicity. The cationic ~CDPs are able to self-assemble with and condense DNA into 
small particles (100-150 nm in diameter). When formulated at a positive charge, the 
complexes are readily internalized by nearly all exposed cultured cells. 
The trans gene expression from the delivered complexes was increased by fine-
tuning the ~CDP structure for optimum reporter gene activity and by modifying the 
polymer to enhance endosomal release. The function of the ~CDPs was found to be 
highly dependent on the polymer structure; changes in position of the ami dine charge 
centers by a few angstroms resulted in transfection and toxicity differences of one order 
of magnitude. The highest transfection is achieved with the ~CDP6 polymer, that 
contains a 2 methylene spacer between the cyclodextrin and amidine group and a 6 
methylene spacer between adjacent ami dine functionalities. The conjugation of a pH-
sensitive moiety, histidine, to ~CDP6 endgroups also increases transgene expression by 
20-fold without a change in polymer toxicity. Flow cytometry and confocal microscopy 
experiments with fluorescently-Iabeled DNA suggest that histidylation of ~CDP6 
enhances transfection by buffering the endosomal pH, thereby delaying lysosomal 
degradation and allowing for more endosome release. 
Vll 
The ~CDP-based particles (~CD-polyplexes) were modified for in vivo stability 
by using the ability of cyclodextrins to form inclusion complexes with hydrophobic guest 
molecules. Various compounds were conjugated to adamantane, a molecule that has a 
high cyclodextrin association constant. The adamantane conjugates, when added to 
preformed ~CD-polyplexes, are able to self-assemble with the ~CD-polyplexes without 
disrupting the polymerlDNA binding interactions. Using this method, ~CD-polyplexes 
were modified with adamantane-polyethylene glycol (PEG) conjugates. The PEGylated 
particles were salt stabilized in a PEG length-dependent manner. In a second example, 
modification of ~CD-polyplexes with anionic peptide-adamantane conjugates prevented 
non-specific cellular uptake in cultured cells. The assembly of the three components, 
DNA, ~CDP, and adamantane-based modi fer, results in a particle with the potential for 
achieving systemic, in vivo gene delivery. Finally, a small molecule, fluorescein, was 
conjugated to adamantane and co-delivered with ~CD-polyplexes to cultured cells, thus 
demonstrating the possibility for therapeutic pouches of small molecule and gene-drugs. 
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1.1 OBJECTIVES 
Chapter 1 
Introduction 
The potential for providing new disease treatments by gene-based therapies has 
been hampered by limitations in gene delivery. Viral vectors, extensively studied in both 
in vitro and in vivo settings, have shown problems in host immunogenicity, 
manufacturing, and scale-up. Non-viral vectors, while bypassing many problems 
encountered with viral vectors, have suffered in clinical progress due to their toxicity, low 
transfection efficiency, and in vivo instability. The objective of this research was to 
develop a non-toxic, polymeric gene delivery system capable of accomplishing efficient 
gene delivery and adaptable for in vivo applications. 
The following design strategy was adopted in order to meet these goals. First, a 
new family of cationic polymers was designed from non-toxic starting materials. These 
polymers are capable of condensing and delivering DNA while maintaining the low 
toxicity characteristic of the monomeric materials. Next, transfection efficiency and in 
vivo stability of the delivery system were independently addressed. Delivery efficiency 
was optimized by studying the effect of polymer structure on gene delivery and by 
providing methods to enhance intracellular trafficking. A modification method capable 
of providing salt stability and preventing non-specific cell interactions is described. The 
polymer can also be modified with this method to incorporate a targeting ligand to 
accomplish cell specific delivery. The three components - therapeutic gene, polymer and 
modifier - can be self-assembled to yield a polymeric delivery system for in vivo gene 
delivery. 
A review of gene-based therapeutic intervention and current delivery technologies 
is important to better understand the motivation behind this work. Therefore, an 
2 
introduction to gene therapy and gene delivery is presented here. Methods of genetic 
intervention for human gene therapy are discussed, followed by a brief synopsis of the 
status of clinical gene therapy trials. The current viral and non viral delivery vectors are 
described, including advantages and disadvantages for each vector and their progress as 
delivery agents for human gene therapy. Finally, some background information 
important for the development of the ~-cyclodextrin polymer-based delivery system is 
discussed. 
1.2. HUMAN GENE THERAPY 
Rapid advances SInce the mid-1970s in molecular genetics along with near 
completion of the Human Genome Project are paving the way for a revolution in medical 
therapy. Techniques allowing identification and characterization of genetic mutations 
give scientists the ability to better understand the cause of many diseases. The 
development of gene-based therapies will continue to improve on conventional 
treatments, and may provide treatments for genetic diseases such as adenosine deaminase 
deficiency, cystic fibrosis, or hemophilia. The list will continue to expand as the genetic 
basis of more diseases are determined. 
1.2.1. Methods of Genetic Intervention 
Genetic diseases result from one or more DNA mutations that are felt on the 
protein level. Gene therapy provides an opportunity to address the root causes of diseases 
by targeting and correcting faulty DNA instead of the mutated protein products. This 
approach has the advantage in that it prevents disease progression rather than postponing 
or masking deterioration. The type of genetic intervention used depends on the effect of 
the mutation on the protein product. One possible effect is altered protein activity that 
can be treated by short sequences of DNA or RNA known as antisense oligonucleotides 
3 
(oligos). The oligos are used to inhibit mutant protein production by binding to their 
complementary sequence, thus preventing proper RNA splicing, halting mRNA 
translation, or triggering RNase cleavage of the mRNA (Fig. 1.1)(1). For example, 90% 
of chronic myelogenous leukemia patients have a mutation of the abl gene resulting in a 
hybrid protein p2IO. Antisense oligos directed to the altered gene reduce growth of 
malignant cells in leukemia patients while having no effect on normal cells (2). 
Splice Site 
Duplex DNA 
Oligo 
/ 'A 
Primary RNA 
Transcript 
(a) Splicing 
) 
mRNA 
(b) RNA polymerase 
recognition 
/ 
~ 
(c) RNase activation 
80 RNA polymerase 
I 
RNase cleavage 
Figure 1.1. Antisense gene therapy. Antisense oligos can prevent protein production 
by (a) interfering with splicing, (b) blocking RNA polymerase recognition of promoter 
sites, or (c) triggering degradation of duplex mRNA by RNase activation. 
Other anticode drugs can also prevent protein production. Triplex-forming 
oligonucleotides (known as anti gene oJigos) bind to duplex DNA and block transcription. 
Ribozymes are RNA molecules that have a sequence capable of recognizing and binding 
complementary mRNA and a catalytic subunit to cleave the bound mRNA. Thus, 
antisense oligos, anti gene oligos, and ribozymes can all be used to disable a potential 
disease-causing protein (Fig. 1.2) (3). 
duplex 
DNA 
transcription splicing 
primary RNA 
transcript f--.I",-~ 
4 
o 
substrate 
translation binding 
Figure 1.2(3). Targets for oligonucleotide therapeutics. The four steps to gene 
expression are represented in the rectangles. Conceptual targets for intervening drugs are 
represented in the ovals. 
Adverse genetic mutations can also result in decrease or knockout of protein 
activity. In this case, the missing or flawed protein product can be replaced by the 
introduction of a gene, either by integration into the chromosome or episomally in 
plasmid form, that codes for an active protein. For example, p53, a tumor suppressor 
protein, is inactivated in over half of all human cancers (4, 5). Because p53 prevents cell 
proliferation in response to DNA damage, p53 inactivation allows the damaged cells to 
replicate, often resulting in tumor growth. Therefore, reintroduction of a wild-type p53 
gene into tumor cells may serve to control tumor growth or sensitize cells to radiation and 
chemotherapy. Indeed, delivery of p53 to several tumor cell lines and cancer xenographs 
prevents cell growth (6, 7). 
1.2.2. History of Human Gene Therapy 
The vision for human gene therapy emerged in the late 1960s with the new 
understanding of the genetic information flow from DNA to RNA to protein. With this 
knowledge, scientists began to reach beyond the traditional metabolic approach to disease 
treatment in search of methods directed at the causative genetic defects (8). Rogers 
hypothesized in 1968 that viruses, that deliver DNA to cells with high efficiency, could 
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be modified and used to deliver unnatural genetic information (9). The technology to 
realize this goal was developed in the 1970s as recombinant DNA techniques 
revolutionalized biochemistry by providing a way to alter and replicate DNA. 
The first recombinant viruses, viruses modified to contain an unnatural gene of 
interest while remaining infectious, were produced in 1981 (10). The work was followed 
in 1984 by Willis et al. who demonstrated correction of an enzymatic defect by a 
recombinant retroviral vector delivered to cells derived from patients with Lesch Nyhan 
syndrome (8, 11). Other viruses, including adenovirus, adeno-associated virus, and 
herpes simplex virus were added to the list of possible delivery vectors by the early 1990s 
(12-15). Wu et al. and FeIgner et al. began the study of non-viral approaches for gene 
delivery in 1987 by using a polycation, poly-L-lysine, and cationic lipids, respectively, to 
mediate DNA delivery (16-17). The gene delivery tools available by the end of the 1980s 
set the stage for the first clinical human gene therapy trial. 
The first approved clinical gene therapy trial began in 1990 at the NIH with a 
protocol for treating a form of severe combined immunodeficiency (SCID) resulting from 
a defect in the adenosine deaminase gene (ADA-SCID). A deficiency in the purine 
catabolic enzyme ADA results in decreased T and B lymphocytes (18). The clinical 
manifestation of this defect is a greatly weakened immune system; patients with ADA-
SCID are not able to combat minor infections and, left untreated, rarely have a lifespan 
over 2 years. ADA-SCID is an ideal gene therapy target for several reasons: the 
biological basis for the disease is well understood, the disease is caused by a single gene 
defect, and correction to 1-5% of normal activity results in disease attenuation (19). The 
first trial involved ex vivo treatment of two ADA-SCID patients (20). Peripheral T cells 
were collected from the patients, transduced with a retroviral vector expressing human 
ADA, expanded, and reinfused back into the patients. The T-cell count in both patients 
rose to normal range after the treatment. The effect remained stable in one patient but fell 
to original enrollment levels for the second patient, probably due to the low gene transfer 
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efficiency achieved in the second patient. Both patients are alive 10 years after the initial 
gene therapy treatment. Although the patients continued to receive traditional ADA 
protein injections, the results from the trial were encouraging and provided impetus for 
the rapidly expanding field of human gene therapy. 
1.2.3. Current Status of Gene Therapy 
The interest in gene therapy rose quickly after the ADA-SCID trials. A Web of 
Science search under "gene therapy" reveals that the number of publications after 1990 
nearly doubles every two years (Fig. 1.3). In addition, the target diseases expanded to 
include other monogenic diseases, various forms of cancer, and infectious diseases (Table 
1.1). Major pharmaceutical companies now include either in-house gene therapy 
divisions or have partnered with other companies specializing in gene therapy. The 
search for gene-based treatments has continued with enthusiasm. 
2500 
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1980 1985 1990 1995 2000 
Year 
Figure 1.3. Gene therapy publications over the past two decades. 
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Monogenic Diseases Cancer Other Diseases 
AA T deficiency Gynecological tumors HIY infection 
ADA-SCID/X-linked SCID Nervous system tumors Amyotrophic lateral sclerosis 
Canavan disease Gastrointestinal tumors Coronary artery disease 
Chronic granulomatous disease Genito-urinary tumors Cubital tunnel syndrome 
Cystic fibrosis Skin tumors Peripheral artery disease 
Familial hypercholesterolemia Head and neck tumors Restenosis 
Fanconi's anemia Lung tumors Rheumatoid arthritis 
Gaucher's disease Mesothelioma 
Hemophilia B Hematological malignancies 
Hunter'slHurler syndrome Sarcomas 
Leukocyte adherence deficiency Germ cell cancers 
OTC deficiency 
Purine nucleoside phosphorylase 
deficiency 
Table 1.1. Disease Targets in Human Gene Therapy Trials 
(www. wiley .co. ukl genetherapy) 
The number of clinical gene therapy trials as of June 2000 exceeds 400 (Table 
1.2). Upon first glance, the gene therapy field appears to be burgeoning fruitfully; 
however, closer inspection reveals that only 2 of the 425 trials are Phase III protocols and 
over 90% of the trials are Phase I or III!. Indeed, ten years after the first trial, gene 
therapy remains largely in the research stage with only one approved antisense molecule 
for treating CMV retinitis in AIDS patients. 
Phase Number 
Phase I 288 
Phase IIII 98 
Phase II 37 
Phase III 2 
Total 425 
Table 1.2. Gene Therapy Clinical Trials as of June 2000. 
www. wi ley .co. uk! genetherapy 
1.3. GENE DELIVERY 
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Dr. Harold Varrnus, the director of the NIH, along with other investigators, 
realized the unforeseen difficulties in gene therapy by 1995 (21-23). The road to the new 
genetic medicines would not be as straight as expected. Varrnus assembled two advisory 
committees to assess the progress of gene therapy. The report from the first committee, 
chaired by Drs. Orkin and Motulsky, delivered a stinging diagnosis of gene therapy: 
"The Panel finds that. .. while the expectations and the promise of gene therapy 
are great, clinical efficacy has not been definitively demonstrated at this time in any gene 
therapy protocol, despite anecdotal claims of successful therapy and the initiation of more 
than 100 Recombinant DNA Advisory Committee (RAC)-approved protocols. 
Significant problems remain in all basic aspects of gene therapy. Major difficulties at the 
basic level include shortcomings in all current gene transfer vectors and an inadequate 
understanding of the biological interaction of these vectors with the host."(24) 
Although harsh, the assessment of the NIH advisory committee rang true. Five 
years after the report publication, gene delivery remains the bottleneck in gene therapy. 
In the words of J.P. Behr, "the weak link of gene therapy is paradoxically the vehicle 
rather than the 'drug' itself."(25) 
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1.3.1. The Need for a DNA Carrier 
Unlike traditional small molecule medicines that can easily diffuse into target 
cells, gene-based therapeutics are large, highly anionic entities. The size of these 
molecules prevents passive diffusion into cells; the charge of the molecules results in 
nonspecific binding to cationic serum proteins instead of the desired interaction with 
anionic cell surfaces. In addition, nucleases in the body rapidly digest any free DNA 
found outside of cell nuclei. Finally, the desired destination for most genetic drugs is the 
cell nuclei; thus, the essence of gene delivery lies in the intricate design of the delivery 
system (vector) and its ability to facilitate DNA delivery, not only to the cell but also to 
the nucleus. One method for cell-specific internalization and intracellular trafficking is 
receptor-mediated endocytosis. 
1.3.2. Receptor-mediated Delivery 
The basic mechanism for receptor mediated deli very is shown in Fig. 1.4. 
Vector Assemble with DNA 
and condence to small size 
Target DNA to cell 
via receptor/ligand interactions 
Endosomal uptake into cell 
Adapted from: 
Cristiano, et al. Cancer Gene Therapy v3: 1 pp.49-57 
Figure 1.4. Gene delivery to the cell via receptor-mediated endocytosis. 
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The vector and attached ligand interacts with the DNA and directs the complex to 
receptors on the cell. The receptor and bound ligand-complex is endocytosed into the cell 
and brought into endosomes. At this point, gene transfer is maximized if there is a 
mechanism for the DNA to escape from the endosomal vesicle and detach from the 
vector. Without endosomal escape, the DNA is shuttled to the Golgi network or 
delivered to lysosomes where it is rapidly degraded by nucleases. Finally, the DNA 
needs to be delivered to the nucleus for transcription to take place. 
1.3.3. The Ideal Gene Delivery System 
The ideal gene carrier therefore needs to have several characteristics in order to 
overcome barriers encountered in vivo (Table 1.3). The barriers are divided into three 
categories: extracellular, intracellular, and development barriers. Extracellular barriers 
include physiological salt conditions, serum and cell-associated proteins, and the immune 
system. The carrier should therefore condense the DNA to small particles, be serum-
stable, not aggregate in 150 mM salt solutions, and be stealthy to the immune system. 
Intracellular barriers include the cell, endosomal and nuclear membranes. An efficient 
carrier would provide mechanisms for traversing the cell membrane, escaping endosomal 
vesicles and delivering the therapeutic load to the nucleus. In order to become part of a 
commercial therapeutic drug, the delivery vehicle would have to be manufactured at large 
scales under cGMP (current good manufacturing practice) conditions. The delivery 
vehicle should also be well defined, both under formulation conditions and after 
administration. Preferably, the carrier would also be easily applied to different nucleic 
acid drugs without much modification to the basic carrier. Finally, the carrier should 
have a substantial shelf-storage time and, if necessary, straightforward formulation 
methods. 
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Type of Barrier Barrier Vector Characteristic 
Protects DNA from proteases, 
Extracellular Serum Proteins prevents nonspecific protein 
interactions 
.... . ................ ......... 
Physiological Ionic Non-aggregating in 150 mM salt Conditions 
I- ........................ 
Adaptive Immune System No foreign peptide sequences 
: .... ........ 
Not highly charged to prevent 
Humoral Immune System opsonization or complement 
activation 
Extracellular Matrices Condenses DNA to small particles 
I ........ I······· 
Toxicity Nontoxic both intact and after biodegradation 
Intracell ular Cell Membrane Able to enter cells, preferably by 
1 .............................. .............. E~~~pt.?~=I?~~i~~~~~~~?~Xt~~i~ 
Endosomal Membrane Capable of releasing DNA from 
endosomal vesicles 
Cytoplasm Mobile in the cytoplasm 
I" 
Nuclear Membrane Traverses nuclear pores 
Development Versatility Can be easily applied to different 
nucleic acids 
t 
Holding Capacity Large nucleic acid holding capacity 
I··· 
Production Able to be manufactured at 
cGMP conditions 
.............................. 
Scale-up Able to be produced in large scales 
··1 ................ 
Storage Has a long shelf-life 
Table 1.3. Barriers and Ideal Vector Characteristics 
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1.3.4. Viral Delivery Systems 
Viruses are natural DNA deliverers, and therefore contain efficient processes for 
specific targeting to cells, endosomal uptake, endosomal release, and nuclear trafficking 
(26). Not surprisingly, viral vectors were the first gene delivery agents to be developed. 
Viral vectors are shells of the virus made replication incompetant by using recombinant 
DNA techniques to replace viral genes with genes of interest. The two most commonly 
used viral vectors, retroviruses and adenoviruses, are briefly described here. Together, 
these two vector types account for over 90% of the viral vectors used in clinical trials. 
Retroviruses were the first viruses studied for gene delivery (11), and remain the 
most popular delivery vector in clinical trials (used in 38% of protocols in gene therapy 
trials). Although retroviruses are very efficient at overcoming intracellular barriers, they 
are limited by low cellular uptake. In addition, retroviruses suffer from many safety 
issues, including random chromosomal integration that may disrupt protein functions and 
the possibility of replication competent retroviruses arising during manufacturing (27). 
Another major impediment in retroviral vector development is the difficulty in producing 
high titers of retroviruses. Purification of recombinant viruses is difficult, making it 
challenging to produce the vectors under cOMP standards. 
Adenoviruses have received a lot of attention as a possible viral alternative to 
retroviral vectors. Unlike retroviruses, adenoviruses are able to transduce a wide range of 
both dividing and quiescent cell types. Adenoviruses can also be grown to high titers and 
are easier to purify than retroviruses. Transgene expression is usually high due to 
efficient endosomal release, cytoplasmic trafficking, and nuclear localization available in 
adenoviral delivery. However, any achieved expression is usually transient as a result of 
immune responses to viral proteins displayed on transduced cells. Repeat administrations 
of the viruses are therefore necessary but are unfortunately generally rendered ineffective 
by the humoral immune system. In addition to silencing transgene expression, immune 
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responses pose a significant health threat to patients. For example, in 1999, J. Gelsinger, 
a young patient in gene therapy trials, passed away suddenly after treatment. The 
incident was highly publicized because the cause of death was found to be an immune 
response to the adenoviral vector used in the treatment. 
Many second and third generation viral vectors are being developed to address the 
issues discussed above. However, a trouble-free viral vector is not expected in the near 
future. While significant progress is being made in viral vector refinement, viable 
alternatives are being developed in nonviral delivery methods. 
1.3.5. Nonviral Delivery Systems 
The two major approaches to nonviral gene delivery involve the use of cationic 
lipids and/or cationic polymers. These synthetic systems are cationic to facilitate the self-
assembly with anionic DNA that results in DNA condensation to small particles. Thus, 
cationic lipids and polymers assist DNA delivery on a basic level by neutralizing the 
highly anionic charge associated with DNA and by reducing the size of the DNA 
macromolecules. The self-assembly of cationic lipidlDNA and cationic polymerlDNA 
complexes results in simple formulation procedures. In addition, the non-specific 
assembly by electrostatic interaction allows the systems to be applied for different genes 
without alterations in the delivery vectors. The ease of use and versatility of these 
synthetic systems have made them a standard as molecular biology transfection reagents. 
However, application to human in vivo systems is not nearly as straightforward. The 
hurdles that are faced by cationic lipid and cationic polymer systems are described in the 
following paragraphs. 
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Lipoplexes: cationic lipid/DNA complexes 
FeIgner et al. demonstrated in 1987 the use of cationic lipids as DNA transfection 
agents (17). Since then, scores of cationic lipids have been developed and tested as 
transfection agents. The cationic lipids interact with negatively charged DNA to facilitate 
cellular entry. Since lipoplexes do not involve foreign proteins or peptide sequences, they 
do not elicit immune responses. Cationic lipids are also capable of delivering DNA of 
nearly any size. Like viruses, delivery occurs by endosomal uptake. The basic lipoplexes 
studied in the early 1990s have been modified to include "smart" functions, including 
receptor-mediated targeting (28), pH-sensitive lipids that assist in endosomal release, and 
stabilization to serum proteins (29). These modifications have increased the in vivo 
compatibility of lipoplexes. 
Cationic lipids are the most advanced non-viral vector in clinical trials, 
accounting for 20% of approved protocols. The Allovectin-7 Phase III clinical trials 
(developed by Vical) involve direct injection of a lipoplex product to a tumor site. 
However, despite the improvement in design, current cationic lipids are not suitable for 
systemic delivery due to their in vivo instability and low delivery efficiency. Cationic 
lipoplexes interact with serum proteins. The new physiological environment encountered 
by the lipoplexes upon injection also causes dynamic changes in their structure. FeIgner 
et al. used fluorescently labeled plasmids to quantitate cationic lipid-mediated DNA 
uptake in cultured cells and found that less than 0.1 % of plasmid DNA is successfully 
delivered to cell nuclei (30). In addition, the toxicity associated with the cationic lipid 
remains a problem for in vitro and in vivo applications. 
Polyplexes: cationic polymer/DNA complexes 
Lipoplexes and polyplexes debuted almost concomitantly in 1987 with Wu et aI.' s 
work demonstrating poly-L-lysine (PLL)-mediated gene transfection. PLL was followed 
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by other cationic polymer systems, the most popular ones being dendrimers and 
polyethylenimine. However, while many cationic lipids were designed de novo, most of 
the studied cationic polymers are commercially available chemicals adapted for gene 
delivery and are therefore not optimized for biological use. 
Cationic polymers self-assemble with DNA and condense into small particles 
suitable for cellular uptake. When formulated at a positive charge, the particles interact 
readily with the cell surface and are internalized by endocytosis. Like cationic lipids, 
cationic polymers are generally non-immunogenic and can be easily applied to nucleic 
acid-based macromolecules of varying sizes. Polyplexes tend to be more stable than 
lipoplexes because their multivalent interaction with DNA is not readily reversed. 
However, polypI exes also suffer from high toxicity and low transfection efficiencies. 
While 100 viral particles (in the absence of an immune response) can transfect 100 cells, 
polypI ex delivery requires over 100 million plasmid copies to achieve transgene 
expression in 100 cells (30). Cationic polymers simply do not have the efficient viral 
mechanisms for cell entry and trafficking. Each membrane encountered (cell, endosome 
and nucleus) represents a major barrier for the non-viral delivery systems. Polyplexes are 
also colloidal particles and suffer from colloidal stability problems. For example, 
poJypJexes aggregate quickly under high concentrations and physiological salt conditions. 
The aggregation problem prevents the possibility of systemic delivery of polyplexes. 
Although cationic polymers are useful in in vitro settings, their current in vivo 
applications are few and have mainly been limited to direct injections. Systemic delivery 
has been difficult owing to the aggregation of the polyplexes and interaction with blood 
components upon injection. In addition, toxicity of the polyplexes remains a major issue. 
Hence, there are currently no cationic polymers in clinical gene therapy trials. 
A summary of the advantages and disadvantages of viral and non-viral vectors is 
presented in Table 1.4. The immunogenicity of viruses and their difficulty in large scale 
manufacture have plagued viral gene delivery since its inception. It is evident that the 
16 
development of a nontoxic, efficient non-viral delivery vector is essential for the 
implementation of genetic intervention as a method of medical therapy. We address this 
issue in this work by developing novel cyclodextrin-based polymers for gene delivery 
applications. 
VIRAL VECTORS NON-VIRAL VECTORS 
•••••••••••••••••• M ...... ••.•.. ·.····.·.··M····.·····M ••• •••••••••• M •••••• 
Advantages Disad vantages Advantages Disadvantages 
Efficient cellular Host immune Ease of use Toxic to cells 
entry response 
........................................................ 
.................................................................. M ••••• 
Efficient intracellular Difficult to scale up Versatility Low delivery 
trafficking and manufacture efficiency 
.................. _ ....... 
Generally non-toxic Safety issues Non-immunogenic Low in vivo stability 
Table 1.4. Comparison of Viral and Non-viral Vectors 
1.4. CYCLODEXTRINS 
Cyclodextrins (CDs) are cyclic oligomers of 6,7, or 8 glucoses (called a,B, and y-
cyclodextrin, respectively). The structure of B-cyclodextrin (B-CD) is shown in Fig 1.5. 
Cyclodextrins are cup-shaped molecules with a hydrophobic cavity that forms inclusion 
complexes with guest molecules. 
(H ,0, 
"\1r0~~"(" 
o0<~HOH ~ 
HO~OH H~~OH 
~~ H ~\ o~o~o 
HO OH 
o 
~-cyclodextrin (CD) 
Figure 1.5. Schematic illustration of ~-cyclodextrin. (31) 
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Cyclodextrins and cyclodextrin derivatives are used in several pharmaceutical 
formulations, generally as solubilizing agents for their complexation ability with 
hydrophobic compounds. Thus, the safety of CDs for drug use is well established; CDs 
are non-immunogenic and have low toxicity. In addition, CD chemistry is well studied 
with significant literature precedence for various functionalization procedures. Finally, 
CDs are available on large scales in pharmaceutical grade. 
Cyclodextrins therefore possess many advantageous properties: non-
immunogenic, non-toxic, available in large quantities at pharmaceutical grade, and 
capable of forming inclusion complexes. The first objective of this work was to 
incorporate CDs in a polymeric form that is able to self-assemble with and condense 
DNA without eliminating these advantageous properties. The development of a linear, ~­
cyclodextrin-based polymer (~CDP) that mediates gene delivery with low toxicity is 
described in Chapter 2. The polymers are synthesized by modular assembly, that allows 
for detailed structure-function studies. Therefore, Chapter 3 describes the synthesis of a 
family of ~CDPs with various charge densities. The effect of polymer structure on gene 
delivery and toxicity is elucidated and an optimal polymer structure for transfection 
efficiency is determined. 
In addition to toxicity, traditional non-viral vectors also suffer from low 
transfection efficiencies. One of the major limiting steps in achieving trans gene 
expression is escape from vesicular compartments after the particles are endocytosed by 
cells. Confocal microscopy of fluorescently-Iabeled plasmids delivered by cationic 
polymers generally show punctate staining indicative of endosomal trapping. Viruses 
and certain polymers such as polyethylenimine take advantage of endosomal acidification 
to assist in release from these vesicles. Chapter 4 discusses the incorporation of a pH-
sensitive moiety, histidine, in the I3CDP to enhance endosomal release and increase 
trans gene expression. 
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The ultimate application for the ~-cyclodextrin polymers is systemic gene 
delivery. In order achieve this, the ~CDP-based polyplexes need to be stabilized against 
salt-induced aggregation, serum proteins, and non-specific cell interactions. PEGylation, 
that involves grafting of polyethylene glycol (PEG) to polyplexes, is a commonly used 
strategy to impart particle stability to colloidal systems (32). Because PEGylation 
prevents particle uptake by cells, the polyplexes would need to enter cells by receptor-
mediated endocytosis. Therefore, the polyplexes also need to be modified with a ligand 
for cell targeting. Chapter 5 presents a new method for modifying polyplexes by taking 
advantage of the ability of cyclodextrins to complex with hydrophobic molecules. 
~CDP-based polyplexes are modified with adamantane-peptide conjugates. The 
modification does not interfere with DNA binding and condensation but is able to prevent 
non-specific cellular uptake. Chapter 6 studies further applications of the modification 
method, including salt stabilization by PEGylation and co-delivery of genes and small 
molecules. 
Thus, the application of the initial design strategy taken by this work (Fig 1.6) 
resulted in the development of a non-toxic polymer capable of binding, condensing and 
protecting DNA and a modifier molecule for providing additional functionalities such as 
stabilization and targeting. The assembly of the three components - therapeutic gene, 
~CDP, and modifier - to provide a non-viral, systemic gene delivery system is discussed 
in Chapter 7. 
/ 
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Figure 1.6. Polymer Design Strategy. 
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2.1 ABSTRACT 
Chapter 2 
A New Class of Polymers for the Delivery 
of Macromolecular Therapeutics 
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Cationic polymers show promIse for the in vitro and in VlVO delivery of 
macromolecular therapeutics. Known cationic polymers, e.g., poly-(L)lysine (PLL) and 
polyethylenimine (PEl), have been employed in native and modified forms for the 
delivery of plasmid DNA (pDNA) and reveal varying levels of toxicity. Here, we report 
the preparation of a new class of cationic polymers that are specifically designed to 
deliver macromolecular therapeutics. Linear, cationic, beta-cyclodextrin (~-CD)-
containing polymers (CD-polymers) are synthesized by copolymerizing difunctionalized 
~-CD monomers (AA) with other difunctionalized comonomers (BB) such that an 
AABBAABB product is formed. The ~-CD polymers are able to bind - 5 kbp pDNA 
above polymer to DNA (+/-) charge ratios of 1.5, compact the bound pDNA into particles 
of approximately 100-150 nm in size at charge ratios above 5 +/-, and transfect cultured 
cells at charge ratios above 10 +/-. In vitro transfections with the new ~-CD-polymers 
are comparable to the best results obtained in our hands with PEl and Lipofectamine. 
Some cell line-dependent toxicities are observed for serum-free transfections; however, 
no toxicity is revealed at charge ratios as high as 70+/- in transfections conducted in 10% 
serum. Single IV and IP doses as high as 200 mg/kg in mice showed no mortalities. 
The contents of this chapter were published in Bioconjugate Chemistry (1999) 10, 1068-
1074 and were reprinted with permission of the publisher. 
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2.2 INTRODUCTION 
Methodologies currently under investigation for the in VlVO delivery of 
macromolecular therapeutics, e.g, proteins, oligonucleotides, ribozymes, plasmid DNA, 
etc., include both viral and non-viral constructs. Viral transfection systems can produce 
efficient expression of transgenes within cells of interest. However, they have several 
disadvantages, e.g., adenoviruses have high immunogenicity, retroviruses produce 
random genomic integration and both vectors have severely limiting capacities for the 
size of a foreign transgene. Additionally, scaled-up manufacture of replication-deficient 
viral constructs in the absence of recovered replication-competency is problematic (1). In 
contrast, non-viral transfection systems have low immunogenicity, the capacity to handle 
larger sizes of DNA than viruses, and are amenable to large-scale manufacture. A recent 
review has appeared on non-viral gene delivery constructs (2). In spite of the advantages 
of non-viral delivery systems, they reveal numerous problems such as substantially less 
gene expression than viral vectors and toxicity. 
The goal of our work was to synthesize new non-viral vectors for the delivery of 
therapeutic macromolecules. Our approach was to construct a completely new family of 
materials specifically prepared for this application. We chose to work with polymeric 
materials and attempted to specifically address the issue of toxicity. To this end, we 
synthesized a new class of cyclodextrin-containing polymers in the hope of creating a 
relatively non-toxic vector for the delivery of macromolecules since numerous 
cyclodextrins are known to have low toxicity (3). 
Cyclodextrins (CDs) are cup-shaped molecules formed by cyclic oligomers of 
glucose (see Fig. 2.1). Cyclodextrins comprised of 6, 7, and 8 glucose units are called a-, 
B- and y-cyclodextrins, respectively. The three-dimensional structure of CDs is such that 
the cavity is relatively hydrophobic when compared to the exterior and thus can be used 
to imbibe hydrophobic compounds to form host-guest complexes. The ability of CDs to 
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form inclusion complexes has been exploited in CD drug formulations throughout the 
world (including the US -- the first drug formulation to contain a CD, Sporanox®, was 
approved by the FDA in 1997). Because of this, it is known that CDs have relatively low 
toxicity and lack immunogenicity (3). The question addressed here is whether these 
desirable features can be maintained in polymeric form in order to deliver 
macromolecules. 
21=> hydroxy 
o 
HO OH 
HO 1 I=> hydroxyl 
7 
Figure 2.1. Schematic of beta-cyclodextrin. 
In this paper, the synthesis and characterization of a new family of ~-CD 
containing polymers is presented. Numerous polymers have been prepared (4), and here 
we provide several representative examples. It is shown that these polymers can bind and 
condense pDNA and transfect cells with a low level of toxicity. 
2.3 MA TERIALS AND METHODS 
2.3.1. Polymer Synthesis and Characterization 
Monomers. 6A,6D-Dideoxy-6A,6D-diamino-~-cyclodextrin (1, Figure 2.2) and 6A,6D-
Dideoxy-6A,6D-di(2-aminoethanethio )-~-cyclodextrin (2, Figure 2.2) were synthesized 
according to literature procedures (4) and had satisfactory NMR, mass spectral and 
elemental analyses. All reagents were purchased from the Aldrich Chemical Co. 
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(Milwaukee, WI) and used as received except for dimethylsuberimidate·2HCI (DMS) and 
dithiobis(succinimidyl propionate) (DSP), which were purchased from Pierce Chemical 
Co. (Rockford, IL), and used as received. The degree of hydration of the cyclodextrin 
samples was determined by measuring the weight loss on a TA Instruments TGA 951 
thermogravimetric analyzer operating from 25°C to 140°C at a SO/min heating rate. 
1 
2 
Figure 2.2. ~-Cyclodextrin comonomers. 
Polymers containing /3-Cyclodextrin (3-5). ~-CD copolymers 3-5 were prepared by the 
polymerization of a difunctionalized ~-CD (AA) monomer with a difunctionalized 
comonomer (BB) to give an AABBAABB product (Figure 2.3). One procedure to form 4 
is provided below. Additional synthetic methodologies can be found elsewhere (4). An 8 
mL vial was charged with a solution of the bis(hydrogen carbonate) salt of 6A,6D-
dideoxy-6A,6D-di(2-aminoethanethio )-~-cyclodextrin hexahydrate (184.6 mg, 1.36 x 10-
4 mol) dissolved in 0.5M Na2C03. DMS (37.0 mg, 1.36 x 10-4 mol) was added and the 
solution was centrifuged briefly to dissolve the components. The resulting mixture was 
stirred at 25°C for 15 h. The mixture was then diluted with ca. 10 mL of water and the 
pH brought to 4 with 10% HCl. This material was then dialyzed against a Spectra/Por® 
7 MWCO 3,500 dialysis membrane (Spectrum, Houston, TX) in dH20 for 24 h. The 
dialyzed solution was lyophilized to dryness yielding 51 mg (24%) of a white amorphous 
solid. Calculated for C54H94N4Ch033S2·7H20; C:40.83, H: 6.85, N: 3.53; Found C: 
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40.77, H: 6.52, N: 3.46. IH NMR (500MHz, D20) 8 1.39 (br, 4H), 1.69 (br, 4H), 2.49 
(br, 4H), 2.92 (br, 4H), 3.16 (br, 4H), 3.5-4.0 (m, 42H), 5.05 (m, 7H). l3C NMR (125 
MHz, D20) 8 27.5, 28.6, 3l.5, 33.8, 39.6,42.6, 6l.6, 73.2, 74.2,82.7,85.2,103.2, 169.4. 
IR (KEr) 1652 (C=N). 
DMS 
DMF 
DMS 
DMF 
DSP 
DMF 
3 
4 
5 
DSP = NHS~S S ........-yNHS 
o 
Figure 2.3. Schematic of B-cyclodextrin polymer (3 - 5) syntheses. 
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Light Scattering and Molecular Weight Detennination. The specific refractive index 
increment, dn/dc, was measured in 0.3 M NaCl using a Waters 2410 differential 
refractive index detector at a flow rate of l.0 mL/min. The value of dn/dc for 4 in 0.3 M 
NaCl at A = 930 nm and 25 'C was 0.155 mUg. Polymer samples were then analyzed on 
a Hitachi D6000 HPLC system equipped with a ERC-7512 RI detector, a Precision 
Detectors PD2020IDLS light scattering detector and a Progel-TSK G2000 SWXL column 
using 0.3 M NaCI as eluant at a 0.7 mLimin flow rate. The weight average molecular 
weight, Mw, was determined to be 8.8 KDa, with a polydispersity index, MwlMn of l.1O. 
2.3.2. Solid Phase DNA Binding Assay. A 5'-amino-modified 50-mer oligonucleotide 
(5'-Amino-AAA ACT GCT TAC CAG GGA TTT CAG TGC ATG TAC ACG TTC 
GTC ACA TCT CA -3', "NMODSOL") and its complementary oligonucleotide 
("COMPSOL") were synthesized by the Biopolymer Synthesis and Analysis Research 
Center at Caltech (Pasadena, CA). NMODSOL was covalently coupled to magnetic 
porous glass (MPG) supports according to manufacturer's instructions (Solid Phase Oligo 
COUPLE-IT Kit, CPG. Inc, Lincoln Park, NJ). UV absorption analysis revealed 
successful coupling of 190 Ilg of oligo to 10 mg of MPG particles. The complementary 
oligo, COMPSOL, was then annealed to the coupled strand by heating a solution of 
COMPSOL in 45 mM NaCl with the MPG-coupled oligo in boiling water for 2 minutes 
and then allowing the solution to slowly cool to room temperature. UV analysis 
confirmed successful annealing of the complementary strand. 
Primary amine-containing compounds to be analyzed for DNA binding capability 
were added at a 1:5 (+1-) charge ratio in 1 mL of distilled water to the MPG-supported 
DNA (dsDNA-MPG) and incubated with gentle rotation for 2 h. The particles were 
magnetically separated and the supernatant removed. Unbound molecules remaining in 
the supernatant were quantified by amine reaction with TNBS at pH 8.5 (6) and 
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compared to amine quantification of the solution before exposure to dsDNA-MPG to 
determine extent of DNA binding. 
2.3.3. Polyplex Formation and Characterization 
Plasm ids. pGL3-Control Vector (pGL3-CV) plasmid, which contains the luciferase gene 
under the control of the SV 40 promoter, was purchased from Promega (Madison, WI). 
Plasmids were amplified by E. Coli strain DH5a and purified using Qiagen's Endotoxin-
free Megaprep Kit (Valencia, CA). 
Preparation of DNA/polymer complexes and DNA Gel Retardation Assay. One 
microgram of pGL3-CV (0.1 Ilg/IlL in distilled water) was mixed with an equal volume 
of polymer (10 ilL in distilled water) at the appropriate charge ratios. After a 15-30 
minute incubation, the samples were pi petted with 1 ilL of loading buffer into wells of a 
0.6% agarose gel containing 6 Ilg ethidium bromidellOO mL TAE buffer (40 mM Tris-
acetate, 1 mM EDT A) and electrophoresed. 
Transmission Electron Microscopy. PolymerlDNA complexes were prepared at different 
charge ratios as described above for the gel retardation assay. After one hour incubation, 
five microliters of sample were applied in duplicate to 400-mesh carbon-coated copper 
grids for 45 seconds, after which excess liquid was removed by blotting with filter paper. 
The 400-mesh carbon-coated copper grids were glow-discharged immediately prior to 
sample loading. One set of samples was then rotary shadowed at a 6° angle with a 3 em 
tungsten wire while the duplicate set was negatively stained with 2% uranyl acetate for 45 
seconds before blotting. Images were recorded using a Philips 201 electron microscope 
operated at 80 kV. 
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Dynamic Light Scattering (DLS) and Zeta Potential. For determination of particle size 
and charge, 2 ~g of pGL-CV3 (O.l~g/~L in dH20) was mixed with an equal volume of 
polymer (20 ~L in dH20) and allowed to stand for 30 minutes before diluting to a final 
volume of 1.3 mL for measurements. Particle size and zeta potential of the complexes 
were measured using a ZetaPals dynamic light scattering detector (Brookhaven 
Instruments Corporation, Holtsville, NY). Three measurements were taken for each 
sample and data reported as average size and zeta potential. 
2.3.4. Cell Culture and Transfections. 
Cell Lines and Cell Culture. BHK-21 cells were purchased from ATCC (Rockville, 
MD) and maintained in Dulbecco's Modified Eagle Medium supplemented with 10% 
fetal bovine serum (FBS), 100 units/mL penicillin, 100 ~g/mL streptomycin and 0.25 
~g/mL amphotericin. CHO-Kl cells were purchased from ATCC and maintained in 
Ham's F-12 medium with the above listed supplements. All cells were cultured at 37°C 
in a 5% C02 humidified atmosphere and passaged every 4-5 days. Media and 
supplements were purchased from Gibco BRL (Gaithersberg, MD). 
Cell Transfections and Luciferase Assay. BHK-21 cells were plated at 60,000 cells/well 
in 24-well plates 24 hours before transfection. Immediately prior to transfection, cells 
were rinsed once with PBS (pH 7.4) and 200 ~L of Optimem (Gibco), for serum-free 
transfections, or complete media, for transfections in 10% serum, were added to each 
well. Polymer 4IDNA complexes were prepared as described above. Lipofectamine 
(Gibco) and Superfect (Qiagen) complexes were prepared according to manufacturers' 
instructions. PEl (branched 25 kDa, Sigma) and poly lysine (35 kDa, Sigma) complexes 
were prepared as described above, except in 150 mM NaCI at pH 7.0 instead of distilled 
water. Thirty minutes was allowed for complex formation before addition to cells. After 
5 h, 800 ~L of appropriate media with 10% FBS were added to cells. Twenty-four hours 
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after transfection, the medium in each well was replaced with 1 mL of culture media per 
well. After another 24 hours, medium was removed by aspiration, cells were washed 
twice with PBS (pH 7.4), and lysed by one freeze-thaw cycle in 50 ilL Cell Culture Lysis 
Buffer (Promega, Madison, WI). Cell lysates were analyzed for luciferase activity with 
Promega's luciferase assay reagent and for vector toxicity as described below. Light units 
were integrated over 10 seconds in duplicate with a luminometer (Monolight 2010, 
Analytical Luminescence Laboratory, San Diego, CA). 
Toxicity. The amount of protein in cell lysates obtained 48 hours after transfection was 
used as a measure of cell viability. Protein levels of transfected cells were determined by 
Biorad's DC protein assay (Hercules, CA) and normalized with protein levels of cells 
transfected with naked DNA. A protein standard curve was run with various 
concentrations of bovine IgG (Biorad) in Cell Culture Lysis Buffer. 
2.4. RESUL TS 
2.4.1 Binding of Functionalized CD Monomers 1 and 2 to DNA. DNA is not 
retarded in the electrophoresis assay by contact with the functionalized CD monomers 1 
and 2 (data not shown) and this is most likely due to weak binding interactions that are 
disrupted by the presence of salts. Therefore, a solid phase DNA binding assay 
conducted in deionized water was developed as described in Materials and Methods. 
Using this assay, the CD-monomer 1 does not bind to DNA (0% binding), possibly due to 
the steric hinderance of the bulky cYclodextrin cups that are in very close proximity to the 
positive charge center. In order to test this hypothesis, 2 was prepared to specifically 
remove the amine further from the CD. CD-monomer 2 readily binds to DNA, with 88% 
binding. This binding compares favorably to other short polycations, such as spermine 
(19% binding). 
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2.4.2. DNA Binding of CD-Polymer. Although CD monomer 2 is not able to bind to 
DNA in the presence of salt, polymer 4 is able to completely bind DNA above 
polymerlDNA charge ratios of 1.5, as shown by DNA gel retardation (Figure 2.4). 
Binding is observed for complex formation in dH20, 150 mM NaCI, and complete media 
(data not shown). Polymer 3 does not bind to DNA even at polymerlDNA charge ratios 
as high as 50 (data not shown) and is likely due to the same reasons as mentioned 
previously with compound 1. 
DNA 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
Charge (+/-) Ratio 
Figure 2.4. P-CD polymer 4IDNA binding. 
Determination of P-CD polymer 4IDNA charge ratio necessary for complex formation by 
DNA retardation. DNA is visualized by ethidium bromide. 
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2.4.3. In Vitro Transfection and Toxicity of DNA Complexes. One microgram of 
pGL3-CV, encoding for the luciferase gene under the control of the SV40 promoter, was 
complexed with 4 at various charge ratios in 10% serum and serum-free conditions and 
added to BHK-21 and CHO-K1 cells plated in 24-well plates. Transfection efficiencies 
of these complexes were determined by assaying for luciferase protein activity and 
reported in relative light units (RLU) per milligram of total cell protein. Luciferase 
protein activity in BHK-21 cells transfected in serum-free conditions reached a stable 
maximum at 30 +/- with -1 x 109 RLU/mg of protein. The presence of 10% serum in the 
transfection media decreased luciferase activity at all charge ratios (Figure 2.5a). With 
CHO-Kl cells, increasing charge ratio also enhanced the transfection for all conditions 
tested. Additionally, transfection in serum decreased light units by an order of magnitude 
(Figure 2.5b). The toxicity of the B-CD polymer to cells was measured by determining 
total cellular protein in the wells 48 h after transfection. Polymer 4 showed toxicity only 
to BHK-21 cells for transfections in the absence of serum. Toxicity was minimized with 
the presence of 10% serum during transfection (Figure 2.5a). No noticeable toxicity was 
observed from transfections to CHO-K1 cells (Figure 2.5b). 
pGL3-CV was complexed with various commercially available transfection 
agents and exposed to BHK-21 and CHO-Kl cells under the same protocol as used with 4 
for comparison. The transfection and toxicity results for PEl (branched 25 kDa) are 
shown in Figure 2.6. Maximum transfection was obtained at a charge ratio of 3+/- for 
BHK-21 cells and 6+/- for CHO-Kl cells, and decreased slightly at high charge ratios 
(probably as a result of increased toxicity at those ratios). The presence of 10% serum 
decreased transfection efficiencies in both cell lines, although more dramatically for 
BHK-21 cells. Concentration-dependent toxicity was observed for both cell lines 
regardless of serum conditions. 
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Figure 2.5. P-CD polymer 4-mediated transfection to BHK-21 and CHO-Kl. 
The effect of P-CD polymer 4IDNA charge ratio and serum conditions on transfection 
efficiency (e and .) and cell survival ( .... and .A.) in BHK-21 (a) and CHO-Kl (b) cells. 
Results from transfections in 10% serum and serum-free media are shown with the dotted 
and solid lines, respectively. Data are reported as the mean +/- S.D. of three samples. 
Toxicity data are presented as best fit lines. 
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Figure 2.6. PEl-mediated transfection to BHK-21 and CHO-Kl. 
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pGL3-CV transfected with 4 gave RLUs that are two orders of magnitude higher 
than transfection with Superfect and on of the same order of magnitude as transfection 
with PEl and Lipofectamine (Figure 2.7a). The toxicity of the vectors at conditions for 
maximum transfection are shown in Figure 2.7b. While transfection with some of the 
vectors resulted in less than 60% cell survival in one or both of the cell lines tested, 
transfection with 4 showed low toxicity. 
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Figure 2.7h. Comparison of the toxicities of various non-viral vectors. BHK-21 and 
CHO-Kl cells were transfected with ~-CD polymer 4. Percent survival was determined 
by a modified Lowry protein assay at serum-free conditions giving the maximum 
transfection for each non-viral vector. 
2.4.4. Particle Characterization. Previously, it has been reported that negative staining 
with uranyl acetate may affect DNA condensation (7,8). Here, samples for electron 
microscopy were prepared by both rotary shadowing and negative staining. Electron 
microscopy of rotary-shadowed 4IDNA samples showed discrete particles around 100-
150 nm in diameter; however, these samples did not appear focused due to low electron 
density. Negatively-stained samples revealed uniform structures at charge ratios of 5+/-
and above (Figure 2.8), as observed by Tang, et al. (7), that were not present in samples 
without polymer addition. 
Figure 2.8. TEM of polymer 4IDNA complexes. 
Iil Y' 
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Electron micrographs of negatively-stained complexes of polymer 4 complexed with 
DNA at 30 +/- charge ratio in distilled water. Bar represents 200 nm. 
Particle size was also confirmed by dynamic light scattering and surface charge of 
the particles was determined by zeta potential measurements (Figure 2.9a). Particle 
charge increased with increasing polymer addition, reaching neutrality between 
polymerlDNA charge ratios of 1 and 2. Zeta potential of the particles approached +32 
m V as charge ratios increased. Polymer 4 begins to condense DNA at a charge ratio of 
1 +/-, although the particles have a net negative charge. When the charge ratio is 
increased to 2 +/-, the particles are near neutrality (zeta potential = 5.8 m V) and particle 
aggregation occurs. The 4IDNA particle diameter remains relatively constant at 150-180 
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nm above charge ratios of 10+/-. The particle size measured by DLS is slightly higher 
than that observed by TEM because the DLS measures the hydrodynamic diameter. 
Particles formed in water remained stable for several hours. Addition of 150 mM salt to 
the particles results in extensive aggregation that begins almost immediately. These 
results are consistent with those observed for peptidelDNA complexes (9). 
A similar zeta potential and particle diameter profile is observed for PEIIDNA 
complexes (Figure 2.9b). PEl begins to condense DNA at 1+/-. Neutral particles are 
formed around a charge ratio of 1.5+/- (I.5m V) as demonstrated by the aggregation of 
particles at this charge ratio. PEl also forms particles with pDNA of ca. 150 nm in 
diameter above charge ratios of 3. The zeta potential of the particles increases with 
charge ratio, reaching +40 mV at 21+/-. 
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Figure 2.9. Particle size and zeta potential. 
The effect of polymer 4IDNA (a) and PEIIDNA (b) charge ratio on particle size (e), as 
determined by dynamic light scattering, and particle charge (.A.), as estimated by zeta 
potential measurements. 
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2.5 DISCUSSION 
The polyamidine-CD copolymer 4 prepared here is obtained with an overall yield 
of 24%. This yield is comparable to other synthetic, sugar-containing cationic polymers 
that are prepared via an AABB-type polymerization(10). The molecular weight, as 
determined by light scattering, was ca. 8,800. This molecular weight corresponds to a 
degree of polymerization of 6, and an end-group analysis by 13C NMR spectroscopy is 
consistent with this degree of polymerization. Polymers with pendent cyclodextrins of 
equivalent molecular weight have been prepared (11), but those reported here are the first 
to have the cyclodextrin as a part of the polymer backbone. Polymer 4 is found to be 
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highly water soluble; solutions of at least 0.4 M concentration can be prepared. Thus, we 
were able to successfully incorporate a rather insoluble ~-cyclodextrin moiety (1.6 mM) 
in a water-soluble polymer formulation. 
The cationic nature of 4 allows for complexation to DNA. Plank, et al. report that 
a minimum chain length of six to eight cationic amino acids is required to compact DNA 
into structures active in receptor-mediated gene delivery (9). Polymer 4 contains an 
average of twelve cationic charges and is able to condense plasmid DNA into discrete 
particles of 150 nm size in dH20. Although 4IDNA particles aggregate under 
physiological salt conditions, there are methods of inhibiting particle aggregation by 
PEGylation (12) and we are currently exploring these and other techniques for preparing 
particle formulations that would be stable at physiological conditions. 
The 4IDNA complexes are also able to efficiently transfect cells in vitro. 
Transfection is observed for particles formed at and above +/- ratios of 10, which 
corresponds to an average zeta potential of at least +24mV. Increasing +/- ratios also 
increases transfection efficiency. Thus, particles are probably transfecting cells by 
proteoglycan-mediated entry (13). The presence of 10% serum during transfection 
decreases transfection efficiency in both BHK-21 and CHO-K1 cell lines. 
Although positively-charged 4IDNA complexes of 150 nm diameter are formed 
by charge ratios of 5+/- (Figure 2.9a), transfection efficiencies continue to improve with 
increasing charge ratios despite little change in particle size and charge (Figure 2.5). It is 
possible that increasing the polymerlDNA ratio only serves to increase the concentration 
of free polymer in solution, which may in tum aid transfection by affecting the integrity 
of the cell membrane. To test this possibility, plasmid DNA was complexed with PEl 
under low charge ratio conditions which allow for complete DNA binding, but negligible 
transfection. Polymer 4 was then added to the transfection mixture at charge ratios up to 
50+/-. Because PEl essentially binds irreversibly to pDNA, increases in transfection 
efficiency could be attributed to the effects of free 4 in the media. Instead, transfection 
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efficiencies remained slightly above baseline at all concentrations of 4. These results 
indicate that the increasing ratios of 4IDNA aid transfection by affecting the properties of 
the 4IDNA complexes. The nature of these phenomena are currently under investigation. 
Initial trafficking studies with fluorescently-Iabeled DNA (Gene Therapy 
Systems, San Diego, CA) show successful penetration of nearly 100% of cells; however, 
most of the complexes appear trapped in intracellular vesicles, even 24 hours after initial 
cell contact. The high percentage of cell transfection followed by subsequent vesicular 
entrapment has also been reported in lipid-based systems (14). Transfections at various 
charge ratios were therefore conducted in the presence of 25 J-lM chloroquine, an agent 
which delays lysosomal degradation of the pDNA by buffering the endosomal pH (15). 
The addition of chloroquine enhanced transfection efficiencies by over two orders of 
magnitude (an increase from 1 x 108 RLU/mg of protein to 7x 1010 RLU/mg of protein at 
20+1-). The transfection efficiency in the presence of chloroquine was also dependent on 
the polymer to DNA charge ratio; as seen before, increasing the polymer concentration 
also increases transfection efficiency. The transfection enhancement due to chloroquine 
addition confirms particle entry by endocytosis and the lack of efficient endosomal 
release. Nevertheless, the 4IDNA complexes show transfection efficiencies comparable 
to vectors with endosome-escape mechanisms: PEl, that is speculated to act as a "proton 
sponge" to release complexes from endosomes by osmotic pressure (16, 17) and 
lipofectamine, which supposedly releases DNA by destabilizing endosomal membranes 
(18). 
The cyclodextrin-based polymer 4 provides for efficient in vitro transfection of 
cells while remaining non-toxic under most conditions. Most cationic materials, such as 
lipid-based vectors and dendrimers have revealed some toxicity in in vitro studies (17). 
Polymer 4 showed toxicity to BHK-21 cells at increasing charge ratios in serum-free 
media (Figure 2.5a). However, no toxicity is observed with 10% serum for BHK-21 and 
CHO-Kl cell lines (Figure 2.5b), and in serum-free conditions for CHO-Kl cells, even 
up to charge ratios of 200 +1- (data not shown). 
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Cytotoxicity of individual cyclodextrins is dependent upon type, e.g., a,~, y, and 
functionalization, e.g., native vs. hydroxypropylated (19). Cyclodextrins can produce cell 
membrane solubilization by complexation with membrane components such as 
cholesterol (19). In order to test whether observed toxicity with 4 is from the 
polycationic nature of the polymer or from the cyclodextrin itself, BHK-21 and CHO-Kl 
cells were contacted with polymer 5 (no cationic charge), ~-CD, and comonomer 2. No 
toxicity was observed at ~-CD monomer concentrations or monomer concentrations of 5 
up to 700 IlM, which is equivalent to the monomer concentration of 4 used for 
transfections at 200+/-. Finally, the cells were contacted with difunctionalized monomer 
DMS at concentrations up to 700 IlM. Because DMS is a membrane permeable 
molecule, it is possible that the cell toxicity noted at high polymer concentrations is 
caused by the DMS end groups of the polymers. However, no cell toxicity was seen at 
the tested concentrations. These results indicate that the toxicity of 4 in BHK-21 cells is 
likely due to the polycationic nature of the polymer. 
Preliminary in vivo toxicity studies have also been consistent with the in vitro 
findings. Single intravenous and intraperitoneal injections in mice of a cyclodextrin 
polymer similar to 4 at concentrations up to 200 mg/kg showed no mortalities. 
Macroscopic examinations at necropsy revealed no evidence of damage 5 days after 
polymer administration. For comparison, 22 kDa linear PEl has a LD50 of 
approximately 30 mg/kg in the presence of 5 mg/kg pDNA in mice (20) and a PEG-
terminated copolymer of d-Iysine/d-serine is lethal to mice within 30 minutes of i. v. 
administration at 200 mg/kg (21). 
~-Cyclodextrin containing cationic polymers were synthesized in an effort to 
develop a delivery vehicle that would be non-toxic and would condense DNA to particles 
sufficiently small to enable efficient transfection. The polyamidine polymer 4 satisfies 
these criteria. 
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Chapter 3 
Effects of Structure of ~-Cyclodextrin-Containing 
Polymers on Gene Delivery 
3.1. ABSTRACT 
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Linear cationic B-cyclodextrin-based polymers (BCDPs) are capable of forming 
polyplexes with nucleic acids and transfecting cultured cells. The BCDPs are synthesized 
by the condensation of a diamino-cyclodextrin monomer A with a diimidate comonomer B. 
In this paper, the effects of polymer structure on polyplex formation, in vitro transfection 
efficiency and toxicity are elucidated. By comparison of the BCDPs to polyamidines 
lacking cyclodextrins, the inclusion of a cyclodextrin moiety in the comonomer A units 
reduces the IC50s of the polymer by up to three orders of magnitude. The spacing between 
the cationic amidine groups is also important. Different polymers with 4, 5, 6, 7, 8 and 10 
methylene units (BCDP4, 5, 6, 7, 8, 10) in the comonomer B molecule are synthesized. 
Transfection efficiency is dependent on comonomer B length with up to 20-fold difference 
between polymers. Optimum transfection is achieved with the BCDP6 polymer. In vitro 
toxicity varied by one order of magnitude and the lowest toxicity is observed with BCDP8. 
The LD40 of the BCDP6 to mice is 200 mglkg, making this polymer a promising agent for 
in vivo gene delivery applications. 
Reproduced with permission from Bioconjugate Chemistry, in press 
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3.2. INTRODUCTION 
The development of polyplexes (cationic polymer + nucleic acid (1)) for gene 
delivery has grown rapidly to include cationic polymers such as poly-L-Iysine (PLL) (2), 
chitosan (3), pAMAM dendrimers (4), polyethylenimine (PEl) (5) and many other 
polycations. A recent review of cationic polymer based delivery systems is presented by De 
Smedt et al. (6). Cationic polymers are able to deliver plasmid DNA into cells by self-
assembling with the anionic DNA via electrostatic interactions with subsequent 
condensation into small particles that are readily entocytosed. 
While cationic polymers share a similar mechanism of delivery, their transfection 
efficiencies differ greatly from polymer to polymer. Indeed, significant transfection and 
toxicity variations have been noted with the use of various molecular weight fractions of the 
same polymer. Ziady et al. observed both in vitro and in vivo behavioral differences with the 
use of short (36-mer) and long (256-mer)-chain PLL (7). Additionally, polyplexes formed 
with these polymers had different physicochemical characteristics. The transfection 
efficiency of PEl is also highly dependent on molecular weight and structure (8,9). Remy 
et al. compared in vitro gene delivery for various branched and linear PEls and found 
significant variations with PEl structure (10). Malik et al. also found that the dendrimer 
generation influences the efficacy of pAMAM dendrimers (11). 
Plank et al. studied peptide derivatives within a low molecular weight range by 
synthesizing branched cationic peptides with variations in number and type of amino acids 
within the peptides (12). They found DNA binding affinity to be mainly a function of the 
number of cationic residues, and the transfection efficiency to be influenced by the type of 
cationic residues used. It is evident from these reports that polycation structure impacts 
delivery efficiency. Additionally, it is clear that further investigation into the features of 
polycations that influence their behavior in gene delivery is merited. Here, we perform a 
structure-property study of this type. 
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We have reported the synthesis of a new family of B-cycIodextrin-based polymers 
(BCDPs) that are prepared by the condensation of difunctionalized CD monomers 
(comonomer A) with other difunctionalized comonomers (comonomer B) (13). The 
modular synthesis of the BCDPs allows for the systematic study of the effects of polymer 
structure on polyplex formation and polyfection. Previously, the importance of a spacer 
between the cyclodextrin and amine functional groups in the comonomer A units has been 
discussed (13). The spacer was shown to be required for DNA binding of comonomer A, 
most likely by relieving the steric hindrance of the bulky cyclodextrin cups. Here, we study 
the effect of comonomer B structure on DNA delivery and toxicity, since variations in 
comonomer B result in changes in polymer charge density and hydrophobicity. In order to 
better understand the origin of the functional differences, the polyplexes are characterized 
by comparing particle size, DNase protection ability, and relative DNA binding constants. 
3.3. MATERIALS AND METHODS 
3.3.1. B-Cyclodextrin-Polymers. 
B-cyclodextrin polymers (BCDPs) were prepared by the polymerization of a 
difunctionalized B-CD monomer (A) with a difunctionalized comonomer (B) to give an 
ABAB product as described previously (13). The synthesis procedure involves the 
preparation of the difunctionalized B-CD (6A, 6D-dideoxy-6A, 6D-di(2-aminoethanethio)-
B-cyclodextrin; denoted dicysteamine-B-cyclodextrin) and the synthesis of the 
difunctionalized comonomer B. 
Synthesis o/the comonomer A (3, Fig. 3.1). 
B-CD (Wacker Biochem Corp, Adrian, MI) was dried in vacuo « 0.1 mTorr) at 120°C for 
14 h before use. Biphenyl-4,4'-disulfonyl chloride (Aldrich, Milwaukee, WI) was 
recrystallized from chloroformlhexane. Potassium iodide was powdered with a mortar and 
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pestle and dried in an oven at 200°C. Cysteamine (Fluka, Milwaukee, WI) was sublimed at 
40°C under vacuo before use. All other reagents were obtained from commercial suppliers 
and were used as received without further purification. 
First step HOJ7a~ 
6'OH OHOHO~~ 
oiOH Ho'~ CIO~-@-@SO~I 
HO~H HU 
O§H HO OH Pyridine, 60 QC, 3h 
OH HO 0 
o HO,,-A 0 
HO O~~ 
HO 
OH 
Second step HC( l"?:'~\ 0 t-lo~H ~ ~gH °rf" 00 o?"O~ HO OH 0 [1:0  o 0 OH 
lXlOH HO H 0 °i~o~O 
°HO 
KI 
DMF, 80 QC, 2h 
Hqll;;~&1 t-lo~' OH 0 
o 0 ~OH HO HO llHOO OH o 0 OH ~~~00 
I °HO 2 
Third step HO~~Q OH~
OH OHOHO~ 
~gH HO 0 HO HO OH {f0 0 
o HO OH ~OH HOHO 0 
~XO~ 
I 0 HO 
HP, 100 QC, 2h 
Figure 3.1. Synthesis of the como no mer A (dicysteamine-!)-cyclodextrin). 
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First step: Synthesis of biphenyl-4,4'-disulfonate-capped f)-CD 1. The capped f)-CD 
was synthesized according to a modified procedure of Tabushi et al. (14). To a solution of 
dried f)-CD (lOg, 8.81 mmol) in 2S0 mL of freshly distilled anhydrous pyridine (Aldrich) 
was added 2.78g (7.93 mmol) of biphenyl-4,4'-disulfonyl chloride in four equal portions at 
IS min intervals. The resulting solution was stirred at 60°C under nitrogen for an 
additional 3 h and the solvent was removed to dryness in vacuo at room temperature. The 
residue was subjected to C8 reversed-phase column chromatography using a gradient 
elution of 0-40% acetonitrile in water. Fractions were analyzed by HPLC and the 
appropriate fractions were combined. After removing the acetonitrile on a rotary evaporator, 
the resulting aqueous suspension was lyophilized to dryness. This procedure gave S.42g 
(40% yield) of 1. 13C NMR (Bruker SOO MHz, Me2SO-d6) 8 ppm: 60.3 (C6), 70.9, 71.6, 
72.7 (C2, C3, CS), 82.4 (C4), 102.0 (Cl), 128.4-143.2 (phenyl). 
Second step: Synthesis of diiodo f)-CD 2 (15). To a solution of S.42g (3.S2 mmol) of 
1 in 100 mL of anhydrous DMF (Aldrich) was added 17.S3g (0.106 mol) of dry powdered 
potassium iodide. The solution was kept at 80°C for 2 h with stirring. After the mixture 
cooled to room temperature, insoluble materials were removed by filtration and the solution 
was evaporated to dryness in vacuo. The residue was then dissolved in 60 rnL of water and 
6 rnL of tetrachloroethylene was added at 0 °C with vigorous stirring. The precipitate 
formed was collected and dried in vacuo to give 4.69g (90% yield) of a slightly yellow 
colored solid. l3C NMR (Bruker SOO MHz, Me2SO-d6) 8 ppm: 10.4 (C6 adjacent to I), 
60.3 (C6 adjacent to OH), 70.9, 71.6, 72.7 (C2, C3, CS), 82.4 (C4), 102.0 (CI). 
Third step: Synthesis of dicysteamine f)-CD 3. To a solution of 4.69g (3.17 mmol) of 
2 in 100 mL of degassed water was added 0.489g (6.34 mmo!) of freshly sublimed 
cysteamine. The solution was stirred under reflux for 2 h. After cooling to room 
temperature and acidifying with IN HCl, the solution was applied to a Toyopearl SP-650M 
ion-exchange column (NH./ form) and the product was eluted with a 0 to O.2M ammonium 
bicarbonate gradient. Appropriate fractions were combined and lyophilized to dryness. This 
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procedure gave 1.87g (39% yield) of a white solid. The solid was characterized by TLC 
(silica gel, n-PrOH-AcOEt-H20-NH3aq 5/3/3/1, detection by ninhydrin) and exhibited a 
major spot corresponding to 3 and a minor spot corresponding to free cysteamine. This 
unreacted cysteamine was eliminated on a rotary evaporator after dissolution of the solid in 
water with monitoring by Ellman's reagent (16). Matrix-assisted laser desorption/ionization 
(MALDI) time-of flight (TOF) mass spectrum was recorded on 2 meter ELITE instrument 
supplied by PerSeptive Biosystems, Inc. MALDI-TOF rnIz ca1cd for 3: 1252, found: 
1253.5 [M+Ht, 1275.5 [M+Nat, 1291.4 [M+Kt. l3C NMR (Bruker 500 MHz, D20) 8 
ppm: 32.1 (S-CH2 ) and 38.8 (CH2-NH2), 32.9 (C6 adjacent to S), 60.2 (C6 adjacent to 
OH), 70.8,71.4,72.5 (C2, C3, C5), 81.8 (C4), 101.7 (Cl). 
Synthesis of the comonomer B (4a-f, (17). 
1. CH30H 
2. HCI anhydrous 
Ether, 0 QC , 24 h 
n=4,5,6,7,8,10 4a,n=4 4b,n=5 
4c,n=6 
4d,n=7 
4e,n=8 
4f, n=10 
Dimethyladipimidate.2HCI 4a, dimethylpimelimidate.2HCI 4b, and 
dimethylsuberimidate.2HCI 4c (DMS) were purchased from Pierce Chemical Co. and were 
used as received. 
Synthesis of dimethylazelimidate.2HCI4d. Azelanitrile (1.08g, 7.2 mrnol) (Aldrich) was 
dissolved in an ice-cold mixture of anhydrous methanol (4 mL) and anhydrous diethylether 
(30 mL). Anhydrous hydrogen chloride was passed through the solution for 60 min and 
the reaction mixture was left at 0 °C for 24 h. Dry diethyl ether (50 mL) was added to 
precipitate the product that was washed twice with 100 mL of dry methanolldiethylether 
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(mixture (volume ratio 1:3)) under anhydrous conditions. The solid was dried under 
vacuum for 2 h. This procedure gave 1.64g (79% yield) of 4d. Calcd for CIIH2402NzCI2: 
C, 45.96; H, 8.36; N, 9.75. Found: C, 45.48; H, 8.30; N, 9.71. l3C NMR (Bruker 500 MHz, 
CD30D) 8 ppm: 26.1, 29.4, 29.5, 33.9 (4 CHz)' 59.9 (OCH3), 183.2 (C=NH). 
Synthesis of dimethylsebacimidate.2HCI4e. This compound was obtained from 1.16g (7.1 
mmol) of sebaconitrile (Aldrich) by the same procedure used to prepare 4d and gave 2.04g 
(96% yield). Calcd. for ClzHz602N2C12: C, 47.81; H, 8.63; N, 9.30. Found: C, 47.68; H, 
8.51; N, 9.23. 13C NMR (Bruker 500 MHz, CD30D) 8 ppm: 26.2, 29.6, 29.7, 33.9 (4 
CHz), 59.9 (OCH3), 183.2 (C=NH). 
Synthesis of dodecanediimidate.2HCI 4f. This compound was obtained from 1.35g (7.0 
mmol) of dodecanedinitrile (TCI America Organic Chemicals, Portland, OR) by the same 
procedure used to prepare 4d and gave 1.85g (80% yield). Calcd for C14H3002N2C12: C, 
51.03; H, 9.11; N, 8.51. Found: C, 50.96; H, 9.08; N, 8.44. l3C NMR (Bruker 500 MHz, 
CD30D) 8 ppm: 26.3,29.8,30.0,30.3,33.9 (5 CH2), 60.0 (OCH3), 183.4 (C=NH). 
Polymerization (Fig. 3.2). 
~CDPs were synthesized as described previously (13). In a typical experiment, a 25 rnL 
vial was charged with a solution of the bis(hydrogen carbonate) salt of dicysteamine ~-CD 
3 (399.6 mg, 0.269 mmol) dissolved in 500 ML of 0.5M Na2C03. The comonomer B, e.g., 
4c (73.5 mg, 0.269 mmol) was added and the solution was centrifuged briefly to dissolve 
the components. The resulting mixture was stirred at 25°C for 15 h. The mixture was then 
diluted with 10 mL of water and the pH brought below 4 with the addition of IN HCI. This 
solution was then dialyzed against a SpectraIPor 7 MWCO 3500 dialysis membrane 
(Spectrum) in dHzO for 24 h. The dialyzed solution was lyophilized to dryness. l3C NMR 
(Bruker 500 MHz, D20) 8 ppm: 25.8, 26.0, 27.0, 28.7, 29.9, 32.2, 37.5, 38.1, 41.1, 60.0, 
71.6,72.3,72.6,80.8, 101.4, 167.9. 
3 
I3-CDPs 
4a-f 
n=4: I3-CDP4 
n=5: I3-CDP5 
n=6: I3-CDP6 (I3-CD-DMS) 
n=7: I3-CDP7 
n=8: I3-CDP8 
n=10: I3-CDPI0 
Figure 3.2. Polymerization scheme for ~-cyclodextrin polymers. 
3.3.2. Polyamidine Polymers 
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rt, 15 h 
Polyamidine polymers were synthesized as described for ~CDPs except methylene 
diamines were used as the comonomer A instead of dicysteamine ~-CD. These non-
~-CD-containing polymers were prepared for comparison to the ~CDPs In order to 
ascertain the influence of the ~-CD in the polymer backbone upon gene delivery. 
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C6-C6 polyamidine: A 8 rnL glass vial was charged with 80 mg of hexamethylenediamine 
(comonomer A, 0.690 mmol, Aldrich) and 195 mg of dimethylsuberimidate.2HCI 
(comonomer B, 0.714 mmol, Pierce). The solids were dissolved by the addition of 0.25 mL 
of 0.5M Na2C03. The mixture was stirred at 25°C for 15 h, yielding a viscous, clear 
solution. The mixture was diluted with water and pH brought below 4 with the addtion of 
IN HCI. The solution was transferred to a SpectraIPor 7 MWCO 1000 dialysis membrane 
and dialyzed for 24 h in dH20. The dialyzed material was lyophilized to dryness, yielding 
30 mg of a white, fluffy solid (13% yield). 
C6-C6 Polyamidine: 
4c 
C9-C6 polyamidine. The C9-C6 polyamidine polymer was synthesized as described above 
for the C6-C6 polyamidine polymer except 1, 9 diaminononane (comonomer A, Aldrich) 
was reacted with dimethylsuberimidate.2HCI (comonomer B) to result in a 21 % yield of a 
white, fluffy solid. The C9 distance is a reasonable approximation to that of the ~-CD. 
C9-C6 Polyamidine: 
4c 
3.3.3. Polymer Characterization. 
Light Scattering and Molecular Weight Determination. ~CDPs were analyzed on a Hitachi 
D6000 HPLC system equipped with a ERC-7512 RI detector, a Precision Detectors 
PD2020/SLS light scattering detector and a Progel-TSK G2000 SW XL column using 0.3M 
NaCI as eluant at a 0.7 mLImin flow rate as described previously (13). 
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End Group Analysis by Amine Quantification. BCDPs were dissolved in O.lM NaHC03 at 
a concentration of 0.25 mg/rnL, and the amine concentration of these solutions was 
determined by reaction with TNBS (16). In brief, 250 JlL of 0.01 % TNBS in O.lM 
NaHC03 were added to 500 JlL of polymer solutions and resulting mixture placed in a 37 
°C water bath. After 2 h, 250 JlL of 10% sodium dodecyl sulfate and 125 JlL of IN HCI 
was added to each sample. The absorbance at 335 nm was determined and compared to a 
dicysteamine-BCD standard curve. 
3.3.4. Polyplexes 
Plasm ids. Plasmid pGL3-CV (Promega, Madison, WI), that contains the luciferase gene 
under the control of the SV40 promoter, and plasmid pCA-EGFP (generously donated by 
Dr. Rusty Lansford and Prof. Scott Fraser at the California Institute of Technology), that 
contains the EGFP gene under a chick actin promoter, were amplified by Escherichia Coli 
strain DH5a and were purfied using Qiagen's Endotoxin-free Megaprep kit (Valencia, CA). 
Complex Formation. An equal volume of cationic polymer dissolved in dH20 was added to 
plasmid DNA (0.1 mg/rnL in dH20) at the appropriate charge ratios (cationic to anionic, 
denoted as "+/-"). 
Dynamic Light Scattering. For particle sizing by dynamic light scattering (DLS), 2 Jlg of 
pCA-EGFP was complexed with polymers at 50 +/- and allowed to stand for 10 min before 
diluting with l.2 rnL of dH20. Particle size was measured using a ZetaPals dynamic light 
scattering instrument (Brookhaven Instruments Corporation, Holtsville, NY). 
Transmission Electron Microscopy. One microgram of DNA was complexed with cationic 
polymer at 50 +/- charge ratio and applied to formvar carbon-coated grids for 45 seconds 
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before removing excess liquid. Samples were then stained with 2% uranyl acetate for 45s 
before blotting. Images were recorded using a Philips 201 Electron Microscope operated at 
80V. 
DNase Protection Assay. The DNase protection assay was modified from a procedure by 
Gao et al. (18). One microgram of DNA (pCA-EGFP) was complexed with cationic 
polymer at 5 +/-. The complexes were then incubated with 20 ML of fetal bovine serum 
(FBS, Gibco BRL, Gaithersburg, MD) for 30 min. Five microliters of 10% SDS were 
added to the complexes to displace the polymers from the DNA. Twenty microliters of 
FBS were added to "control" complexes followed by immediate addition of SDS for the "0 
minute" timepoint. The samples were then applied to a 0.8% agarose gel containing 6 Mg 
ethidium bromide/lOO mL TAE buffer (40 mM Tris-Acetate, 1 mM EDTA) after the 
addition of 1 ML loading buffer and electrophoresed. 
Competitive Displacement by Heparan Sulfate. Cationic polymer was complexed with 0.5 
Mg of pGL3-CV at a 20 +/- charge ratio. Heparan sulfate (5 mglmL in water, Sigma, from 
procine intestinal muscosa, St. Louis, MO) was then added to the complexes. After a 5 min 
incubation, 1 ML of loading buffer was added and samples were electrophoresed in an 
agarose gel as described for the DNase protection assay. 
3.3.5. Cell Culture and Polyfections. BHK-21 cells were purchased from ATCC 
(Rockville, MD) and maintained in Dulbecco's Modified Eagle Medium supplemented with 
10% FBS, 100 units/mL penicillin, 100 MglmL streptomycin, and 0.25 MglmL amphotericin 
at 37° C and 5% CO2. Media and supplements were purchased from Gibco BRL 
(Gaithersburg, MD). For transfections, BHK-21 cells were plated at 50,000 cells/well in 
24-well plates. Cells were transfected with 1 Mg of pGL3-CV complexed with /3CDPs at 
various charge ratios in serum-free media and lysates analyzed for luciferase activity as 
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described previously (13). The toxicities associated with the transfections were assessed by 
the Lowry protein assay, also described previously (13). 
3.3.6. ICso Determination. BHK-21 cells were plated at 5000 cells/0.1 mUwell in 96 
well plates and incubated at 37° C for 24 h. ~CDPs (16 mglmL in complete media) were 
then added to the third column of cells and diluted serially across the rows. The cells were 
incubated with the polymers for 24 h at 37° C. The media was then removed from the cells 
and cells were washed once with PBS. Fifty microliters of MTT (2 mglmL in PBS) were 
added to each well followed by 150 ilL of complete media. The cells were incubated for an 
additional 24 h before the media was removed and blue formazan crystals formed were 
dissolved in 150 ilL of DMSO. The absorbances were read at 562 nm in a microplate 
reader (EL-312e Biokinetics Reader, Biotek Instruments, Winooski, VT). 
3.3.7. Intravenous Toxicity of ~CDP6 in Mice. Groupings of five outbred mice were 
injected intravenously with a single dose of ~CDP6 (8.33 IlUg mouse). Stock dosing 
solutions of ~CDP6 were prepared in 0.9% sodium chloride, sterilized by passing through 
a 0.2 11m filter, and diluted with 0.9% sodium chloride as needed. Mice were observed for 3 
days post-injection. 
3.4. RESULTS 
3.4.1. ~CDPs Synthesis and Characterization. ~CDPs were synthesized usmg 
comonomer B's with 4,5,6, 7, 8 and 10 methylene units. The length of the comonomer B 
was found to influence the polymerization as shown by the data given in Table 3.1. The 
molecular weight Mw and the polydispersity index MjMn as determined by light scattering 
are provided in Table 1 for each polymer. Molecular weight Mn was also estimated by end 
group analysis. The two possible terminal functional groups for the ~CDPs are carboxylic 
acids or amines. Attempts to conjugate a fluorescent tag to the polymer assuming 
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carboxylic end groups resulted in no observed reaction. However, the conjugation of TNBS 
(reacts with primary amines) resulted in the detection of molecular weights Mn very similar 
to those detected by SLS (Table 3.1). These molecular weights give a degree of 
polymerization of 4 to 5 for all ~CDPs studied. The yield of polymer increased with the 
number of methylene groups within comonomer B. The yield of ~CDPlO was 56%; 
however, this polymer was synthesized from a different batch of comonomer A than all the 
other polymers. Therefore, direct comparison to the other ~CDPs may not be appropriate. 
Degree of 
Polymer Yield (%) Mw (kDa)" MwlMn 
polymerization 
Mw (kDa)b 
t3CDP4 18 6.1 1.13 4 5.7 
t3CDP5 21 5.8 1.12 4 5.2 
t3CDP6 20 5.8 1.12 4 55 
t3CDP7 29 6.9 1.14 4 4.9 
t3CDP8 37 7.6 1.16 5 6.7 
a Determined by static light scattering. b Estimated by end group analysis. 
Table 3.1. Effect of the length of comonomer B on the polymerization 
3.4.2. Polyplex Characterization. ~CDPs were complexed with plasmids at various 
charge ratios and polyplex size was measured by dynamic light scattering (DLS) and TEM. 
Particle size depended on polymer and DNA concentrations during polyplex formulations. 
However, above 3+/-, polyplex size remained largely independent of charge ratio. When 
measured by DLS, particle sizes of polyplexes formulated at DNA concentrations of 50 
/-lglmL ranged from 124-152 nm (Fig. 3.3). ~CDP4, t3CDP5 and ~CDPlO-based 
polyplexes gave the largest particles, with diameters of 148, 141, and 144 nm respectively. 
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f)CDP6, f)CDP7, and f)CDP8-based particles had smaller diameters of 127, 128, and 124 
nm respectively. Electron micrographs of all f)CDP-polyplexes prepared in water showed 
uniform particles that appeared spherical in shape. f)CDP6-based polyplexes are shown in 
Fig. 3.4 as an example. 
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Figure 3.3. Hydrodynamic diameter of f)CDP-based polyplexes. 
Polyplexes were prepared with 2 Mg of plasmid DNA at a DNA concentration of 0.05 
mglmL and then diluted with dH20 to 1.2 mL final volume for hydrodynamic 
measurements by dynamic light scattering. The results shown are mean +/- S.D. for three 
experiments, each measured in triplicate. 
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lOOnm 
Figure 3.4. Electron micrograph depicting polyplexes of j3CDP6 and pGL3-CV at a 
50+/- charge ratio. 
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3.4.3. DNase Protection. The ability of the ~CDPs to protect plasmid DNA from DNase 
degradation was assessed. Plasmid DNA was complexed with ~CDPs and incubated with 
an equal volume of fetal bovine serum for 30 min at 37° C. The DNA was released from 
the complexes by the addition of sodium dodecyl sulfate and run on an agarose gel (Fig. 
3.5). ~CDPs with 4, 6, 8, and 10 methylene units completely protected DNA, while ~CDP5 
and ~CDP7 offered only partial protection. 
DNA ~CDP4 ~CDPS ~CDP6 
Minutes 0 30 0 30 0 30 0 30 
Minutes 0 30 0 30 0 30 0 30 
DNA ~CDP7 ~CDP8 ~CDPI0 
Figure 3.5. DNase protection of plasmid DNA by ~CDP complexation. 
PolypI exes of DNA complexed with the various ~CDPs were incubated with an equal 
volume of fetal bovine serum for zero or thirty min. ~CDPs were then displaced by SDS 
and DNA visualized by electrophoresis in an agarose gel. 
3.4.4. In Vitro Transfection and Toxicity of ~CDP Polyplexes. BHK-21 cells were 
plated in 24-well plates and transfected under serum-free conditions with 1 Ilg of pGL3-CV 
complexed with the I3CDPs at various charge ratios. Transfection efficiencies were 
determined by assaying for luciferase protein activity, with results reported in relative light 
units (RLUs). Several polymer to DNA charge ratios were tested (Fig. 3.6) and a 
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comparison of relative transfection efficiencies and cell survival are reported here for 50 +/-
(Fig. 3.7). At this charge ratio, the transfection efficiencies have reached their maximum 
and the toxicity differences between the polymers become evident. The ~CDP with six 
methylene units, ~CDP6, gives the highest transfection efficiency: 2.5 x 10 10 RLU/mg 
protein. The transfection efficiencies of all the polymers are normalized to the ~CDP6 
transfection achieved at 50 +/- and reported as a fraction of ~CDP6 transfection (Fig. 3.7). 
~CDP7 and ~CDP8 transfected at 50% and 64%, respectively, of the ~CDP6 levels while 
~CDP4, ~CDP5, and ~CDPlO compared even less favorably at 22%, 6%, and 10%, 
respectively. 
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Figure 3.6. Transfection and toxicity of I3CDP5 and I3CDP6 to BHK-21 Transfection 
efficiencies (.) and cell survival (.) for BHK-21 cells transfected with 1 J..lg of pGL3-CV 
complexed with ~CDP5 (dashed lines) and ~CDP6 (solid lines) at charge ratios ranging 
from 10 to 50 +/-. Luciferase protein activity is reported as relative light units (RLU) per 
mg of total cellular protein, as determined by Lowry protein assay. Cell survival was 
calculated by dividing cellular protein levels of transfected cells by untransfected cells. Data 
are reported as the mean ±SD of three samples. 
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Figure 3.7. Comparison of transfection and toxicity of various ~CDP-based 
polyplexes. 
A comparison of luciferase transfection and cell survival for ~CDP-based polyplexes at 50 
+/- charge ratios. The data reported are the mean ± S.D. of three experiments, each 
performed in triplicate. Transfection results for the different polymers are normalized with 
the average transfection achieved by ~CDP6-based polyplexes for each experiment. Cell 
survival (X) was determined by assaying for total protein concentrations and normalizing 
each sample with protein levels for untransfected cells. 
The toxicity of the ~CDPs associated with the transfections at 50 +/- was measured 
by determining the total protein concentration in cell lysates 48 h after transfection and 
comparing with protein levels of untransfected cells. The fraction cell survival in the 
presence of the polyfection mixture was also dependent on comonomer B length (Fig. 3.7). 
No toxicity was observed for ~CDP8. However, toxicity in general increased for all 
comonomer B lengths differing from that used in ~CDP8. 
The IC50s of the ~CDPs to BHK-21 cells were determined by plating the cells in 
96-well plates, exposing the polymers to the cells in serial dilutions for 24 h and monitoring 
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cell viability by the MIT assay. The polymer IC50s show the same trend as the toxicities 
associated with polyplex transfection (Fig. 3.8). I3CDP8 had the highest IC50 (2200 MM, 
reported as cyclodextrin concentration), followed in order of decreasing IC50s by I3CDP7 
(1800 MM), I3CDP6 (1100 MM), I3CDP4 (380 11M), I3CDP5 (350 11M) and I3CDPIO (330 
11M). 
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Figure 3.8. ICsos of I3CDPs to BHK-21 cells. 
COP7 COP8 COP10 
I3CDPs were added in serial dilutions to BHK-21 cells plated in 96-well plates. Cell 
viability was determined 24 h after polymer exposure by MIT assay. The IC50s, reported 
as cyclodextrin concentration, were determined by interpolation on a best-fit line and are 
reported as the mean ± S.D. for three replicates. 
Polyamidine polymers were synthesized by the condensation of 
dimethylsuberimidate (DMS, comonomer B with 6 methylene units) with 
hexylmethyldiamine or 1,9 diaminononane to give C6-C6 polyamidine and C9-C6 
polyamidine, respectively. The ICsos of the polyarnidine polymers to BHK-21 cells were 
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determined to be 4.6 11M (reported per repeat unit) for C6-C6 polyamidine and 34.0 11M for 
C9-C6 polyamidine. 
3.4.5. Polymer Displacement by Heparan Sulfate. Polyplexes can be unpackaged by 
the addition of an anionic competitor such as heparan sulfate to bind to the cationic polymer 
and release the DNA (19). The relative binding constants of the ~CDPs were determined 
by complexing the polymers with plasmid DNA at a 20 +/- charge ratio and then adding 
increasing amounts of heparan sulfate. The solutions were loaded onto an ethidium 
bromide-containing agarose gel and electrophoresed. Complexed DNA remained in the 
loading well. Successful polymer displacement by heparan sulfate released the DNA, that 
migrated in the electric field and was visualized by ethidium bromide intercalation. A 
comparison of the amount of heparan sulfate required to release the DNA from the ~CDPs 
reflected the relative binding contants. ~CDP6 demonstrated the highest DNA binding 
constant, requiring the addition of 22 Ilg of heparan sulfate before any DNA release could 
be observed (Fig. 3.9). 14 Ilg of heparan sulfate were necessary to displace ~CDP4 while 
161lg were required to displace ~CDP5. The polymers with comonomer B longer than 6 
methylene units showed a different behavior. For ~CDP7, ~CDP8 and ~CDPlO, the 
addition of heparan sulfate, even as low as 6 Ilg, resulted in the visualization of some 
uncomplexed DNA. For f3CDP8 and f3CDPlO, the DNA release remains only partial, even 
with the addition of 32 Ilg of heparan sulfate. 
~CDP4 ~CDP5 
J,lg of Heparan Sulfate 
DNA 6 8 10 12 14 16 18 20 22 24 26 28 30 32 
~CDP6 ~CDP7 
J,lg of Heparan Sulfate 
DNA 6 8 10 12 14 16 18 20 22 24 26 28 30 32 
18 20 22 24 26 28 30 32 
~CDP8 
J,lg of Heparan Sulfate 
~CDPlO 
DNA 6 8 10 12 14 16 18 20 22 24 26 28 30 32 
18 20 22 24 26 28 30 32 
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J,lg of Heparan Sulfate 
DNA 6 8 10 12 
J,lg of Heparan Sulfate 
DNA 6 8 10 12 14 16 
J,lg of Heparan Sulfate 
DNA 6 8 10 12 14 11 
Figure 3.9. Determination of relative binding constants by heparan sulfate 
displacement. 
The amount of heparan sulfate (in J,lg) required to free DNA from ~CDP-based polyplexes 
(prepared with 1 J,lg of DNA at 20 +/-). The first lane of each gel is uncomplexed DNA. 
The uncomplexed and freed DNA was visualized by ethidium bromide in an agarose gel. 
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3.5. DISCUSSION 
The objective of this study is to investigate the structure-property relationships 
between a family of ~-cyclodextrin containing, cationic polymers and their interaction with 
and ability to deliver to cells plasmid DNA. In order to accomplish these goals a series of 
f3CDPs were prepared using comonomer Bs with 4,5,6,7,8, and 10 methylene units. The 
polymer yields were proportional to the comonomer B length with BCDP 10:0:: 
~CDP8>~CDP7>~CDP6>BCDP5>~CDP4. Higher reaction yield with longer diimidate 
4a-f linkers was also noted by Denkinger et al. (17) who crosslinked poly(allylamine) with 
esters of diimidic acids such as those used here (4a-f) to form hydrogels. The BCDP 
molecular weights, detected by both static light scattering and end group analysis, ranged 
from 5800 to 7600, corresponding to a degree of polymerization of 4 to 5 and giving 8 to 
10 cationic charges per chain. Therefore, differences in polymer performance should be a 
result of polymer structure and not molecular weight since they all have similar molecular 
weights and polydispersities. 
The BCDPs form polypI exes with DNA by rapid self-assembly in aqueous 
solutions. Polyplexes formed in water are relatively monodisperse and uniform in size, as 
evidenced by DLS and TEM. The size of the polyplexes depends on the formulation 
conditions, as has been described previously by Duguid et al. (20). Particles formed with 
~CDP6 have an average diameter of 60 nm at 2 ).tg/mL final DNA concentration but an 
average diameter of 130 nm at 50 ).tg/mL as measured by DLS. The latter particles were 
used for the DLS, TEM and transfection studies presented here. Electron micrographs of 
f3CDP6-based polyplexes show particles smaller than 100 nm in diameter. DLS 
measurements, due to calculations that are based on weighting by particle light scattering 
intensity, are biased toward larger particles. DLS also determines the hydrodynamic 
diameter and hence DLS size measurements of particles are larger than the sizes of the 
polyplexes pictured by electron micrographs. 
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Polyplexes fonned from ~CDP4, ~CDP5 and ~CDPlO are larger in diameter than 
polyplexes fonned from the other ~CDPs (Fig. 3.3). These larger particles transfected 
cultured cells less efficiently (Figs. 3.6,3.7). A correlation between particle size and 
transfection efficiency has been described for other systems (6), although it is nonnally 
observed that the larger the particle size, the greater the transfection. Here, the differences in 
the particle size are not large and likely not the reason for the large differences in 
transfection. In addition, the cationic polyplexes are prone to aggregation under 
physiological salt conditions. Thus, the variations in particle size may be indicative of 
differences in the polymer-DNA binding interactions rather than having direct effects on 
particle uptake. 
For effective gene delivery, the polycation must protect the DNA from nuclease 
activity. While ~CDP4, ~CDP6, ~CDP8, and ~CDPlO completely protected plasmid DNA 
from DNase degradation, ~CDP5 and ~CDP7 offered only partial protection (Fig. 3.5). 
Yoshikawa et al. observed a difference in binding of various methylene diamines to DNA; 
however, they noticed greater DNA condensation with odd numbers of methylene units and 
larger particles with even numbers of methylene units (21). Thus, small differences in 
charge separation can produce dramatic effects. It is interesting to note that the two ~CDPs 
with odd numbers of methylenes are the only ones to not completely protect the DNA. 
All of the synthesized ~CDPs are able to transfect BHK-21 cells, although with 
varying efficiencies. Transfection increases with charge ratios up to 50 +/- (Fig. 3.6). This 
high optimal charge ratio is probably due to the short nature of the polymers, a phenomenon 
also noticed by Plank et al. (12) for short peptides. The transfection profiles as a function 
of polymer to DNA charge ratio are similar for all of the polymers; however, the magnitudes 
of the profiles differ greatly between polymers. In order to illustrate differences in 
transfection and toxicity, we chose to compare delivery perfonnance between the polymers 
at 50 +/-, as displayed in Fig. 3.7. The highest transfection efficiency, as determined by 
luciferase protein activity, is consistently achieved by the ~CDP6-based polyplexes. The 
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transfection efficiency is found to be dependent on the comonomer B length. For example, 
when compared to BCDP6, luciferase transfections with BCDP5 result in a 20-fold 
reduction of luciferase protein activity, while the difference between the two comonomer B 
lengths is only 1.8 A. Therefore, a few A change in comonomer B length reduces the 
transfection by up to one order of magnitude (Fig. 3.7). 
A possible rationalization for the large decrease in transfection is that the spacing 
between the cationic amidine groups in BCDP6 is optimal for DNA binding. In an attempt 
to study BCDP-DNA interactions, polymer binding kinetics were monitored via a quartz 
crystal microbalance and DNA condensation kinetics by DLS. It was found that binding 
and condensation were complete within one second for all the polymers. Because of the 
speed of these processes, the procedures used here were unable to provide useful 
information. Thus, only relative binding constants were determined by heparan sulfate 
displacement. The amount of heparan sulfate required to release DNA from the polyplexes 
should be related to the DNA binding constant of the displaced polymer. The heparan 
sulfate displacement studies (Fig. 3.9) reveal that BCDP6 has a significantly higher binding 
constant than the other BCDPs. The polymers synthesized from shorter comonomer Bs 
(BCDP4, BCDP5, and BCDP6) also seem to bind differently from BCDP7, BCDP8, and 
BCDPIO. The former set of polymers bound tightly to the DNA at low heparan sulfate 
concentrations but are mostly displaced from the DNA at a critical heparan sulfate 
concentration that increases with increasing distance between the charges. The latter 
polymers are slightly displaced from the DNA even at low heparan sulfate concentrations, 
with a higher intensity of free DNA visualized with increased heparan sulfate concentration. 
Therefore, the DNA binding characteristic of BCDP6 likely contributes to its gene delivery 
properties. 
The toxicity of the BCDPs also depends on comonomer B length. BCDP8 reveals 
no cell death under the tested transfection conditions while BCDP7 is only slightly toxic. 
Because the comonomer Bs for these polymers were synthesized in our lab while 
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comonomer Bs for ~CDP4, ~CDP5, and ~CDP6 were purchased from commercial 
sources, it is possible that an impurity in the commercial samples could be the origin of 
toxicity. The ~CDP6 was therefore synthesized from three different comonomer Bs: 
(i) purchased DMS, (ii) purchased and recrystallized DMS, and (iii) freshly synthesized in 
our labs DMS. The transfection and toxicity of the three ~CDP6s were very similar, thus 
confirming cell toxicity to be caused by the ~CDPs and not reaction impurities. 
Although no toxicity was detected for ~CDP8 at a charge ratio of 50 +/-, cell death 
was observed for the other ~CDPs at charge ratios above 20 +/- with the toxicity 
differences between the polymers becoming evident by 50 +/- (Fig. 3.7). At this high 
charge ratio, most of the polymer is free in solution and not bound to DNA. The noted 
toxicity is therefore probably due mostly to the free polymer in solution. The IC50s of 
~CDPs alone to BHK-21 cells were determined by the MTT assay. The trends in the IC50s 
for the ~CDPs correlated nicely with the toxicities detected at the 50 +/- transfection 
conditions (Fig. 3.8). Again, the IC50s cover nearly an order of magnitude range. The IC50s 
increase as the charge density decreases in going from ~CDP4 to ~CDP8. Additionally, as 
the comonomer B lengthens, the corresponding polymer becomes less soluble. Therefore, it 
is possible that the lower solubilities may contribute to the toxicity observed for ~CDPlO. 
If such is the case, then there is a trade-off between charge density and solubility and for the 
polymers investigated here, the ~CDP8 appears to be the optimal material with regard to 
toxicity. 
Wadhwa et al. (22) and Fisher et al. (8) reported reduced cytotoxicity for low molecular 
weight fractions of PLL and PEl, respectively. Although the ~CDPs presented here are low 
molecular weight polymers, we tested the cytotoxicity of a ~CDP capable of being further 
degraded in the cell. To this end, we synthesized a disulfide-containing ~CDP (~CDP­
Disulfide), as reported previously (13). 
~l~OLCO: H OH 0 HO~ HO J+ 
OH ~ H 2 
OH HO S~~&..S ~ 
HO 0 ~H2+ H ~H~ X 
~O 0 OH 
HO 
BCDP.Disulfide 
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The disulfide was incorporated in a comonomer of length 11.9 A between the 
charges; that is, 0.9A longer than BCDP6 but shorter than BCDP7. BCDP-Disulfide should 
be reduced to monomeric units in the cellular environment. The BCDP-Disulfide polymer 
was able to bind to DNA at the same charge ratio as the BCDP6 and transfect cells with 
efficiencies between those observed for BCDP6 and BCDP7. However, the toxicity of 
BCDP-Disulfide associated with these transfections was higher than BCDP6 toxicity (62% 
cell survival versus 70%). These results indicate that the BCDP toxicity will not be 
decreased further with a polymer that can be reduced to molecules within the cell. 
The idea behind the synthesis of the BCDPs was to ascertain whether polymers 
incorporating relatively nontoxic building units, i.e., cyclodextrins, could maintain the low 
toxicity of the cyclodextrin while simultaneously providing the properties necessary for 
gene delivery (13). The influence of cyc10dextrin incorporation in the polymer backbone 
was tested by comparing BCDP polymer behavior to those having methylene diamines as 
comonomer As rather than CD-dicysteamine. Because the non-cyclodextrin polymers were 
also synthesized by an A-B condensation, the degree of polymerization was comparable to 
those achieved for BCDPs (degree of polymerization of 5 for C6-C6 polyamidine and 8 for 
C9-C6 polyamidine). These polyamidine polymers are able to bind to plasmid DNA by 
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charge ratios of 1.5 +/-, form polyplexes with hydrodynamic diameters of -140 nm, and 
transfect cultured cells as well as the ~CDPs. However, their IC50s are 2-3 orders of 
magnitude lower than the IC50s for ~CDP8. These results indicate that cyclodextrin 
incoporation into the backbone of the cationic polymers greatly reduces the polymer 
toxicity. 
Based on the in vitro results, the ~CDP6 polymer was chosen for in vivo toxicity 
testing. This polymer gives the highest transfection efficiency with a reasonably high IC50. 
Groupings of five mice were injected intravenously with a single dose of ~CDP6 ranging 
from 2-200 mglkg. No toxicity was observed at 100 mglkg and the LD 40 was found to be 
200 mglkg. Previously, we have tested a disulfide-containing ~CDP for in vivo toxicity, and 
determined it to be well tolerated at 200 mglkg (13). However, the previous disulfide-
containing ~CDP displayed lower DNA binding affinity and transfection efficiency than the 
~CDP6. The in vivo toxicity parallels the in vitro studies in that increased charge density 
appears to yield higher toxicities. Thus, the in vivo toxicity limit should increase when the 
~CDP are complexed with DNA. 
Here, it is demonstrated that the structure of the ~CDPs critically determines 
performance in DNA delivery and cell toxicity. The difference of a few A in comonomer B 
length can affect transfection and polymer IC50 values by orders of magnitude. In addition, 
the incorporation of ~-cyclodextrin in the polymer backbone is shown to significantly 
decrease polymer toxicity. The low in vitro and in vivo toxicity of these ~CDPs make them 
promising and attractive agents for in vivo gene delivery applications. 
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Chapter 4 
Increased Transfection by Histidylation of a 
Cationic Cyclodextrin-based Polymer 
4.1. ABSTRACT 
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Cationic, cyclodextrin-based polymers (CDPs) are capable of efficient DNA 
delivery to cells but remain largely trapped in endosomal vesicles. The goal of this work 
is to synthesize a pH-sensitive CDP capable of enhancing endosomal escape. One 
approach to this problem is to attach a weak base to the polymer that has a sufficient pKa 
to allow for protonation under acidic conditions of the endosome in order to buffer the 
pH, thereby delaying the transition to lysosomes (subsequent degradation of endocytosed 
material). Histidine contains an imidazole group that is protonated below pH 6.0, and 
was conjugated to the amine endgroups of a CDP, ~CDP6, to form histidylated ~CDP6 
(Hist-CDP6). This polymer is capable of self-assembling with and condensing DNA, to 
form uniform, positively-charged particles above charge ratios of 2 +/-. The transfection 
efficiency of CDP6 is increased 20-fold by histidylation with no increase in cell toxicity. 
Visualization by confocal microscopy revealed greater intracellular accumulation of Hist-
CDP6-delivered DNA than CDP6-delivered DNA. Hist-CDP6 transfection in the 
presence of chloroquine revealed no synergistic effect. Therefore, Hist-CDP6 is capable 
of increasing transfection efficiency in cultured cells most likely by buffering the 
endosomal pH and delaying DNA degradation in lysosomes. 
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4.2. INTRODUCTION 
The potential of synthetic gene delivery systems to bypass the major limitations of 
viral vectors has spawned a rapidly growing field of research. In order to have efficient 
delivery ability, lipoplexes and polyplexes must be able to overcome cellular barriers: 
cell, endosome, and nuclear membranes. When formulated with a net positive charge, 
lipoplexes and polyplexes are readily taken into cells by interaction with cell surface 
glycoproteins and endocytosis (1,2). The attachment of a targeting ligand such as 
galactose or folate results in receptor-mediated uptake of complexes (3-7). Both methods 
result in internalization and accumulation of complexes into cellular vesicles. Unless 
released, these complexes are shuttled to lysosomes and rapidly degraded. 
FeIgner et al. quantitated the uptake of fluorescently labeled plasmids into 
cultured cells by cationic lipofection and found that only 2% of intracellular plasmids are 
found in the nucleus (8). In our lab, microscopy studies of fluorescently-Iabeled plasmids 
transfected by cationic cyclodextrin-based polymers (CDPs) reveal punctate staining 
indicative of endosomal trapping. Curiel et al. noted a 3 order of magnitude increase in 
reporter gene activity by including adenovirus in transferrin/poly(L)lysine (PLL) 
transfection media. Adenovirus mediate endosomal disruption and polyplex release (9). 
Clearly, endosomal release is a major limitation in non-viral delivery. 
Most polyplexes and lipoplexes are internalized by cells into vesicles that fuse 
with endosomes. As the endosomes mature from early endosomes to late endosomes, the 
pH of the vesicles rapidly drops due to ATP-dependent proton pumps in the membrane. 
Most endosomal material is then transferred to lysosomes and degraded by nucleases and 
proteases (10). Viruses escape from the endosome by taking advantage of this pH drop. 
For example, the adenovirus capsid undergoes a change in conformation at the acidic 
conditions, allowing escape of the virus into the cytoplasm (11). Some lipoplexes 
include in their formulation a pH-sensitive lipid such as DOPE, that causes the lipoplexes 
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to undergo a phase transition to hexagonal arrays at the low pH, and thus destabilizing the 
endosomal membrane for releasing DNA into the cytosol (12). Amphiphilic peptides that 
become fusogenic at acid conditions have been used to increase transfection efficiencies 
of cationic polymers (13-16). Cationic polymers such as polyethylenimine and pAMAM 
dendrimers contain multiple secondary amines with pKa - 6 (17,18). These secondary 
amines proton ate as the endosomal pH drops, thus buffering the pH and protecting 
endosome material from lysosomal degradation. In addition, it is hypothesized that 
influx of water into the endosome results in osmotic swelling and eventually rupture. 
The imidazole group in histidine also has a pKa around 6.0 and has been studied 
for its endosomal buffering abilities. Poly(L)histidine (PLH) initiates fusion of 
negatively-charge liposomes at acidic conditions (19,20). However, PLH is neutral at pH 
7.4 and does not bind to DNA at physiological conditions. Investigations with 
histidylated PLL reveal substantial increase in transfections over PLL (21,22). 
In this work, conjugation of histidine to a previously described cationic 
cyclodextrin-based polymer (~CDP6, (23) to produce a pH-sensitive derivative polymer 
is carried out. Here, it is shown that (i) the resulting polymer remains water soluble, (ii) 
it is able to bind and condense DNA, and (iii) the formed polyplexes transfect cultured 
cells more effectively than those made with the parent polymer. It is also demonstrated 
that the histidine moieties act as a buffer in the endosome to increase transfection 
efficiencies. 
4.3. MA TERIALS AND METHODS 
4.3.1. Polymer Synthesis. 
{3-cyclodextrin-DMS. /3-cyclodextrin-DMS (/3CDP6) was prepared by the polymerization 
of a difunctionalized /3-CD monomer (A) with a difunctionalized comonomer (B) to give 
an ABAB product as described previously (23). In brief, ~-CD dicysteamine (1.193 g, 
866 /-lmol) and dimethyl suberimidate (DMS, 866 /-lmol, Pierce, Rockford, Illinois) were 
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dissolved in 2.3 mL of 0.5 M Na2C03 and stirred overnight at room temperature. The pH 
of the resulting solution was brought below 5.0 by the addition of 1 M HCI and dialyzed 
extensively against dH20 in a MWCO 3500 dialysis membrane (Pierce) for 24 hours. 
The dialyzed solution was lyophilized to dryness to give 530 mg (38.4% yield). 
Synthesis of Histidylated {3CDP6 (Hist-CDP6). 0CDP6 (57.2 mg, 9.9 /lmol) was 
dissolved in 1.0 mL of 50 mM NaHC03 and reacted for 12 hours with a solution of 
FMOC-His(trt)-OH (123 mg, 200 /lmol, Novabiochem), DCC (40 mg, 200 /lmol, 
Aldrich) and I-HOBt (2.5 mg, 20 /lmol, Aldrich) dissolved in 4.0 mL THF. The solvent 
was removed in vacuo and the trityl protecting groups were cleaved by adding 
trifluoroacetic acidlwater/triisopropylsilane (95:2.5:2.5) and mixing for one hour at room 
temperature. The solvent was removed in vacuo and the residue was washed several 
times with ether before lyophilizing. The histidine conjugation was 70% (determined by 
TNBS assay to quantify the amount of unreacted polymer endgroups). The FMOC 
protecting groups were removed by adding 20% piperidine in DMF and stirring for 20 
minutes before removing the solvent under reduced pressure. The remaining solid was 
redissolved in water, centrifuged to remove the precipitated FMOC, dialyzed extensively, 
and lyophilized to yield 23.2 mg (40%). 
4.3.2. Polyplexes. 
Plasm ids and oligonucleotides. Plasmid pGL3-CV (Promega, Madison, WI), containing 
the luciferase gene under the control of the SV40 promoter, was amplified by Esherichia 
Coli and purified using Qiagen's Endotoxin-free Megaprep kit (Valencia, CA). 
Fluorescein-labeled oligonucleotides (FITC-oligos) of approximately 50 bases were used. 
Rhodamine-labeled plasmids were purchased from Gene Therapy Systems (San Diego, 
CA) and used as received. 
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Po lyp lex formation and characterization. Polyplexes were prepared by mixing an equal 
volume of ~CDP dissolved in dH20 with DNA (0.1 mg/mL in dH20) at the appropriate 
charge ratios. The size and charge of particles were determined by dynamic light 
scattering and zeta potential measurements, respectively. Two Ilg of plasmid DNA were 
complexed with polymer at various charge ratios and diluted with the addition of 1.2 mL 
dH20. Particle size and zeta potential were measured using a ZetaPals dynamic light 
scattering detector (Brookhaven Instruments Corporation, Holtsville, NY). 
4.3.3. Cells and Transfections. 
Cells and cell culture. BHK-21 cells were purchased from ATCC (Rockville, MD) and 
cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 
100 Ilg/mL streptomycin, and 0.25 Ilg/mL amphotericin in a humidified incubator 
operated at 37°C and 5% CO2, Media and supplements were purchased from Gibco 
BRL (Gaithersburg, MD). 
Luciferase transfections. BHK-21 cells were plated in 24-well plates at 50,000 cells/well 
and incubated for 24 hours at 37°C. Media was removed from the cells prior to 
transfection and cells washed with PBS. Optimem (200 ilL per well, Gibco BRL) was 
added to the polyplexes, which were prepared as described above, and the entire 
transfection solution was added to the cells for four hours. After four hours, 800 ilL of 
complete media was added to each well. Media was changed 24 hours after transfection 
and cells were lysed 48 hours after transfection to assay for luciferase activity and cell 
survival as described previously (23). 
Flow cytometry analysis. BHK-21 cells were plated in 6-well plates at 200,000 cells/well 
and incubated for 24 hours at 37 °e. 3 Ilg of rhodamine-labeled EGFP plasmid were 
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complexed with ~CDP6 or Hist-CDP6 at a 5 +/- charge ratio. Media was removed from 
the cells and cells washed with PBS. For transfection, one mL of Optimem was added to 
each polyplex solution and the entire solution transferred to the cells. The cells were 
incubated with the transfection mixture for four hours before another four mL of 
complete media was added to each well. 24 hours after transfection, the cells were 
collected by trypsinization and prepared for F ACs analysis. Cells were washed twice in 
wash buffer (Hank's Balanced Salt Solution containing DNase and MgCI2 ) and 
resuspended in 500 ilL FACS buffer (Hank's Balanced Salt Solution, 2.5 mg/mL bovine 
serum albumin, 10 Ilg/mL propidium iodide). FACS analysis was performed using a 
FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) and Cell Quest software. 
Confocal Microscopy. BHK-21 cells were plated on 22 mm glass coverslips in 6-well 
plates at 2 x 105 cells/well. Cells were maintained at 37°C for 24 hours before 
transfection. Transfection solutions were prepared by complexing 5 Ilg of FITC-oligos 
with ~CDP6 and Hist-CDP6 at charge ratios of 6, 8, and 10 +/-. To prepare the cells for 
transfection, media was removed from the cells and the cells were washed once with 
PBS. Serum-free media (Optimem, 1 mL,) was added to each transfection solution and 
the entire solution transferred to each well. The cells were incubated at 37°C for another 
four hours before adding 4 mL of complete media to each well and incubating for another 
20 hours at 37°C. After the incubation, the cells were rinsed twice with PBS and fixed 
with 4% p-formaldehyde for 10 minutes. The cells were washed three times with PBS 
and then stained with 20 JlM DiI (Molecular Probes, Eugene, Oregon) in 0.32 M sucrose 
for 10 minutes. The cells were washed twice with 0.32 M sucrose and once with PBS. 
Coverslips were then removed from the wells and mounted on glass slides with Prolong 
Antifade reagent (Molecular Probes). After drying, the slides were analyzed with a Zeiss 
310 Axiophot Upright confocal microscope (Caltech Biological Imaging Center) with 
488 nm fluorescein excitation and 543 nm DiI excitation. 
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4.4. RESUL TS 
4.4.1. Histidylated ~-cyclodextrin-DMS. The amine endgroups of ~CDP6 were 
substituted with protected histidine residues by DCC coupling with (FMOC)-His(Trt)-
OH. The trityl groups were removed after coupling and TNBS (reacts with primary 
amines) monitoring of the polymer endgroups revealed 70.0% conjugation. The a-amino 
groups of the histidine residues were then deprotected to obtain histidylated ~CDP6 
(Hist-CDP6, Fig 4.1). 
DCC, HOBt ~CDP6 + FMOC-Hist(Trt)-OH .-
DMF 
Figure 4.1. Synthesis of Hist-CDP6. 
TFA:H20:TIPS 
.. 
20 % Piperidine 
DMF 
4.4.2. Polyplex Formation. The ability of Hist-CDP6 to bind to and condense plasmid 
DNA was determined by monitoring particle size and charge. 2 Jlg of DNA in 20 JlL was 
mixed with an equal volume of solution containing Hist-CDP6 at various charge ratios. 
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The resulting solution was diluted for measurements. The hydrodynamic diameter was 
determined by dynamic light scattering and the particle mobility and charge assessed by 
zeta potential measurements (Fig 4.2). Neutral particles are formed at 2 +/- charge ratios, 
with corresponding diameters of 730 nm. These particles are not very stable and have 
gradually increasing diameters (evidenced by the larger S.D.). Stable particle sizes of 
around 200 nm in diameter were achieved above charge ratios of 4+/-. At this charge 
ratio, the particles have an average zeta potential of 27.3 m V. 
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Figure 4.2. Zeta potential and hydrodynamic diameter of Hist-CDP6 polyplexes. 
2 /-lg of plasmid DNA in 20 /-lL was mixed with an equal volume of Hist-CDP6 at various 
charge ratios. Zeta potential (solid line) and hydrodynamic diameter (dashed line) were 
determined by light scattering measurements. Results are presented as mean ± standard 
deviation of three measurements. 
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4.4.3. Transfection Ability of Hist-CDP6. The ability of polyplexes formed from Hist-
CDP6 to transfect cultured cells was determined by delivery of a luciferase reporter gene. 
BHK-21 cells were plated in 24-well plates and transfected with 1 /lg of pGL-CV3 
(plasmid containing the luciferase gene under the control of the SV 40 promoter) 
complexed with ~CDP6 or Hist-CDP6 at various charge ratios. The cells were lysed 48 
hours after transfection and analyzed for luciferase activity (results are reported in 
relative light units (RLUs) (Fig 4.3)). 
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Figure 4.3. Comparison of I3CDP6 and Hist-CDP6-mediated luciferase transfection 
to BHK-21 cells. 
1 Ilg of polymer was complexed with ~CDP (dashed line) or Hist-CDP6 (solid line) at 
various charge ratios and exposed to BHK-21 cells seeded in 24-well plates. 
Transfection efficiency was determined by assaying for luciferase protein activity and 
presented as relative light units. Results are presented as mean ± standard deviation of 
three assays. Background RLU=6 x 103. 
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While both polymers successfully deliver plasmid DNA to cells, Hist-CDP6 is 
able to transfect BHK-21 cells with higher efficiencies than the unmodified I3CDP6 at all 
charge ratios up to 50 +/-. The relative transfection efficiency between the two polymers 
is shown in Fig 4.4. Histidylation of I3CDP6 enhances transfection by over 20-fold below 
charge ratios of 30 +/- and by 2-fold at 30 and 40 +/-. 
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Figure 4.4. Relative transfection efficiencies of Hist-CDP6 to I3CDP6 at various 
charge ratios. 
BHk-21 cells were transfected with the luciferase plasmid complexed with Hist-CDP6 or 
I3CDP6 at various charge ratios. Luciferase protein activity was measured in relative 
light units in triplicate assays. Relative transfection efficiency was calculated by dividing 
average Hist-CDP6 RLU by average I3CDP6 RLU measured at each charge ratio. 
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4.4.4. Plasmid Delivery by Hist-CDP6. The plasmid cellular uptake by Hist-CDP6-
based polyplexes was determined by flow cytometry. BHK-21 cells were exposed for 24 
hours to rhodamine-labeled plasmids complexed with Hist-CDP6 or ~CDP6 at a charge 
ratios of 5+/-. DNA uptake levels for individual cells were then determined by recording 
the rhodamine fluorescence intensity in each cell. The rhodamine fluorescence profiles 
are presented in Fig 4.5. The instrument parameters were set such that the background 
rhodamine fluorescence of all BHK-21 cells resides in the first decile (Fig 4.5a) The 
fluorescence profiles of ~CDP6 (Fig 4.5b) and Hist-CDP6 (Fig 4.5c) transfected cells are 
nearly identical; only 35.6% of the ~CDP6-transfected cells and 36.1 % of the Hist-CDP6 
transfected cells remain in the first decile, indicating -65% plasmid uptake (lower bound 
estimate due to the low rhodamine fluorescence intensity and conservative gate setting 
during flow cytometry analysis). 
4.4.5. Intracellular Distribution of Hist-CDP6-delivered Oligos. The intracellular 
distribution of DNA due to Hist-CDP6-mediated delivery was visualized by confocal 
microscopy. BHK-21 cells were plated onto glass coverslips in 6-well plates and 
transfected with 5 J,.lg of FITC-Oligo complexed with ~CDP6 or Hist-CDP6. The cells 
were incubated with polyplexes for 24 hours before fixing and staining with DiI. 
Transfected cells showed punctate fluorescein fluorescence indicative of vesicular 
staining (Fig 4.6). FITC-Oligocomplexed with Hist-CDP6 was delivered to over 95% of 
BHK-21 cells, even at the 6 +/- charge ratio. Cells transfected with Hist-CDP6 
polyplexes exhibited stronger fluorescence than CDP6-transfected cells at all charge 
ratios tested, indicating either higher polyplex uptake or reduced fluorescence quenching 
at the lower late endosomal pH. Images recorded at higher magnification confirmed 
stronger punctate fluorescence in Hist-CDP6 transfected cells (Fig 4.7). In addition, 
these cells showed cytosolic delivery, as indicated by the orange color due to the overlay 
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Figure 4.5. Rhodamine-labeled plasmid uptake mediated by BCDP6 and Hist-CDP6. 
Rhodamine labeled plasmids complexed with /3CDP6 (Fig 5b) or Hist-CDP6 (Fig 5c) at 
5+/- were delivered to BHK-21 cells. The amount of DNA uptake was determined by 
FACS. The fluorescence distribution is plotted with number of cell counts on the y-axis 
and fluorescence intensity on the x-axis. 
~CDP6 Hist-CDP6 
Figure 4. 6. Transfection of fluorescein-labeled oligos to BHK-21 cells with ~CDP6 and Hist-CDP6. 
BHK-21 cells were transfected with FITC-Oligos complexed with ~CDP6 and Hist-CDP6 at various 
charge ratios and visualized by confocal microsopy. Cells on the left were transfected with ~CDP6 and 
cells on the right with Hist-CDP6. 
Figure 7a. ~CDP6-transfected cells 
Figure 7b. Hist-CDP6-transfected cells 
Figure 4.7. Confocal images of BHK-21 cells transfected with fluorescently labeled oligos 
complexed with ~CDP6 and Hist-CDP6 at 10 +/-. 
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of cellular staining in red with the FITC Oligo staining in green. No cytosolic delivery 
was observed for cells transfected with CDP6 polyplexes. Nuclear localization was not 
observed for transfection with either polymer. 
4.4.6. Transfections in the Presence of Chloroquine. BHK-21 cells were transfected 
with a plasmid containing the luciferase gene complexed with ~CDP6 or Hist-CDP6 in 
the presence of 25 JlM chloroquine, an endosomal buffering agent. Because chloroquine 
is toxic to cells (35% cell survival in the presence of chloroquine), luciferase protein 
activity, typically measured in RLUs, was normalized with total cellular protein levels. 
The relative transfection efficiencies were calculated by dividing the normalized RLUs of 
each sample by the normalized RLUs measured for ~CDP6-based transfections in the 
absence of chloroquine. The effect of chloroquine on transfections is reported in Fig 4.8. 
Chloroquine addition increases transfection efficiency by nearly two orders of magnitude 
over ~CDP6-mediated transfections. The presence of chloroquine further increases Hist-
CDP6 transfection efficiencies by 3-fold. However, the combination of Hist-CDP6 
transfection and chloroquine does not enhance transfection efficiencies over the use of 
chloroquine alone. 
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Figure 4.8. Effect of chloroquine on BCDP6 and Hist-CDP6-rnediated transfections. 
BHK-21 cells were transfected with BCDP6 and Hist-CDP6 in the presence of 25 J,lM 
chloroquine Transfection efficiency was determined in RLU/mg total protein with 
luciferase protein activity measured in RLU and total cellular protein determined by 
Lowry's protein assay. Results are normalized with RLU/mg of BCDP6 transfections 
and presented as the average of two assays. 
4.5. DISCUSSION 
The desired endpoint for therapeutic plasmid delivery is the cell nucleus. 
Cationic CDP-based polyplexes are efficiently endocytosed into acidic compartments by 
cells but remain largely trapped there. Here, Hist-CDP6 was prepared in an attempt to 
overcome this problem. Histidine, a pH-sensitive moiety, was conjugated to the amine 
termini of BCDP6 by peptide-bond formation chemistry. 70% of polymer endgroups 
were reacted, corresponding to a polymer charge increase of 15% below pH 6.0 due to 
histidine protonation. At pH 7.4, most of the histidine groups are neutral. Therefore, 
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while BCDP6 is completely soluble even at 50 mg/mL, Hist-CDP6 precipitates from 
solutions prepared at 10 mg/mL. 
Benns et al. (24) report that polyhistidylated PLL binds DNA less effectively than 
PLL, requiring 20 times as much polymer to condense DNA to the same particle size. 
However, Hist-CDP6 is able to bind and condense plasmid DNA as with the same 
particle diameter profile as BCDP6 (Fig 4.2). Stable particles are formed above 3 +/-
charge ratios and exhibit the same physicochemical characteristics as BCDP6 polyplexes. 
These particles are positively charged (zeta potential - +25 mY), uniform in size (-200 
nm in diameter) and are able to transfect cultured cells. 
Hist-CDP6 polyplexes are able to transfect cells more efficiently than BCDP6 
polypI exes without showing any difference in toxicity. Free histidine in solution does not 
improve transfection efficiency, probably because it is not taken into the endosome at 
sufficient concentrations. Hist-CDP6-mediated transfection of a luciferase plasmid 
results in 20-fold higher luciferase activity than transfection with BCDP6 (Fig 4.3). It 
should be noted that Midoux et al. report a four orders of magnitude increase in luciferase 
activity with histidylated PLL over PLL (21). However, BCDP6 itself is able to deliver 
the luciferase plasmid to cultured cells with higher efficiency than PLL. Luciferase 
activity of BHK-21 cells transfected with BCDP6/pGL-CV3 polyplexes is three orders of 
magnitude higher than activity of PLLlpGL-CV3 transfected cells (data not shown). 
There are several possible explanations for increased transfection efficiency with 
Hist-CDP6: (i) cells may uptake Hist-CDP6 particles more readily than CDP6 particles. 
(ii) Hist-CDP6 may offer pH-buffering abilities in the endosomes (because the imidazole 
in the histidine has a pKa of 6.0, thereby reducing DNA degradation and delivery to 
lysosomes, (iii) Hist-CDP6 may aid in membrane destabilization and endosomal release, 
and (iv) Hist-CDP6 may assist in nuclear trafficking of the delivered DNA. In order to 
assess these possibilities, transfections were conducted with fluorescentlly labeled DNA 
and in the presence of chloroquine. 
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Delivery of rhodamine labeled plasmid revealed no difference in DNA uptake 
between Hist-CDP6 and ~CDP6 polyplexes (Fig 4.5). Plasmids were delivered to -65% 
of cells with both polymers. Therefore, Hist-CDP6 does not improve transfection 
efficiency by increasing DNA uptake. Next, the intracellular localization of ~CDP6 and 
Hist-CDP6-delivered oligos (labeled with fluorescein) was visualized by confocal 
microscopy (Figs 4.6 and 4.7). Cells transfected with Hist-CDP6 show much stronger 
fluorescence in larger vesicles. Because there is no difference in DNA uptake between 
the two polymers, the increase in fluorescence is likely due to greater DNA accumulation 
and lack of fluorescein quenching at low pH as a result of endosomal buffering. 
Polypi exes are taken up into vesicles that fuse with early endosomes. These endosomes 
acidify and mature into late endosomes and finally fuse with lysosomes. Histidine, with 
its imidazole pK of 6.0, is likely to affect the acidification of endosomes. Endosomal 
buffering is known to delay the transition of endosomes to lysosomes and allows for 
greater polyplex accumulation. 
In addition, fluorescein fluorescence is strongly quenched below pH 6.5. 
Buffering the endosomal pH prevents the fluorescence quenching that occurs with 
~CDP6 delivery. The overlaying fluorescence intensity profiles (as determined by flow 
cytometry, Fig 4.5) of BHK-21 cells transfected with ~CDP6/Rhod-DNA and Hist-
CDP6IRhod-DNA indicates that polypi ex uptake is the same for ~CDP6 and Hist-CDP6. 
Therefore, the lower fluorescence observed by confocal microscopy in ~CDP6IFITC­
Oligo transfected cells (Fig 4.6 and 4.7) is likely due to fluorescence quenching of FITC-
Oligo in the endosomes. In contrast, Hist-CDP6, with its buffering capacity, may prevent 
endosomal acidification and subsequent fluorescence quenching. Thus, because polyplex 
uptake is the same for both polymers, the higher fluorescence intensity in Hist-CDP6 
transfected cells suggests successful endosomal buffering by the histidine imidazole 
groups. In addition, Pichon et al. (22) also noticed a large difference in fluorescence 
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intensity for fluorescein-labeled oligos delivered with histidylated-oligolysines versus 
histidine-free oligolysine. 
Despite the greater accumulation of oligos in Hist-CDP6-transfected cells, neither 
polymer appears to assist significantly in endosomal escape. Hist-CDP6-transfected cells 
demonstrate slightly increased cytosolic delivery, as evidenced directly by the low 
intensity of fluorescein fluorescence in cell cytosol and indirectly by the higher luciferase 
expression described previously. However, because fluorescence is mostly observed in 
punctate vesicular areas, endosomal escape is likely a sporadic event that occurs in higher 
incidence in Hist-CDP6-transfected cells due to the large accumulation of material in the 
endosome. In addition, neither BCDP6 nor Hist-CDP6-transfected cells show significant 
nuclear localization of oligos. Therefore, based on flow cytometry and confocal 
microscopy, Hist-CDP6 increases transfection efficiency by introducing a buffering 
capacity in the endosomal vesicles. Increased cellular uptake due to histidylation is not 
observed, nor is increased delivery to the nucleus. Although polyhistidine is known to 
destabilize membranes at pH < 6.5 «(19,20), the conjugation of monohistidine to BCDP6 
is not enough to impart fusogenic properties to the polymer. 
Luciferase transfections with the CDPs were also conducted in the presence of 
chloroquine. Chloroquine (a weakly basic molecule) is known to enhance transfection by 
raising the pH of endocytotic vesicles, reducing lysosomal degradation, protecting DNA 
from nuclease degradation, and aiding in the dissociation of DNA from cationic polymers 
«(25). The presence of 25 ~M chloroquine in the transfection media increased the 
efficiency of both f3CDP6 and Hist-CDP6 transfection by -70-fold over the f3CDP6 
transfection alone. Hist-CDP6 transfection efficiency is further increased by over 3-fold 
in the presence of chloroquine. Therefore, the buffering capability of Hist-CDP6 is not 
optimal; further improvements are possible with chloroquine. Also, the use of histidine 
in conjunction with chloroquine results in no synergistic effects. Histidine and 
chloroquine are both able to prevent lysosomal degradation by endosomal buffering. 
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However, because chloroquine freely passes the cell membrane and accumulates in the 
endosome, it may be present at a higher concentration and have a stronger buffering 
effect that results in the higher transfection efficiencies. 
In conclusion, the conjugation of histidine to f3CDP6 results in a polymer with 
improved transfection abilities. Hist-CDP6 increases transfection by buffering the pH 
drop in the endosome that protects the DNA from degradation and allows for greater 
more opportunities for endosomal escape. Because Hist-CDP6 does not actively mediate 
endosomal escape, the possibility of incorporating fusogenic peptides into the CDP 
polyplexes is currently being pursued. Nonetheless, the ability of Hist-CDP6 to 
efficiently transfect cells at low charge ratios make it a promising in vivo delivery agent. 
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Chapter 5 
Modification of ~-Cyclodextrin Polymer-based Polyplexes by 
Cyclodextrin-Adamantane Inclusion Complex Formation 
5.1. ABSTRACT 
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Most polymeric gene delivery systems developed for in vitro applications require 
alteractions before they can be applied in in vivo settings. Modification of polymers by 
direct grafting of secondary components may interfere with polymerlDNA binding 
interactions; this is a particular problem for short polymers such as linear, ~-cyclodextrin 
polymers (~CDPs) that have intrinsically lower DNA binding contants. Here, ~CDP-
based polyplexes are modified by taking advantage of the ability of cyclodextrin 
molecules to form inclusion compounds with hydrophobic guest molecules. An anionic 
peptide (GALA) is conjugated to adamantane, a molecule that has a high cyclodextrin 
association constant. The resulting GALA-adamantane (GALA-Ad) peptide associates 
with the ~CDP-based polyplexes without disrupting polymerlDNA interactions. While 
unmodified polyplex particles and 100% GALA-modified polyplexes prepared at 5 +1-
have zeta potentials of +13 mV and -15 mY, respectively, 100% GALA-Ad modified 
polyplexes has a zeta potential of -43 mY. GALA-Ad modification of polyplexes 
inhibits DNA uptake in cultured cells and reporter gene expression, while GALA 
addition results in minimal changes in polyplex transfection. Modification of ~CDP-
based polypI exes by cyclodextrin/adamantane association provides a new method of 
grafting desired entities to preformed polyplexes without disruption of polymerlDNA 
interactions. 
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5.2 INTRODUCTION 
Cationic polymers are routinely used as transfection reagents for DNA delivery to 
cultured cells (1-3). These polycations are able to self-assemble with and condense DNA 
to small particles called polyplexes (4). When formulated with a net positive charge, 
polyplexes bind to cell surfaces and are internalized (5). Despite laboratory success with 
polyplexes, there are to date no cationic polymers used in human trials for gene delivery. 
Cationic polymers are often highly toxic to cells. In addition, polyplex formulation 
optimized for in vitro delivery is typically not amenable for in vivo use as successful in 
vivo systemic delivery requires very different particle characteristics. First, cationic 
polypi exes interact with serum proteins and are quickly eliminated from the bloodstream 
by phagocytic cells after intravenous injection (6,7). Also, these polyplexes are unstable 
at physiological salt conditions, resulting in rapid aggregation. Finally, the polyplexes 
normally need to be directed to specific cells in the body and cationic polyplexes are 
known to be captured by the first tissue they encounter, e.g., with i.v. injection, the lungs. 
Therefore, cationic polyplexes need to be modified before they can be applied for in vivo 
gene delivery. 
Most polymers investigated thus far are cationic in order to facilitate the binding 
to DNA. The charge normally is derived from amine groups on the polymer. Therefore, 
one possible way of modifying the polymers is to modify the polymer amine groups. 
This method has been used for pegylating polyethylenimine (PEl) and poly(L)lysine 
(PLL) to impart steric stabilization to particles formed with these polymers (8,9). In 
doing so, the charge density associated with the primary amines is reduced. This method 
does not work well for short polymers that have lower DNA binding constants, i.e., the 
polymer-DNA interactions are disrupted. 
A family of ~-cyclodextrin-containing polymers (~CDPs) suitable for DNA 
delivery has been described (10). These polymers contain ~-cyclodextrin in the polymer 
backbone and are cationic due to repeating amidine groups. [3CDP6-based polyplexes 
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show low in vitro toxicity and are therefore promising in vivo agents; however, they also 
suffer from the limitations mentioned above. Because the I3CDPs are amine-terminated, 
these polymers were initially modified by coupling to the polymer endgroups segments of 
PEG. However, the I3CDPs are, on average, 5-mers and modification of the polymer 
even with small molecules can disrupt DNA binding. Thus, a different method of 
polyplex modification must be developed for I3CDPs. 
Cyclodextrins are capable of forming inclusion compounds with hydrophobic 
moieties (Fig 5.1). For some molecules, this association can be quite strong. For 
example, adamantane derivatives have ~-cyclodextrin association constants (KJ on the 
order of 104-105 (11,12). Here, I make use of this cyclodextrin/hydrophobic compound 
complexation as a method for modifying ~CDP-based polyplexes. The hypothesis is that 
utilizing the cyclodextrin cups for modification would cause minimum disturbance to 
pre-formed polyplexes. The ~CDPs bind to DNA via electrostatic interactions of the 
cationic amidine groups on the ~CDP and the anionic phosphate groups on the DNA. 
The cyclodextrin cups should therefore be available on the polyplex surface for 
complexation. 
+ 
Adamantane I3-Cyclodextrin Inclusion Complex 
Figure 5.1. Schematic illustration of inclusion complexation of adamantane with 13-
cyciodextrin. Adamantane displaces associated water molecules from the hydrophobic 
cylodextrin cavity to form the inclusion complex. 
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To test the hypothesis listed above, adamantane was selected as the hydrophobic 
complexation agent because it has a high binding constant with B-cyclodextrin (104-105). 
GALA, a highly anionic peptide, was used as the modifying agent. The anionic nature of 
the peptide allows for monitoring of polyplex modification by zeta potential 
measurements. In addition, GALA is a water-soluble peptide that becomes fusogenic at 
low pH ( 13,14). GALA has been shown to enhance transfection efficiencies, possibly by 
acting as an endosomal disrupting agent at low pH (15). Therefore, GALA modification 
may also be useful for increasing transfection efficiencies. Here, it is shown that 
adamantane-conjugated GALA (GALA-Ad) successfully modifies BCDP6-based 
polyplexes without disrupting polymerlDNA binding. Modification of the polypI exes 
results in highly anionic particles with inhibited cellular uptake. 
5.3. MA TERIALS AND METHODS 
5.3.1. Polymer and Peptide Preparation 
{3-cyclodextrin-DMS copolymer ((3CDP6) preparation. BCDP6 was synthesized 
according to previously described procedures (10). In brief, B-CD dicysteamine and an 
equimolar amount of dimethyl suberimidate (DMS, Pierce, Rockford, Illinois) were 
dissolved in 0.5 M Na2C03 and stirred overnight at room temperature. The pH of the 
resulting solution was brought below 5.0 by the addition of 1 M HCl and dialyzed 
extensively against dH20 in a MWCO 3500 dialysis membrane (Pierce) for 24 hours. 
The dialyzed solution was lyophilized to dryness to yield a white, fluffy solid, with 
typical yields around 25-30%. 
Peptide synthesis. The GALA peptide (sequence: W-E-A-A-L-A-E-A-L-A-E-A-L-A-E-
H-L-A-E-A-L-A-E-A-L-E-A-L-A-A, MW 3032) was synthesized by the Biopolymer 
Synthesis Facility (Beckman Institute, California Institute of Technology) using an 
automatic synthesizer. Before cleaving the peptide from the resin, one-third of the resin 
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was set aside for adamantane conjugation. Analysis of the peptide by HPLC indicated 
greater than 95% purity. 1-Adamantane-carboxylic acid (Aldrich) was conjugated to the 
N-terminal end of the GALA-peptide with DCC coupling chemistry. The resulting 
peptide (GALA-Ad, MW 3194) was cleaved from the resin. Analysis of the peptide by 
HPLC indicated greater than 90% purity. The identities of the peptides were confirmed 
by MALDI-TOF analysis (Biopolymer Analysis Facility, Beckman Institute, California 
Institute of Technology). 
5.3.2. Polyplexes and Modifications with GALA Peptide 
Plasm ids and oligonucleotides. Plasmid pGL3-CV (Promega, Madison, WI), containing 
the luciferase gene under the control of the SV 40 promoter, was amplified by Esherichia 
Coli and purified using Qiagen's Endotoxin-free Megaprep kit (Valencia, CA). 
Fluorescein-labeled oligonucleotides (FITC-oligos, 25-mer, 5' -FITC-ACT GCT TAC 
CAG GGA TTTCAG TGC A-3') were synthesized by the Biopolymer Synthesis Facility 
(California Institute of Technology). 
Particle formation and characterization. Polyplexes were prepared by mixing an equal 
volume of ~CDP6 dissolved in dH20 with DNA (0.1 mg/mL in dH20) at the appropriate 
charge ratios. The same volume of GALA or GALA-Ad dissolved in 50 mM phosphate 
buffered saline (PBS, pH 7.2) was then added to the complexes. For example, with 
particle characterization studies, 2 )lg of plasmid DNA (20 IlL) were complexed with 
j3CDP6 (20 )lL) at a 5+/- charge ratio. 20)lL of GALA solution, GALA-Ad solution or 
50 mM PBS (for control samples) were then added to the complexes. The solution was 
then diluted with the addition of l.2 mL dH20. The size and charge of particles were 
determined by dynamic light scattering and zeta potential measurements, respectively, 
using a ZetaPals dynamic light scattering detector (Brookhaven Instruments Corporation, 
Holtsville, NY). 
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5.3.3. Cells and Transfections. 
Cell Culture. BHK-21 cells were purchased from ATCC (Rockville, MD) and HUH-7 
cells were generously donated by Valigen (Newtown, PA). Both cell lines were cultured 
in DMEM supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 
J,!g/mL streptomycin, and 0.25 J,!g/mL amphotericin in a humidified incubator operated at 
37°C and 5% CO2 and passaged every 4-5 days. Media and supplements were purchased 
from Gibco BRL (Gaithersburg, MD). 
Polyplex uptake by cultured cells. BHK-21 cells were plated in 6-well plates at 150,000 
cells/well and incubated for 24 hours at 37°C. 5 J,!g of FITC-oligo were complexed with 
j3CDP6 at a 5 +1- charge ratio. After a 5 minute complexation time, 50 J,!L of GALA or 
GALA-Ad in 50 ruM of PBS (pH 7.2) were added to the complexes. Media was removed 
from the cells and cells washed with PBS. For transfection, 900 J,!L of Optimem were 
added to each polyplex solution and the entire solution transferred to the cells. The cells 
were incubated with the transfection mixture for five hours before removing the media 
and washing the cells twice with PBS. The cells were collected by trypsinization and 
prepared for FACs analysis. Cells were washed twice in wash buffer (Hank's Balanced 
Salt Solution containing DNase and MgCI2) and resuspended in 500 J,!L FACS buffer 
(Hank's Balanced Salt Solution, 2.5 mg/mL bovine serum albumin, 10 J,!g/mL propidium 
iodide). FACS analysis was performed using a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA) and Cell Quest software. 
Luciferase Transfection and Toxicity. BHK-21 cells were plated in 24-well plates at 
50,000 cells/well and incubated for 24 hours at 37°C. 3 J,!g of pGL3-CV plasmid were 
complexed with j3CDP6 at 5+1- charge ratio. 30 J,!L of Gala or Gala-Ad in 50 mM PBS, 
pH 7.2 were then added to the complexes. Media was removed from the cells prior to 
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transfection and cells washed with PBS. 600 ~L of Optimem were added to each 
polyplex solution and 230 ~L transfection solution of this transfection solution were 
added to each of 3 wells for four hours. After four hours, 800 ilL of complete media 
were added to each well. Media was changed 24 hours after transfection and cells were 
lysed in 50 ~L of Cell Culture Lysis Buffer (Promega, Madison, WI) 48 hours after 
transfection. Luciferase activity was analyzed using Promega's luciferase assay reagent 
and cell survival was measured by determining total cellular protein with Biorad's DC 
protein assay (Hercules, CA) as described previously (10). 
5.4. RESULTS 
5.4.1. Particle Size of Modified Complexes. The hydrodynamic diameter of 
BCDP6/pGL3-CV polyplexes prepared at 5+/- was measured by dynamic light scattering 
and found to be 260 nm. The GALA peptide undergoes a transition from a water-soluble 
random coil conformation at pH 7.5 to a water-insoluble helix at pH 5 (14). Therefore, 
the GALA and adamantane-modified GALA (GALA-Ad) peptides were dissolved in 50 
mM PBS (pH 7.2) and added to the polyplexes at various peptide/cyclodextrin ratios. The 
amount of peptide added is reported as mol/mol of GALA peptide to cyclodextrin. The 
mixture was diluted with dH20 and particle sizes determined by dynamic light scattering 
(Fig 5.2). Because the particle count rate remains the same for all concentrations of 
peptide added, the addition of peptide does not appear to disrupt the polyplexes. The 
particle size profiles as a function of GALA and GALA-Ad addition are very similar. 
The hydrodynamic diameter increases from 250 nm (1 % GALA or GALA-Ad) to 400 nm 
(10% GALA or GALA-Ad). As more peptide is added, the particle size again decreases 
to that of the unmodified polyplex. The diameter returns to around 250 nm with the 
addition of 30% or more GALA-Ad and 50% or more GALA. 
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Figure 5.2. Hydrodynamic diameter of GALA (dashed line) and GALA-Ad (solid 
line)-modified polyplexes. 
2 IJ.g of plasmid DNA in 20 IJ.L were mixed with an equal volume of ~CDP6 at 5+/-. 
Various ratios of GALA or GALA-Ad were then added to the particles. Hydrodynamic 
diameter was determined by light scattering measurements. Results are presented as 
mean ± standard deviation of three measurements. 
5.4.2. Zeta Potential of Modified Complexes. The particle charge of ~CDP6/pGL3-
CY polyplexes at 5+/- was determined by zeta potential measurements and found to be 
+13 mV. GALA or GALA-Ad was added to polyplexes at various peptide/cyclodextrin 
ratios before dilution with dH20. The zeta potential of the particles in the presence of the 
peptides was determined and shown in Fig 5.3. 
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Figure 5.3. Zeta potential of GALA (dashed line) and GALA-Ad (solid line)-
modified polyplexes. 
2 J.!g of plasmid DNA in 20 J.!L were mixed with an equal volume of f)CDP6 at 5+/-. 
Various ratios of GALA or GALA-Ad were then added to the particles. Particle charge 
was determined by electrophoretic mobility measurements and presented as particle zeta 
potential in mY. Results are presented as mean ± standard deviation of three 
measurements. 
Because the GALA peptide is an anionic peptide at pH 7.2 (contains several glutamic 
acid residues), the association of GALA and GALA-Ad with the polypI exes decreases 
their zeta potential. The polyplexes become negatively charged by 30% GALA (-11 mY) 
or GALA-Ad (-23 m V). The zeta potential of GALA + polyplex solutions plateaus at 
this point; adding more GALA only increases the zeta potential slightly (-15 mV at 150% 
GALA). However, the particles become more negatively charged with higher GALA-Ad 
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concentrations. Polyplexes with the addition of 150% GALA-Ad have zeta potentials of 
-42 mY. 
5.4.3. DNA Delivery Efficiency of Modified Complexes. The DNA delivery 
efficiency of GALA and GALA-Ad modified polyplexes was determined by flow 
cytometry. BHK-21 cells were exposed for 5 hours to fluorescein-labeled oligos (FITC-
Oligos) complexed with ~CDP6 at 5+/- and modified with 50% GALA or GALA-Ad. 
DNA uptake levels for individual cells were then determined by recording the fluorescein 
fluorescence intensity in each cell. The fluorescence profiles are presented in Fig 5.4. 
The parameters of the instrument were set such that the background fluorescein 
fluorescence of all BHK-21 cells resides in the first decile (Fig 5.4a). ~CDP6-transfected 
cells show over 99% DNA uptake with average fluorescence levels around 103 (Fig 5.4b). 
Over 99% of cells exposed to ~CDP6IFITC-Oligo/50% GALA also uptake FITC-Oligo 
with average fluorescence around 103 (Fig 5.4c). However, these cells have a broader 
fluorescence distribution than the cells transfected with ~CDP6 alone. 80% of cells 
exposed to ~CDP6IFITC-Oligo/50% GALA-Ad uptake the polyplexes. In addition, the 
mean fluorescence of BHK-21 cells transfected with ~CDP6IFITC-Oligo/50% GALA-Ad 
is 2 orders of magnitude lower than ~CDP6 and ~CDP6IFITC-Oligo/50% GALA 
-transfected cells (Fig 5.4d). 
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Fig 5.4d. BHK-21 cells transfected 
with !3CDP6IFITC-Oligo/500/0GALA-Ad 
Fig 5.4. Uptake of GALA-Ad and GALA modified polyplexes by BHK-21 cells. 
BHK-21 cells (4a) were transfected with !3CDP6/FITC-Oligo (4b), !3CDP6IFITC-
Oligo/50%GALA (4c) and !3CDP6IFITC-Oligo/50%GALA-Ad (4d). Polyplex uptake 
was determined by flow cytometry analysis. Data is presented as fluorescence profiles, 
with cell count number plotted along the y-axis and fluorescein fluorescence intensity 
plotted along the x-axis. 
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A hepatoma cell line, HUH-7, was also transfected with ~CDP6IFITC-Oligo at 5 
+/- and ~CDP6IFITC Oligo/50% GALA-Ad polyplexes. DNA uptake was monitored as 
described for BHK-21 cells. The fluorescence profile for untransfected HUH-7 cells lies 
in the first decile (Fig 5.5a). FITC-Oligo was successfully delivered to 95% of HUH-7 
cells with ~CDP6 (Fig 5.5b). The addition of 50% GALA-Ad to the polyplexes inhibits 
FITC-Oligo uptake by two orders of magnitude, as observed with the BHK-21 cells (Fig 
5.5c). 
5.4.4. Transfection Efficiency of Modified Complexes. The transfection ability of 
GALA and GALA-Ad modified polyplexes was determined by delivery of a luciferase 
reporter gene to cultured cells. BHK-21 cells were plated in 24-well plates and 
transfected with 1 Ilg of pGL-CV3 (a plasmid that contains the luciferase gene) 
complexed with ~CDP6 at a charge ratio of 5+/-. These complexes were modified with 
the addition of GALA or GALA-Ad at various peptide/cyclodextrin ratios. The cells 
were lysed 48 hours after transfection and analyzed for luciferase activity , with results 
reported in relative light units (RLUs) (Fig 5.6). 
Cells were successfully transfected with ~CDP6/pGL-CV3 polyplexes, with 
RLUs - 1 x 105. The addition of GALA did not have a large effect on transfection 
efficiency; however, polyplex modification with GALA-Ad greatly inhibited transfection. 
The addition of 1 % GALA increased transfection by two-fold to 2 x 105 RLU, and 
I3CDP6/pGL-CV3/10 % GALA also resulted in slightly higher transfections (1.5 x 105 
RLU). The addition of 100% GALA decreased transfection by 50% to 5 x 104 RLU 
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Fig S.Sc. HUH-7 transfected with j3CDP6IFITC-Oligo/SO% GALA-Ad. 
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Figure S.5. Uptake of GALA-Ad and GALA modified polyplexes by HUH-7 cells. 
HUH-7 cells (5a) were transfected with f3CDP6/PITC-Oligo (5b) f3CDP6/PITC-
Oligo/50%GALA-Ad (5c). Polyplex uptake was determined by flow cytometry analysis. 
Data is presented as fluorescence profiles, with cell count number plotted along the y-axis 
and fluorescein fluorescence intensity plotted along the x-axis. 
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Figure 5.6. Luciferase transfection of BHK-21 cells with ~CDP-based polyplexes 
modified with GALA (shaded bars) and GALA-Ad (white bars). 
BHK-21 cells were transfected with ~CDP6/pGL-CV3 (at S+/-) in the presence of 
various ratios of GALA and GALA-Ad. Transfection efficiency was determined by 
monitoring for luciferase activity and is reported in RLU. Data are reported as the mean 
±SD of three samples. Background =300 RLU. 
The addition of 1 % GALA-Ad to ~CDP6/pGL-CV3 polyplexes also increased 
transfection (1.S x 105 RLU). Increasing the GALA-Ad/cyclodextrin ratio further results 
in transfection inhibition. ~CDP6/pGL-CV31l0% GALA-Ad decreases transfection by 
114 to 2.S x 104 RLU. ~CDP6/pGL-CV31l00% GALA-Ad eliminates nearly all 
transfection, with RLUs decreased by three orders of magnitude (SOO RLU, background 
is 300 RLU). 
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5.4.5. Toxicity of Modified Complexes. The toxicity of GALA and GALA-Ad 
modified polyplexes was determined by measuring the protein concentrations of the cell 
lyates obtained in the transfection experiments. The protein concentrations of three 
replicates were averaged and divided by the average protein concentration of cells 
transfected with f)CDP6/pGL-CV3 polyplexes alone and reported as fraction cell survival 
(Fig 5.7). The addition of GALA and GALA-Ad to the transfection solution resulted in 
no observable toxicity to BHK-21 cells. 
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Figure 5.7. Toxicity of GALA and GALA-Ad modified polyplexes to BHK-21 cells. 
BHK-21 cells were transfected with 1 ~g of pGL-CV3 complexed with bCDP6 at 5+/-. 
Prior to transfection, various ratios of GALA and GALA-Ad were added to the 
complexes. Cell survival for transfections in the presence of GALA (solid bars) and 
GALA-Ad (white bars) was determined by assaying for total protein concentrations 48 
hours after transfection and normalizing each sample with protein levels for untransfected 
cells. Data are reported as the mean ±SD of three samples. 
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5.5. DISCUSSION 
The need exists for a method of modifying polymerlDNA particles for in vivo use 
after complexation without disrupting the polymerlDNA interactions that would result in 
a change in polyplex size. Cationic, cyclodextrin-based polymers have been used as 
efficient DNA delivery agents for cultured cells. The ability of cyclodextrins to form 
inclusion complexes with hydrophobic molecules provides a method of modifying 
cyclodextrin-based polyplexes. Here, adamantane is conjugated to a water soluble 
peptide. Adamantane is chosen as the cyclodextrin-inclusion compound because it is 
reported to have a binding constant with B-cyclodextrin of 104_105 (11,12). GALA is 
selected as the modifying peptide because it is water soluble and highly anionic at 
physiological pH and has fusogenic abilities under acidic conditions. 
The addition of GALA or GALA-Ad to BCDP6-based polyplexes does not disrupt 
DNA/polymer interactions, as evidenced by the consistency in particle count rate for all 
samples. However, GALA and GALA-Ad addition does influence polyplex size (Fig 
5.2). The particle size changes can be explained by taking into account the zeta 
potentials of the particles (Fig 5.3). Particles with higher zeta potential magnitudes are 
less likely to aggregate due to electrostatic repulsion. BCDP6/plasmid DNA complexes 
prepared at 5+/- are stable with diameters of 260 nm and zeta potentials of +13 mY. 
GALA or GALA-Ad-modified BCDP6 polyplexes with zeta potentials between -11 and 
11 m V have larger hydrodynamic diameters (-400 nm) as seen for BCDP6 polyplexes 
with 10% GALA, 30% GALA, or 10% GALA-Ad. These particles are less charged and 
have less electrostatic stabilization. Therefore, the increased diameter likely signifies 
particle coagUlation. Particles with 50% or more GALA peptide added are more 
negatively charged (>-13 mY) and therefore return to smaller sizes (-250 nm). Similarly, 
particles with 30% or more GALA-Ad peptide are highly anionic and also have smaller 
particle diameters. 
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The GALA and GALA-Ad-modified polyplexes have similar zeta potential 
profiles at low peptide concentrations but the profiles diverge at high peptide 
concentrations. The zeta potential of GALA-modified polyplexes plateaus around -13 m V 
above 30% GALA. Additionally, the zeta potential of GALA-Ad-modified polypI exes 
continues to decrease as GALA-Ad concentration increases. 
Structures of ~CDP6IDNA/GALA and ~CDP6IDNA/GALA-Ad complexes are 
schematically proposed in Fig 5.8. ~CDP6IDNA complexes (5+1-) are positively charged 
(Fig 5.8a). The anionic GALA peptide binds to the ~CDP6/DNA complexes via 
electrostatic interactions. The addition of GALA at low ratios (up to 10%) begins to 
neutralize the polyplex charge, resulting in decreasing zeta potential (Fig 5.8b). As 
GALA concentration increases, the particles reach some point (-50% GALA) where the 
positi ve charges are neutralized (Fig 5.8c). After this saturation point, an increase in 
GALA concentration doesn't have an affect on the particle zeta potential; the excess 
GALA remains in solution. The particles are slightly anionic, probably due to peptides 
that bind only partly to the complex to neutralize charge with the other part free in 
solution. GALA-Ad has two possible interactions with the ~CDP6/DNA complexes: 
electrostatic interaction by charge and complexation of the adamantane with cyclodextrin 
to form inclusion compounds. At low ratios (up to 10%), the GALA-Ad probably 
interacts with the polyplexes by both mechanisms (Fig 5.8d). The structure of these 
particles is not much different from those of polyplexes with low ratios of GALA. At 
high ratios (30% GALA-Ad and higher), GALA-Ad is likely to interact by both charge 
and adamantanelcyclodextrin complexation (Fig 5.8e). This allows for a much higher 
saturation point for GALA peptides associated with polyplexes. The zeta potential 
continues to increase past 100% GALA-Ad because -25% of the GALA-Ad is likely 
charge associated (estimated by the approximate saturation point of GALA). Assuming 
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Fig 5.8a. ~CDP6/DNA Complexes are positively charged at 5+/-. 
GALA Addition 
Fig 5.8b. At low ratios, the GALA peptide 
begins to neutralize polyplex charge. 
Fig 5.8c. At high ratios, the GALA peptides 
reach a "saturation" point. The positive charges 
are neutralized, leaving no more available 
binding opportunities. 
GALA-Ad Addition 
Fig 5.8d. At low ratios, the GALA-Ad 
likely interacts with the polyplex via 
electrostatic and complexation 
interactions 
Fig 5.8e. At high ratios, most of the 
GALA-Ad is likely to interact by 
adamantane/cyclodextrin complex-
ation, resulting in higher concentra-
tions of peptide on the particle. 
Figure 5.8. Proposed structures of GALA and GALA-Ad modified polyplexes. 
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very high affinity binding between adamantane and ~-cyclodextrin, the zeta potential of 
the particles probably plateaus past 150% GALA-Ad. 
GALA-modified polyplexes are able to efficiently deliver DNA to cultured cells 
(Fig 5.4c). Although ~CDP6IDNA/50% GALA particles are negatively charged, the 
peptide/polyplex interaction is probably dynamic. Once the cell binds to the polyplex, 
the negatively charged glycoproteins on the cell surface may displace some GALA 
peptides from the polyplexes, resulting in stronger association and eventual uptake (5,16). 
The decreased zeta potential of GALA-modified polyplexes does have a small effect on 
DNA uptake, as evidenced by broader fluorescence distribution when compared to 
~CDP6IDNA transfected cells (Fig 5.4b). Polypi ex modification with 50% GALA-Ad 
results in a two orders of magnitude decrease in polyplex uptake for both BHK-21 (Fig 
4d) and HUH-7 (Fig 5.5c) cells. The uptake inhibition by Gala-Ad addition is probably a 
result of the highly negative zeta potential of the modified particles (-38 m V) that 
prevents the particles from close contact with the anionic cell surfaces. The GALA-Ad 
peptide, with MW=3194, may also provide a steric shield for the polyplexes against the 
cell surface, resulting in decreased uptake. 
The protein expression of the delivered reporter gene is also greatly affected by 
GALA-Ad modification but not by GALA addition to the polyplexes (Fig 5.6). At low 
ratios (1 % GALA), GALA or GALA-Ad addition enhances transfection by around 2-
fold. The increase is probably due to the fusogenic properties of GALA at low pH. The 
GALA peptide has been shown to cause lipid vesicle leakage at pH 5 (14). Simoes et al. 
report a 5-fold increase in the transfection efficiency of HeLa cells due to the association 
of GALA peptide with lipoplexes (15). The fusogenic effect has not been optimized in 
this system; however, the increase in transfection efficiency at low ratios is nonetheless 
evident. 
At higher peptide ratios (10% and 100%), GALA-Ad modification impedes DNA 
transfection, such that at 100% GALA-Ad, nearly all reporter gene expression has been 
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eliminated. As discussed previously, the amomc GALA-Ad complexes with the 
cyclodextrin molecules in the polymer and decreases particle uptake. Although some 
complexes are internalized, the number of intracellular complexes is two orders of 
magnitude lower than the amount of non-modified polyplexes internalized under the 
same conditions. The low number of internalized polyplexes, compounded with the low 
frequency of endosomal release (see previous chapter) likely results in the low 
transfection levels observed. DNA uptake and transfection inhibition ability is unique to 
adamantane modified GALA; addition of 100% GALA decreases transfection by only 
50%. 
GALA and GALA-Ad modification of polyplexes does not increase cellular 
toxicity (Fig 5.7). The addition of 100% GALA or GALA-Ad (corresponds to 20 JlM 
peptide in solution during transfection) to cells for 48 hours results in no change in cell 
proliferation. 
In conclusion, this work has shown that ~CDP6-based polyplexes can be modified 
by adamantane-containing conjugates without disrupting polymer/DNA binding 
interactions. In this proof-of-concept example, ~CDP6-based polyplexes were modified 
by adamantane conjugated to an anionic, water-soluble peptide (GALA). The 
adamantane moiety formed inclusion compound with the cyclodextrins. The modified-
polyplexes were highly anionic due to the attached GALA peptides, resulting in 
inhibition of polyplex uptake by cultured cells. One practical application of this system 
could be targeted gene delivery. Cationic polyplexes deliver genes to cells non-
specifically. Coating the polyplexes with an anionic peptide such as GALA prevents 
nonspecific uptake. The polyplexes could then be modified with an appropriate ligand to 
allow for receptor-mediated uptake into targeted cells. Therefore, the ability to modify 
polyplexes provides a way to include multiple alterations, thereby increasing the 
suitability of polyplexes for systemic gene delivery. Some of the possible modifications 
will be discussed in the following chapter. 
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Chapter 6 
Applications of ~-Cyclodextrin Polymer-Containing Polyplexes 
Modified by Inclusion Complex Formation 
6.1. ABSTRACT 
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Modifications of cationic polyplexes to impart salt stability, to add transfection 
enhancing agents, and to target delivery are plausible enhancements that may be required 
for transferring the use of these delivery systems from in vitro settings to in vivo systems. 
Here, the use of inclusion complex formation that was described in the previous chapter 
is applied to ~CDP polyplexes in order to ascertain whether they can be suitably modified 
into agents suitable for in vivo use. While copolymers of PEG and ~CDP6 are unable to 
condense DNA, pegylation of ~CDP polyplexes by inclusion compound formation results 
in small, discrete particles that are salt-stabilized in a PEG length-dependent manner. In 
addition, fluorescein-labeled PEG (Peg-FITC) complexed with ~CDP6 polyplexes 
(~CDP6/Ad-Peg-FITC) are preferentially delivered to cultured cells over uncomplexed 
Peg-FITC, demonstrating the possibility of co-delivery of small molecule therapeutics or 
transfection enhancement agents with ~CDP polyplexes. Finally, hepatocyte-targeted 
delivery via galactose-modified ~CDP6 polyplexes is investigated. Preliminary 
experiments suggest the need for a "spacer" between polyplex and ligand for effective 
delivery as well as a method for preventing non-specific, charge-mediated uptake. Thus, 
this chapter demonstrates and proposes variations to ~CDP6 polyplexes to accommodate 
targeted in vivo delivery. 
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6.2 INTRODUCTION 
The objective of this research was to apply the ~CDP polyplex modification 
method described in the previous chapter towards the development of a suitable ~CDP­
based systemic delivery system. Three possible polyplex modifications will be 
discussed, each with important implications for in vivo applications: steric stabilization 
of polyplexes, co-delivery of transfection enhancement agents or small molecule 
therapeutics, and ligand attachment for targeted delivery. 
Polyplexes need to be small and stable to accommodate sustained systemic 
circulation. Most unmodified polyplexes never arrive at their target site due to self-
aggregation upon injection, trapping in extracellular matrices, and rapid elimination from 
the body by phagocytes (1). Nanoparticles are known to be unstable due to van der 
Waals attraction forces that become important when particles come in close contact with 
each other. When formulated in water, cationic polyplexes have a double layer of anionic 
counterions that serve to stabilize particles by repulsion. However, in aqueous salt, the 
electrostatic double layer around each particle is reduced. At physiological salt 
conditions, the double layer thickness of charged particles is usually reduced to < Inm. 
The electrostatic repulsion at these concentrations is insufficient for overcoming van der 
Waals attractions, and results in rapid particle aggregation. In addition to self-
aggregation, cationic polyplexes bind nonspecifically to extracellular matrices or blood 
proteins. The amount of blood proteins bound to particles correlates with in vivo 
clearance (2) and often results in complement acti vation (3). Charged particles are also a 
target for the phagocytic system (4). 
One method of preventing self-aggregation or unwanted particle interactions is 
polymeric steric stabilization. Polymers attached to particle surfaces serve to stabilize 
particles by sterically inhibiting inter-particle, protein, and cell contact. This method has 
been successfully used in many colloidal systems (5). Polyethylene glygol (PEG) holds 
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particular interest for gene delivery applications due to its biocompatibility. PEG has 
been grafted to Iiposomes (6), poly-L-Iysine (PLL, (7-9)), polyethylenimine (PEl, (10)), 
and various peptides (11,12). In general, pegylated particles show increased salt and 
serum stability with longer in vivo circulation. 
Pegylation of ~-cyclodextrin polymers (~CDPs) is discussed in the first section of 
this chapter. Three pegylation approaches were applied to ~CDP6: pre-DNA-
complexation pegylation, post-DNA-complexation pegylation by grafting, and post-
DNA-complexation pegylation by inclusion compound formation. While the first two 
approaches result in disruption of polymerlDNA binding, post-DNA-complexation of 
~CDP6 polyplexes with an adamantane-modified PEG imparts salt stability to the 
particles. 
The ability to co-deliver small molecules or transfection enhancing agents with 
~CDP polyplexes would increase the efficacy of the delivery system. For example, a 
delivery package with combinations of genes and small molecules could target several 
points in a disease pathway, resulting in a more effective treatment. The co-delivery of a 
fusogenic peptide or pH-sensitive polymer could assist in endosomal release of the 
polyplexes, thus enhancing gene delivery. In the second section of this chapter, ~CDP 
polyplexes are modified with a polymer (PEG) covalently attached to a small molecule 
(fluorescein). Cultured cells exposed to the modified polyplexes show much higher 
fluorescein uptake uptake than cells exposed to free fluorescein-PEG in the presence of 
polyplexes, thus demonstrating the potential of multi component therapeutic delivery 
systems. 
Finally, systemic delivery calls for specific uptake to the cells of interest. One 
method of accomplishing selective gene transfer is via receptor-mediated targeting. 
Ligands such as folate, transferrin or galactose have been used in synthetic delivery 
systems to target cells expressing folate (13-15), transferrin (16,17), or asialoglycoprotein 
receptors (18-20) on their surface. Asialoglycoprotein receptors are expressed on the 
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surface of hepatocytes, and gene therapy systems targeting these receptors are known to 
be effective for in vivo delivery to the liver (21). The liver is an important target organ 
for several genetic diseases such as Crigler-Najjar, Pompe's disease, phenylkenonuria, 
and hemophilia. The asialoglycoprotein receptor recognizes terminal galactose residues 
of oligosaccharides (22). The last section of the paper discusses possible approaches for 
targeting ~CDP polyplexes to hepatocytes by galactose conjugation. 
6.3 MA TERIALS AND METHODS 
6.3.1 Synthesis of Adamantane Conjugates. 
Adamantane-PEG3400-NH2 (Ad-PEG3400-NH2). 266 mg of FMOC-PEG34oo-NHS (78.2 
/lmol, Shearwater Polymers, Huntsville AL) were added to a glass vial equipped with a 
magnetic stirbar. 10 eq. of l-adamantane-methylamine (1.5 mmol, Aldrich) dissolved in 
3 mL of DCM were then added and the solution stirred overnight at room temperature. 
The solvent was removed in vacuo and water was added to the remaining solution to 
dissolve the PEG product. The solution was centrifuged at 20K rcf for 10 minutes, 
whereupon the adamantane-methylamine phase-separated as a denser liquid. The 
aqueous portion was collected and water removed in vacuo. The remainining viscous 
liquid was redissolved in 20% piperidine in DMF for FMOC deprotection and stirred for 
30 minutes at room temperature. The solvent was removed in vacuo, washed several 
times with DMF, redissolved in water, and run on an anionic exchange column to remove 
unreacted PEG. The first fractions were collected and lyophilized to yield 222 mg of a 
white, fluffy powder (76% yield). The desired product was confirmed by MALDI-TOF 
analysis. 
Adamantane-PEG3400-Lactose (Ad-PEG3400-Lac). 60 mg of Ad-PEG3400-NH2 (16.8 /lmol) 
and 5.0 eq of lactose-monosuccidimyl (50 mg, Pierce, Rockford, IL) were added to a 
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glass vial equipped with a stirbar. 2 mL of 50 ruM NaHC03 was added and the resulting 
solution stirred overnight. The reaction of the amine was monitored by TNBS assay, that 
determines amine concentrations (23). Upon full reaction of the amine (99% amine 
reacted), the solution was transferred to a dialysis tubing (Slide-A-Lyzer, MWCO=3500, 
Pierce), dialyzed for 24 hours against water, and lyophilized to yield 65.1 mg of a fluffy 
white powder (93% yield). 
Adamantane-PEG5000 (Ad-PEG5000 ). 279 mg of PEG50oo-NHS (53 Mmol, Shearwater 
Polymers) were added to a glass vial equipped with a magnetic stirbar. 8 eq. of 1-
adamantane-methylamine (420 Mmol, Aldrich) dissolved in 3 mL of DCM were then 
added and the solution stirred overnight at room temperature. The solvent was removed 
in vacuo and water was added to the remaining solution to dissolve the PEG product. 
The solution was centrifuged at 20K ref for 10 minutes, whereupon the adamantane-
methylamine phase separated as a denser liquid. The aqueous portion was collected and 
dialyzed for 24 hours (Slide-A-Lyzer, MWCO=3500) against water. The solution was 
lyophilized to yield 252 mg of a white, fluffy powder (92% yield) . 
Adamantane-(PEG5000)2 (Ad-(PEG5000)2). 315 mg of (PEG50oo>z-NHS (30 Mmol, 
Shearwater Polymers) were added to a glass vial equipped with a magnetic stirbar. 10 eq. 
of 1-adamantane-methylamine (300 Mmol, Aldrich) dissolved in 3 mL of DCM were then 
added and the solution stirred overnight at room temperature. The solvent was removed 
in vacuo and water was added to the remaining solution to dissolve the PEG product. 
The solution was centrifuged at 20K ref for 10 minutes, whereupon the adamantane-
methylamine phase separated as a denser liquid. The aqueous portion was collected and 
dialyzed for 24 hours (Slide-A-Lyzer, MWCO=3500) against water. The solution was 
lyophilized to yield 286 mg of a white, fluffy powder (91 % yield) . 
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Adamantane-PEG34oo-Fluorescein (Ad- PEG34oo-FITC). 20 mg of Ad-PEG340o-NH2 were 
dissolved in 3 mL of O.lM Na2C03 in a glass vial equipped with a magnetic stirbar. To 
this solution were added 3 eq of fluorescein isothiocyanate (FITC, Sigma) in DMSO (4 
mg/mL, 1.6 mL) and the resulting solution was stirred in the dark overnight before 
transferring to dialysis tubing (MWCO=3500) and dialyzing in the dark for 48 hours 
against water. The solution was collected and lyophilized to yield 23 mg of a yellow 
fluffy solid. PEG34oo-FITC was synthesized as a control polymer from PEG3400-NH2 
(Sheaterwater Polymers) with the same protocol to yield 23 mg. 
6.3.2 Synthesis of Cyclodextrin-based Polymers. 
{3-cyclodextrin-DMS copolymer ({3CDP6). The ~ -cyclodextrin-DMS copolymer was 
prepared as described previously (24). In brief, ~-CD dicysteamine and an equimolar 
amount of dimethyl suberimidate (DMS, Pierce, Rockford, Illinois) were dissolved in 0.5 
M Na2C03 and stirred overnight at room temperature. The pH of the resulting solution 
was brought below 5.0 by the addition of 1 M HCI and dialyzed extensively against dH20 
in a MWCO 3500 dialysis membrane (Pierce) for 24 hours. The dialyzed solution was 
lyophilized to dryness to yield a white, fluffy solid, with typical yields around 25-30%. 
Lactose-CDP6 (Lac-CDP6). ~CDP6 (20.5 mg, 3 /lmol), 10 eq of a-lactose (21 mg, 60 
/lmol, Sigma), and 18.6 mg of sodium cyanoborohydride (300 /lmol ) were added to a 
glass vial. 1 mL of borate buffer, pH 8.5 was added to the solids and the resulting 
solution was vortexed briefly before incubating in a 37 DC water bath for 30 hours. The 
solution was acidified to pH 6.0 with the addition of 1M Hel and dialyzed against water 
(28) for 24 hours. TNBS assay for polymer amines revealed 87% conjugation. 
Lactose-(CH2)6-CDP6 (Lac-C6-CDP6). ~CDP6 (43.2 mg, 7.4 /lmol) and 5.6 eq of 
mono(lactosylamido) mono(succinimidyl) suberate (50 mg, 84 /lmol, Pierce) were added 
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to a glass vial equipped with a magnetic stirbar and dissolved in 2 mL of 50 roM 
NaHC03. The resulting solution was stirred overnight. The reaction was followed by 
monitoring the disappearance of the polymer amine endgroups by TNBS assay, which 
revealed 90% conjugation. The solution was acidified to pH 5.0 by the addition of 1M 
HCI and resulting solution dialyzed against water in Pierce MWCO 3500 Slide-A-Lyzer 
for 2 days before lyophilization. A white, fluffy power was obtained in 70% yield. 
PEG3400-CDP6. 20.3 mg of ~CDP6 (3 /lmol) and 10 eq of FMOC-Peg34oo-NHS (190 mg, 
60 /lmol) were added to a glass vial equipped with a magnetic stirbar and dissolved in 1 
mL of 50 roM NaHC03, pH 8.5. The solution was stirred in the dark at room temperature 
for 20 hours and then lyophilized. The solid was dissolved in 0.5 mL of 20% piperidine 
in DMF and stirred for 30 minutes for FMOC deprotection. The solvent was removed in 
vacuo and the remaining viscous liquid dissolved in water and the pH brought below 6.0 
with 0.1 M HCI. The polymer was separated from unreacted PEG by anion exchange 
chromatography and lyophilized to yield a white fluffy powder. 
6.3.3. Polyplex Preparation and Characterization. 
Plasm ids and OUgos. Plasmid pGL3-CV (Promega, Madison, WI), containing the 
luciferase gene under the control of the SV40 promoter, was amplified by Esherichia 
Coli and purified using Qiagen's Endotoxin-free Megaprep kit (Valencia, CA). 
Oligonucleotides with a random sequence (25-mers, 5'-ACT GCT TAC CAG GGA 
TTTCAG TGC A-3') and fluorescein labeled oligos with the same sequence (FITC-
Oligo) were synthesized by the Biopolymer Synthesis Facility (California Institute of 
Technology). 
Particle Sizing. 2)..lg of pGL3-CV in 600 )..lL of dH20 were mixed with an equal volume 
of ~CDP6 (in dH20) at a charge ratio of 5+/-. Particle size was measured using a 
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ZetaPals dynamic light scattering detector (Brookhaven Instruments Corporation, 
Holtsville, NY). 
Post-DNA-complexation Pegylation by Grafting. The procedure used was modified from 
Ogris et al. (10). 5 Mg of pGL3-CV in 500 ML of dH20 were mixed with an equal volume 
of PEl (in dHzO) at 3+1- or 6+1-. ~CDP6 complexes were prepared in the same manner 
at a charge ratio of 5+1-. The polyplex diameters were measured by dynamic light 
scattering (DLS). After complex formation, PEGsooo-SPA (10 mg/mL in DMF) was 
added to the solution mixed at room temperature for two hours. After particle size 
determination, 500 ML of PBS, pH 7.2, were added to the solution. The solution was 
incubated for 30 minutes at room temperature before final particle sizes were measured 
by DLS. 
Post-DNA-complexation Pegylation by Inclusion Compound Formation. 2 Mg of pGL3-
CV in 600 ML of dHzO were mixed with an equal volume of ~CDP6 (in dH20) at a 
charge ratio of 5+1-. The desired amount of Ad-PEG (10 mglmL in dH20) was added and 
particle size determined by DLS. 600 ML of PBS, pH 7.2, were added to the solution and 
particle size monitored in 2 minute intervals for 8 minutes. 
6.3.4. Cell Culture and Transfection Experiments. 
Cells. BHK-2l, baby hamster kidney cells, were purchased from ATCC (Rockville, MD) 
and HUH-7, human hepatoma cells, were generously donated by Valigen (Newtown, 
PA). Both cell lines were cultured in DMEM supplemented with 10% fetal bovine 
serum, 100 unitslmL penicillin, 100 Mg/mL streptomycin, and 0.25 Mg/mL amphotericin 
in a humidified incubator operated at 37°C and 5% CO2 and passaged every 4-5 days. 
Media and supplements were purchased from Gibco BRL (Gaithersburg, MD). 
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{3CDP6IAd-PEG.uoo-FITC Polyplex Formation and Delivery to Cultured Cells. BHK-21 
cells were plated in 6-well plates at 200,000 cells/well and incubated for 24 hours at 
37°C. 3 ~g of Junk-oligo (0.1 mg/mL in dHzO) were complexed with an equal volume 
of ~CDP6 (2 mg/mL in dH20) at a 5 +/- charge ratio. After a 5 minute complexation 
time, 1.5 ~L of PEG-FITC or Ad-PEG-FITC (10 ~g/mL in dH20) were added to the 
complexes. Media was removed from the cells and cells washed with PBS. For 
transfection, 940 ~L of Optimem were added to each polyplex solution and the entire 
solution transferred to the cells. The cells were incubated with the transfection mixture 
for 4 hours before removing the media, washing the cells with PBS, and adding in 4 mL 
of complete media. The cells were incubated for another 24 hours at 37°C before media 
was removed and cells washed twice with PBS. The cells were collected by 
trypsinization and prepared for FACs analysis. Cells were washed twice in wash buffer 
(Hank's Balanced Salt solution containing DNase and MgCI2) and resuspended in 500 ~l 
FACS buffer (Hank's Balanced Salt Solution, 2.5 mg/ml bovine serum albumin, 10 
~g/mL propidium iodide). FACS analysis was performed using a FACSCalibur flow 
cytometer (Becton Dickinson, San Jose, CA) and CellQuest software. 
Luciferase Transfection. HUH-7 cells were plated in 24-well plates at 50,000 cells/well 
and incubated for 24 hours at 37°C. 3 ~g of pGL3-CV plasmid (0.1 mg/mL in dH20) 
were complexed with an equal volume of I3CDP6 or Lac-I3CDP6 at various charge ratios. 
Media was removed from the cells prior to transfection and cells washed with PBS. 600 
~L of Optimem were added to each polyplex solution and 230 ~L transfection solution 
of this transfection solution were added to each of 3 wells for 4 hours. After four hours, 
800 ~L of complete media were added to each well. Media was changed 24 hours after 
transfection and cells were lysed in 50 ~L of Cell Culture Lysis Buffer (Promega, 
Madison, WI) 48 hours after transfection. Luciferase activity was analyzed using 
Promega's luciferase assay reagent. 
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6.4 RESUL TS AND DISCUSSION 
6.4.1. Polyplex Stabilization by Pegylation. 
Pegylation has been used to confer in vivo stability to lipoplexes and polyplexes. In this 
section, three methods of pegylating f3CDPs are discussed: pre-DNA-complexation 
pegylation, post-DNA-complexation pegylation by grafting, and post-DNA-complexation 
pegylation by inclusion compound formation. 
Pre-DNA-complexation pegylation. PEG34oo-NHS was coupled to the f3CDP6 amme 
endgroups to give the polymer shown in Fig 6.1 (f3CDP6- PEG3400). 
o 
Figure 6.1. Structure of f3CDP6-PEG340o' 
The pegylated polymer was mixed with plasmid DNA for particle size measurements. 
While f3CDP6 condenses plasmid DNA to uniform particles with hydrodynamic diameter 
-130 nm, pegylated f3CDP6 is unable to condense DNA. The presence of PEG at the 
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polymer termini disrupts DNA binding. Choi et al. report successful albeit reduced DNA 
binding with pegylated PLL (7). However, they used PLL with MW 25,000, that 
contains on average 170 amines/polymer strand. The higher charge density results in a 
higher DNA binding constant. The ~CDP6 contains on average 10 charges/polymer 
strand. Although the number of charges per polymer strand is unchanged, pegylation 
doubles the molecular weight of each polymer. Therefore, it is not surprising that 
pegylation of the ~CDPs reduces the polymer charge density, thereby eliminating DNA 
binding ability. 
Post-DNA-complexation pegylation by grafting. Ogris et al. pegylated transferrinlPEI 
and PEl after complexation with plasmid DNA by reacting the primary amino groups in 
PEl with PEGsooo-SPA (10). The pegylated polyplexes were stable in salt, whereas the 
unpegylated polyplexes aggregated upon addition of PBS. This method of pegylation 
was applied to ~CDP6-based polyplexes. PEl-based polyplexes were also used as a 
control. A schematic of the experimental method used is shown in Fig 6.2. In Stage 1, 
PEIIDNA or ~CDP6IDNA complexes were formed in 1.2 mL dH20. The sizes of the 
particles were determined by dynamic light scattering (DLS). PEGsooo-SPA was added to 
the polypI ex solutions in Stage 2 and allowed to react with the polymer primary amino 
groups for 1 hour. The sizes of the pegylated samples were measured by DLS. For Stage 
3, 600 JlL of PBS, pH 7.2, were added to each sample to test the salt stability of 
pegylated particles. The particle sizes were determined 30 min after salt addition to 
determine the extent of particle aggregation. 
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Figure 6.2. Scheme for post-DNA-complexation pegylation by grafting. 
Polyplexes are prepared in dH20 in Stage 1 and diluted in dH20 for light scattering 
measurements. The particles are pegylated in Stage 2 by reacting PEGsooo-SPA onto the 
primary amine groups. PBS is then added to the polyplexes and the extent of salt-
induced aggregation is determined after 30 minutes by dynamic light scattering. 
PEl polyplexes were formulated at 3+/- and 6 +/- and ~CDP6 polyplexes were 
formulated at 5+/- for Stage 1. PEGsooo-SPA was added to PEl at 10: 1 w/w according to 
the procedure published by Ogris et al (10). ~CDP6 was pegylated with 100%, 150% 
and 200% PEG:amine (mol%). As a control, unreactive PEG was also added to ~CDP6 
at 100%. The particle diameters at each stage are presented in Table 6.l. The PEl 
polyplexes increased slightly in size upon pegylation (58 nm to 65 nm for 3+/- and 55 nm 
to 60 nm for 6+/-). Pegylation protected the PEl polyplexes against salt-induced 
aggregation. While unmodified PEl particles increase in diameter to -800 nm after salt 
addition, pegylated PEl polyplexes increased slightly in size to 78 nm (for 6+/-) and 115 
nm (for 3+/-). 
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Polyplex PEG Stage 1 (nm) Stage 2 (nm) Stage 3 (nm) 
PEl 3+/- 10:1 58 65 115 
PEl 6+/- 10:1 55 60 78 
13CDP65+/- 100% 70 67.4 303 
13CDP65+/- 150% 70 X· N/A 
13CDP65+/- 200% 70 X N/A 
13CDP65+/- 100% PEG" 67 81 700 
'Poor correlation function; no size measurements possible. 
"Free PEG added instead of PEGsooo-SPA 
Table 6.1. Particle sizes of PEl and 13CDP6 polyplexes during post-DNA-
complexation pegylation by grafting. 
For Stage 1, 5 J,!g of DNA plasmid (in 500 JiL of dH20) was mixed with PEl or 13CDP6 
(in 500 JiL of dH20) at the indicated ratios. PEGsooo-SPA (10 mg/mL in DMF) was then 
added to the polyplexes in Stage 2. The PEGsooo-SPA was allowed to react with the 
polymer primary amines. After 2 hours, 500 J,!L of PBS, pH 7.2, was added to solution. 
The solution was incubated for 30 minutes before particle size measurement. All particle 
sizes were determined by dynamic light scattering and reported as the mean of three 
measurements. 
The addition of 150% and 200% PEGsooo-SPA to 13CDP6-based polyplexes results 
in particle disruption; particle counts drop drastically and no consistent correlation 
function was observed. Pegylation of 13CDP6 likely prevents polymerlDNA binding. 
The particle size is maintained at 67 nm after pegylation with 100% PEGsooo-SPA. 
However, monitoring of particle size as a function of time revealed that the particles were 
disrupted for approximately 30 seconds after PEG addition, after which the small 
particles were again observed. Therefore, the addition of 100% PEGsooo-SPA may 
pegylate a fraction of the 13CDP6. Because the polymer is added in excess with respect to 
the DNA (at a 5+/-), the particles could then rearrange such that the unmodified polymers 
form polyplexes with the plasmid DNA while most of the pegylated polymer remain free 
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in solution. Salt addition to these particles results in particle aggregation (300 nm), 
although not to the extent of unmodified ~CDP6 polyplexes (700 nm). In summary, post-
DNA-complexation pegylation by reaction with polymer primary amino groups is likely 
to be effective for high MW polymers with high charge densities. However, reaction 
with ~CDP6, even post-DNA complexation, results in lack of salt stabilization at 100% 
PEG5000-SPA addition and particle disruption with higher PEG5000-SPA concentrations. 
Post-DNA-complexation pegylation by inclusion compoundfonnation. Another approach 
to post-complexation pegylation is to use the ability of cyclodextrins to form inclusion 
complexes with guest molecules. Therefore, adamantane, that has a 104_105 binding 
constant with cyclodextrin, was conjugated to various PEGs (Fig 6.3). 
The adamantane-PEG (Ad-PEG) molecules were added to solutions of preformed 
polyplexes at 100% adamantane to cyclodextrin (mol%). PBS was then added to the 
solutions and the particle size monitored by DLS in 2 minute intervals (Fig 6.4). The 
average diameter of unpegylated ~CDP6 particles increases from 58 nm to 250 nm within 
8 minutes after salt addition. The presence of free PEG in solution does not prevent 
aggregation (average diameter of 240 nm after salt addition). However, pegylation with 
linear Ad-PEG molecules reduces particle aggregation in a length dependent matter. 8 
minutes after salt addition, particles pegylated with Ad-PEG34oo aggregate to 210 nm in 
diameter while particles with Ad-PEG34oo-Lac aggregate to 200 nm. Particles pegylated 
with Ad-PEG50oo only increase in diameter to 90 nm 8 minutes after salt addition and to 
160 nm 2 hours after salt addition (data not shown). Modification with Ad-( PEG5OOO)2 
had a small effect on aggregation (particle diameter of 200 nm after salt addition). 
Pegylation of polyplexes alleviates salt-induced aggregation by providing a steric 
layer around the particles. The steric layer prevents close contact between particles by 
keeping the van der Waals attraction forces, that is dependent on the interparticle 
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distance, lower than the thermal energy of the particles. Therefore, there should be a 
critical polymer length greater than the range of van der Waals attraction between 
particles that results in polymer stabilization. For many colloidal systems, the necessary 
distance is -5 nm. The length of PEG3400 and PEG5000 is estimated to be 3.5 nm and 4.3 
nm, respectively (5). PEG5000 is sufficient in length for stabilizing f)CDP polypI exes in 50 
mM salt. Ad-PEG34oo- Lac (that has an effective polymer MW of 4000) and PEG3400 do 
not provide enough steric stabilization under the experimental conditions. Interestingly, 
Gref et aI., working with PEG-coated poly(lactic acid) (PLA) nanoparticles of 160-270 in 
diameter, also found 5000 to be the minimum PEG molecular weight necessary for 
significant reductions in the plasma protein binding to the nanoparticles (11). 
The polymer density on the particle surface is another important factor in steric 
stabilization. The branched PEG compound, Ad-(PEG5OOO)2' probably has a much lower 
packing density than the linear PEG compounds. Also, the binding constant of Ad-
(PEG5OOO)2 with f)-cyclodextrin is likely much lower than that of Ad-PEG50oo due to the 
bulkiness of the branched PEG group. Indeed, Ad-(PEG5OOO)2 is not nearly has effective 
as Ad-PEG5ooo in providing steric stabilization. 
Figure 6.3a Ad-PEG3400 
o 0 
~PEG3400' )l II LACTOSE N (CH2~ H 
o 
Figure 6.3b Ad-PEG3400-LAC 
N~PEG5000 
o 
Figure 6.3c Ad-PEGsooo 
o 
HN~O-PEGsooo 
I 
(CH2)4 0 
N0 A /' PEGsooo N 0 
H 
o 
Figure 6.3d Ad-(PEGsoooh 
Figure 6.3. Structures of Various Adamantane-PEG molecules. 
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Figure 6.4. Salt stabilization of polyplexes by pegylation. 
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2 J.lg of plasmid DNA was mixed with bCDP6 at 5+/- and then PEG compounds (100 
mol% of cyclodextrin) was added to the complexes to a total volume of 1200 J.lL. 600 J.lL 
of PBS was added to the solutions and the particles sizes monitored by dynamic light 
scattering for 8 minutes after salt addition. 
Polymers are capable of stabilizing colloidal particles by steric stabilization or 
depletion stabilization (5) (Fig 6.5). Steric stabilization is a result of macromolecules 
attached to the particle surface while depletion stabilization results from macromolecules 
free in solution. If the Ad-PEGsooo were imparting stabilization by depletion stabilization, 
then an equal concentration of unmodified PEG should have the same stabilization effect. 
However, no enhanced stabilization was observed with the addition of an equal 
concentration of PEGIO,ooo in solution. Therefore, Ad-PEGsooo prevents salt-induced 
aggregation of ~CDP6 polyplexes by steric stabilization. 
8 
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Figure 6.Sa Steric Stabilization 
Figure 6.Sb Dispersion Stabilization 
Figure 6.5. Steric stabilization versus dispersion stabilization. 
Despite the preliminary stabilization stuccess with Ad-PEGsooo , this system of 
polymer modification still requires improvement. In particular, the binding constant 
between the Ad-PEGsooo and cyclodextrin molecules needs to be increased. This is 
evident from two experiments. First, stabilization of PEl or PLL polyplexes by grafting 
PEG requires a much lower PEG density on the pmticle than the necessary concentration 
of Ad-PEGsooo . Gref et al. observe stabilization of PLA particles at 5 wt% PEG (11), 
Ogris et al. show that pegylation of every third to fourth primary amine in PEl imparts 
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particle stability (10), and Choi et al. pegylate up to 25% of the E-amino groups in 
PLL(7). Because Ad-Pegsooo does not pegylate by covalent attachment to the particle, the 
Ad-Pegsooo is in dynamic equilibrium between the solution and the particle surface. 
Therefore, it is unknown how much of the added Ad-Pegsooo is actually particle-
associated at a given time. Based on the PLA, PEl, and PLL stabilization results, ~CDPs 
should be stabilized by less than 50% PEG (to cyclodextrin) on the particle surface. 
However, stability of ~CDP6 polyplexes requires 100% Ad-PEGsooo addition; 50% Ad-
PEGsooo only shows a minor advantage over the unpegylated particles. This result 
suggests that Ad-PEGsooo is substantially partitioned into the solution phase. 
Second, although Ad-PEGsooo modification of ~CDP6 polyplexes prevents particle 
uptake by cultured cells on short time scales (15 minutes), Ad-PegsooJ~CDP6 polypI exes 
are efficiently endocytosed into >95% of cells if incubated with cells for 4 hours. These 
data indicate that the Ad-PEGsooo initially shields ~CDP6 polyplexes from cell surface 
interactions; however, because the pegylation is reversible, the particles are eventually 
pegylated at a subcritical density, allowing for cell surface interaction and uptake. A 
systemic delivery system requires circulation times longer than 15 minutes. Therefore, 
the binding constant between Ad-Pegsooo and cyclodextrin needs to be increased. 
One method of increasing the complexation constant is to functionalize the 
PEGsooo with two adamantane molecules. If spaced correctly, the adamantanes could 
complex with two cyclodextrins on the polyplex. The bi-dentate binding should greatly 
increase the association constant between the Peg modification and the ~CDP-based 
polyplex. Another possibility is to include an anionic region near the adamantane to 
increase binding to the cationic polyplex. The modification of polyplexes with the 
anionic GALA-Ad conjugate presented in Chapter 5 decreases polyplex uptake by 2 
orders of magnitude. The higher prevention of cell uptake by GALA-Ad modified 
polyplexes is probably due to the negative zeta potential imparted by the GALA peptide 
and to an increased binding constant of the peptide to the polypI ex surface. While Ad-
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PEGsooo binds to the ~CDP-based polyplex by inclusion complex formation, GALA-Ad 
interacts by both inclusion complex formation and electrostatic interaction. Therefore, 
the inclusion of an anionic region in Ad-PEG sooo should increase its binding to the 
polyplex and thus promote a more effective particle stabilization. 
6.4.2. Adamantane-mediated co-delivery of small molecules and pep tides. 
Postcomplexation modification of ~CDP polyplexes could potentially be used to co-
deliver small molecule therapeutics or transfection-enhancing agents to cells. In a proof-
of-concept experiment, adamantane was conjugated to fluorescein via a PEG3400 linker 
(Ad-PEG340o-FlTC). Ad-PEG340o-FlTC or PEG3400-FlTC was added to ~CDP6 polyplexes 
at 10% mol. (to cyclodextrin) ratio and incubated with BHK-21 cells. Fluorescein uptake 
was monitored by flow cytometry. Polyplex modification with Ad-PEG34oo-FITC 
resulted in substantially increased fluorescein uptake over ~CDP6 polyplexes incubated 
with PEG34oo-FITC (43% vs. 14%, Fig 6.6). Free PEG34oo-FITC in the media may be 
taken into the cell as part of the pinocytotic or endocytotic pathway. However, Ad-
PEG34oo-FITC is also able to enter cells when complexed to ~CDP6. Ad-PEG34oo-FITC 
modification of ~CDP6 polyplexes at low ratios (10%) is unlikely to inhibit polypI ex 
internalization. Rather, the ~CDP6 polyplexes bind readily to the cell surface and co-
delivers Ad-PEG34oo-FITC to the cells as they are internalized. The ~CDP6 polyplex-
assisted delivery results in higher fluorescein fluorescence observed in ~CDP6/ Ad-
PEG340o-FITC transfected cells. This method could be applied for the co-delivery of a 
small molecule therapeutic along with the gene of interest. 
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Fig 6.6. Co-delivery of ~CDP6 polyplexes with PEG340o-FITC. 
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BHK-21 cells were transfected with ~CDP6 polyplexes in the presence of PEG340o-FITC 
or complexed with Ad-PEG340o-FITC. Uptake of FITC was determined by flow 
cytometry analysis. 
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BCDP polyplexes could also be modified with agents such as fusogenic peptides 
or pH-sensitive polymers in order to enhance transfection efficiencies. After 
internalization, these peptides could assist in endosomal release of the polyplexes by 
changing conformations in the acidic compartments and mediating membrane 
destabilization or pore formation. GALA is one example of such a peptide (25). The 
GALA peptide undergoes a transition from a random coil at physiological pH to an 
amphipatic a-helix in the acidic endosomes. Thus, GALA has been used to enhance 
transfection efficiencies in synthetic gene delivery systems (26). 
Adamantane can be easily conjugated to GALA via the formation of a peptide 
bond. In the previous chapter, GALA-Ad was shown to associate readily with BCDP6 
polyplexes by inclusion compound formation with the cyclodextrin moieties. It is 
hypothesized that delivery of these GALA-modified polyplexes should result in efficient 
transgene expression. Indeed, GALA-modification of BCDP6 polyplexes increased 
transfection by 2-fold even at low GALA ratios. However, the effect of GALA 
modification was limited due to the negative zeta potential of the polyplexes that 
prevented charge-mediated uptake of the modified polyplexes. One possible approach is 
the addition of an appropriate ligand to the GALA-modified polyplexes for receptor-
mediated delivery. Some preliminary work toward receptor mediated delivery is 
discussed in the next section. 
6.4.3. Galactose Conjugation for Targeted Delivery to Hepatocytes. 
Unlike in vitro transfection or direct injection where polyplexes are immediately exposed 
to cells of interest, systemic delivery requires cell-specific delivery. A good model 
system with important therapeutic applications is targeted delivery to hepatocytes. 
Polyplexes can be targeted to the asialoglycoprotein receptors on hepatocyte surfaces 
with several ligands such as asialoorosomucoid (20), multiantennary synthetic galactose 
derivatives (27) and galactose (28). Galactose was chosen here for conjugation to 
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BCDP6 because of its simplicity. In addition, the presence of multiple galactose ligands 
attached to each polyplex may mimic the multidentate binding of the protein ligands and 
synthetic branched derivatives. BCDP6 polyplexes were modified with galactose by 
direct conjugation, linker conjugation to polymer termini and by inclusion compound 
formation with the cyclodextrin moieties. 
Lactose-CDP6. Direct conjugation of galactose to BCDP6 was accomplished by a 
reductive amination reaction between lactose (Gal-Glu) and the amine endgroups of 
BCDP6 to form an imine linkage (Lac-CDP6, Zanta, Fig 6.7). 
G"Acr",.AXO~·("'c)'P~C"')'"y(C"'y,"(C")P,(C",(',"*-"" GACAC,"  
HACH l;H HN NH 2 CI- NH 2 CI-
2 H CH 20H 
Figure 6.7. Structure of Lactose-CDP6. 
Lac-CDP6 is able to bind and condense DNA to particles (data not shown); 
however, the particles have slightly larger diameters than those formed with the parent 
BCDP6 polymer (for example, particle diameter of 162 nm for Lac-CDP6 versus 130 nm 
for BCDP6 at 6+/-). To test the ability of Lac-CDP6 polyplexes to deliver to hepatocytes, 
HUH-7 cells (human hepatoma cell line with high levels of asialoglycoprotein 
expression) were transfected with Lac-CDP6 and BCDP6 complexed with the 
fluorescently labeled oligos or the luciferase plasmid at low charge ratios. 
Lac-CDP6 and BCDP6-based polyplexes are nearly neutral when formulated at 
2+/- (data not shown). Therefore, at low charge ratios, unmodified BCDP6 polyplexes 
(that enter cells by charge) should have low transfection efficiencies when compared to 
Lac-CDP6 polyplexes (that enter cells by receptor mediated delivery). Transfection of 
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HUH-7 cells with fluorescently labeled oligos (FITC-Oligo) complexed with Lac-CDP6 
and ~CDP6 at low charge ratios were visualized by confocal microsopy. No difference 
in DNA uptake between the two polymers was observed. In addition, Lac-CDP6 
polypI exes do not demonstrate increased luciferase reporter gene expression in HUH-7 
cells, suggesting that Lac-CDP6 polyplexes are not being delivered by receptor-mediated 
endocytosis (Fig 6.8). 
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Figure 6.8. Transfection of I3CDP (dashed line) and Lac-CDP6 (solid line) 
polyplexes to HUH-7 cells. 
HUH-7 cells were transfected with 1 ~g of pGL3-CV complexed with ~CDP and Lac-
CDP6 at various charge ratios. Transfection efficiency was determined by assaying for 
luciferase protein activity and presented as relative light uaits. Results are presented as 
mean ± standard deviation of three assays. 
150 
One explanation for the low Lac-CDP6 transfection is the inaccessibility of 
galactose conjugated directly to the polymer. Schaffer et al. describe the need for a 
spacer between polyplex and ligand for cellular uptake (29). Longer spaces, e.g., 3 nm, 
result in more efficient receptor-mediated uptake by alleviating steric hinderances. 
Receptor-mediated delivery to hepatocytes has been reported for lactosylated PEl (28) 
and PLL (19). However, while lactose was coupled to the terminal amines of branched 
PEl or to the amine side chains of PLL, ~CDP6, a linear polymer, was lactosylated on the 
polymer backbone. Thus, the branching of PEl and side chains of PLL may serve as a 
spacer between the ligand and polyplex. Based on these results, lactose was conjugated 
to ~CDP6 with a methylene spacer linkage. 
Lactose-(CH2)6-CDP6. An amine-reactive methylene spacer with an extended lactosyl 
moiety was reacted with the ~CDP6 end groups to give a lactosylated polymer with a 6-
carbon cross-linker (Lac-C6-CDP6, Fig 6.9). Unlike Lac-CDP6, Lac-C6-CDP6 is unable 
to condense DNA into small discrete particles; therefore, Lac-C6-CDP6-mediated 
transfection of FITC-Oligo to HUH-7 cells resulted in greatly decreased uptake as 
compared to ~CDP6 and Lac-CDP6 transfections (Table 6.2). 
Figure 6.9 Structure of Lac-C6-CDP6. 
Although conjugation of small molecules such as galactose or histidine (Chapter 
4) to ~CDP6 endgroups does not interfere with DNA binding and condensation, the 
attachment of larger entities such as the methylene linker or polyethylene glycol (Section 
6.4.3) result in reduced DNA binding. Another point worth noting is that the chemistries 
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used for either direct lactose or histidine conjugation do not decrease the charge/polymer 
ratio. However, lactosylation with the methylene spacer occurs by peptide bond 
formation from the terminal polymer amines, reducing the average number of charges per 
polymer decreases from 10 to 8. The reduced charge density further decreases 
polymer/DNA binding. The results from Lac-CDP6 and Lac-C6-CDP6 mediated 
transfections suggest that direct ligand conjugation to polymer termini results in 
inefficient receptor-mediated uptake while ligand conjugation via a spacer group disrupts 
polymerlDNA binding. Therefore, receptor-mediated delivery of BCDPs needs to be 
approached from a different angle. 
Ad-PEG3400-Lac. BCDP6IFITC-Oligo polyplexes were modified as described previously 
with 100% Ad-PEG340o-Lac. The Ad-PEG34oo-Lac provides a hydrophobic guest 
molecule for cyclodextrin inclusion (adamantane), a spacer (PEG3400) and a galactose 
ligand (lactose). HUH-7 cells were contacted with 3 Jlg of FITC-Oligo complexed with 
Lac-CDP6, Lac-C6-CDP6, and BCDP6 at 1 +/- and 3+/- and BCDP6 polyplexes modified 
with Ad-PEG340o-Lac or Ad-PEG34oo • Cellular uptake of the polyplexes was determined 
by flow cytometry. A summary of delivery efficiencies with the various polymers is 
presented in Table 6.2. 
Polymer Charge Ratio 
BCDP6 1+/-
BCDP6 3+/-
Lac-CDP6 1+/-
Lac-CDP6 3+/-
Lac-C6-CDP6 1+/-
Lac-C6-CDP6 3+/-
BCD P6/ Ad-PEG 3400-Lac 3+/-
BCDP6 + Ad- PEG3400 3+/-
Table 6.2 Lactose-mediated uptake into HUH-7 cells. 
Percent Uptake 
72 
94 
70 
97 
16 
41 
94 
92 
152 
HUH-7 cells were exposed to Lac-CDP6, Lac-C6-CDP6, and Ad-PEG3400-Lac-modified 
BCDP6 polypI exes delivering FITC-Oligo for 30 minutes. The polypI exes were 
prepared at 1 +/- and 3+/-. Uptake was determined by flow cytometry analysis. 
The particles pegylated with Ad-PEG34oo are endocytosed by HUH-7 cells as 
efficiently as the unmodified polyplexes (92% vs. 94%). Particles pegylated with Ad-
PEGsooo were delivered to cells with decreased efficiency only at short contact times (see 
Chapter 5). Therefore, the particles were contacted with HUH-7 cells for only 30 
minutes. Because pegylation does not prevent charge-mediated delivery, even for 
particles formed near neutrality (Table 6.2, last row), the exact mechanism of Ad-
PEG3400-Lac modified polyplex delivery remains ambiguous. It is clear from these 
experiments that in addition to attaching a targeting ligand, the BCDP6 polyplexes need 
to be modified to reduce charge-mediated uptake by cells. Chapter 5 discusses polyplex 
modification with an anionic peptide that protects particles from cellular uptake. This 
technique may be applied along with the lactosylated peg linker to prepare BCDP6 
polypi exes for in vivo delivery to the liver. 
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In conclusion, this work has demonstrated the versatility of ~CDP-based polyplex 
modification by inclusion compound formation. In the first section of this chapter, the 
modification method was successfully applied to pegylate ~CDP6 polyplexes. Unlike 
direct conjugation methods that disrupt ~CDP6IDNA binding, pegylation by inclusion 
compound formation results in discrete, small nanoparticles that are stable in salt 
solutions. The success of steric stabilization was found to depend on polymer length, 
with PEG5000 providing the most stability. In the second section of this chapter, the 
possibility for co-delivery of small molecules or polymers was demonstrated. ~CDP6 
polyplexes assisted in Peg-FITC delivery to cultured cells by inclusion compound 
formation. This technique could be applied to co-deliver transfection enhancing agents 
such as fusogenic peptides for endosomal release or nuclear localization peptides to 
increase transport to the nucleus. Finally, the last section of the chapter involved the 
possibility for targeted ~CDP6 polyplex delivery. Lactose directly conjugated to ~CDP6 
was found to be likely inaccessible to cell surface receptors while lactose conjugation via 
a spacer disrupts DNA condensation. Ad-PEG34oo-Lac modification could provide for 
both the tether length and ligand for receptor-mediated uptake without altering the 
~CDP6IDNA interaction. In order to accomplish this, polyplexes need to be first made 
anionic to prevent non-specific uptake. The polyplexes could then be modified with 
PEG-Ligand compounds for ligand-specific delivery. By combining the particle 
stabilization, transfection enhancement and targeted delivery modifications discussed 
here, a polymeric system capable of systemic delivery becomes readily achievable. 
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Chapter 7 
Summary and Recommendations 
7.1. SUMMARY OF RESULTS 
Most of the cationic polymers currently used for gene delivery are commercially 
available polycations that are tested and found to assist in DNA transfection. However, 
these off-the-shelf chemicals are not optimized for biological use and are therefore toxic 
to cells and deliver DNA with low efficiencies. In this work, a synthetic polymeric 
delivery system was developed by rational design. The complete system, formulated by 
self-assembly, consists of three components: the therapeutic gene-drug, a linear 
cyclodextrin-based polymer, and a modifier for in vivo stability and targeting. 
Cyclodextrins (CDs) are discrete, sugar-based entities known to be non-
immunogenic and tolerated at high doses in mammals. It was hypothesized that polymers 
synthesized from non-toxic starting materials would more likely be non-toxic as well. 
Therefore, cyclodextrins were incorporated into the backbone of linear, cationic polymers 
by co-polymerizing difunctionalized ~-CD monomers with other difunctionalized 
comonomers. The ~-cyclodextrin-based polymers (~CDPs) are able to bind to both 
plasmid DNA and oligonucleotides and condense into small particles of approximately 
100-150 nm in diameter. When formulated with an excess of polymer, these particles are 
able to transfect cultured adherent cells with efficiencies comparable to other cationic 
polymers used in gene delivery. The ~CDPs are also able to efficiently transfect 
suspension cell lines that are notoriously difficult to transfect. In addition, while other 
synthetic delivery vehicles are highly toxic to the cells, the I3CDPs show low toxicity to 
all cell lines tested (Fig 7.1). The IC50s of the ~CDPs is roughly one order of magnitude 
above other cationic polymers and two orders of magnitudes above other cationic lipids 
used in gene delivery. The ~CDPs are also relatively non-toxic in vivo. The LD50 of 
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~CDP injected intravenously to mIce is also an order of magnitude above those of 
cationic polymers such as polyethylenimine and poly-L-Iysine. Thus, the ~CDP can be 
used at a large range of concentrations without much concern for polymer-associated 
toxicities. 
Figure 7.1. Toxicity comparison of various non-viral vectors. 
BHK-21 cells were transfected with polyethylenimine (A), Lipofectamine™ (B), 
SuperfectTM (C), and ~CDP (D). The photographs are taken at vector concentrations that 
give approximately the same transgene activity. Untransfected BHK-21 cells are shown 
in the center panel. 
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The modular approach for synthesizing I3CDPs facilitates a study on the effect of 
polymer structure on gene delivery and toxicity. Variations in the cyclodextrin 
comonomer verified the importance of cyclodextrins in the polymer. Incorporation of 
cyclodextrin into the backbone of polyamidine polymers decreases the ICso of the 
polymers by up to three orders of magnitude. Spacer groups between the cyclodextrin 
moieties and the polymer amidine charge centers are also essential. The elimination of 
these spacer groups results in a polymer with no DNA binding ability while incorporation 
of a two methylene unit spacer group results in complete DNA binding, most likely by 
relieving steric hindrance from the bulky CD cups. 
The effect of polymer charge density on polymer function was also studied by 
varying the length of the comonomer B units. DNA binding and condensation was 
achieved for all the polymers with minimal difference in polyplex sizes. However, the 
polymer function was greatly dependent on charge density, with up to 20-fold difference 
in transfection efficiency and one order of magnitude difference in polymer toxicity for 
the polymers studied. Incorporation of a reducible moiety in the polymer backbone had 
no effect on polymer toxicity and transfection. The optimum polymer for DNA 
transfection, I3CDP6, was found to have a 2 methylene spacer between CD and ami dine 
group and a 6 methylene spacer between adjacent amidine functionalities. 
The basic I3CDPs satisfied the first design criterion for a non-toxic polymer for 
DNA delivery. The next goal, increasing transfection efficiency, was achieved by 
conjugating pH-sensitive histidine molecules to the ends of the polymers. The imidazole 
group in histidine protonates below pH 6.0 and therefore could serve as a buffering agent 
in the endosomes. Buffering the endosomes delays degradation of the endosomal 
contents by nucleases and proteases in the lysosome. Indeed, the transfection efficiency 
of the histidylated polymer, Hist-CDP6, is 20-fold greater than unmodified I3CDP6. 
Flow cytometry and confocal microscopy experiments suggest that Hist-CDP6 
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polypI exes are internalized with similar efficiencies as ~CDP6 polyplexes but are 
accumulated at higher concentrations in the endosomes, most probably due to the 
histidine buffering effect. The higher polyplex concentration and delayed degradation 
allows for more opportunities for endosomal escape. Although histidylation reduces 
polymer solubility, no increase in toxicity is observed with Hist-CDP6. Thus, 
histidylation increases the transfection efficiency of ~CDP6 without changing its toxicity 
profile. 
The third objective was to modify the ~CDPIDNA complexes for in vivo stability. 
A common strategy for modifying cationic polymers is conjugation of molecules of 
interest to polymer amines . However, ~CDPs are short polymers and conjugation of 
other molecules directly to the polymer often disrupts polymerlDNA binding ability. The 
f3CDPIDNA complexes were therefore modified by a third component, adamantane, that 
forms inclusion compounds with the cyclodextrin molecules. Adamantane conjugates are 
able to modify ~CDPIDNA complexes without disrupting the core particles. Several 
applications of the polyplex modification with adamantane conjugates were investigated, 
including salt stabilization, co-delivery of genes and small molecules, and prevention of 
non-specific cellular uptake. 
~CDPIDNA complexes were modified with various adamantane-PEG conjugates 
and tested for salt stability. While PEGylated ~CDP6 was unable to bind to DNA and 
grafting of PEG to pre-formed polyplexes by reaction with polymer endgroups resulted in 
complex disruption, adamantane-PEG molecules self-assembled with the cyclodextrin 
molecules without changing either particle size or zeta potential. The effectiveness of the 
PEG conjugates against salt-induced aggregation was length dependent; PEGsooo was 
found to be the minimum applicable length for salt stabilization. The PEG-modified 
complexes were tested for cellular uptake. Although polyplex uptake was reduced at 
short time scales by PEGylation, longer incubation times resulted in efficient particle 
uptake. The PEGylation therefore appears to be reversible; the binding constant between 
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the PEG modifier and cyclodextrin polymer needs to be increased in order to prevent cell 
interactions. 
The modifier component could also be used to co-deliver small molecules with 
the polyplex. One possible application could be the delivery of a tumor suppressor gene 
with a chemotherapeutic drug to tumor cells for cancer therapy. Another example 
involves the delivery of prodrugs. Because hundreds of small molecules could 
potentially be delivered with each polyplex, prodrugs could be delivered along with a 
gene coding for a catalytic protein. Expression of the protein would convert the prodrug 
into its therapeutically active form. As a proof-of-concept example, ~CDP-based 
polypi exes were coated with adamantane-PEG-fluorescein molecules. Cells incubated 
with these particles were preferentially labeled over cells exposed to uncomplexed PEG-
fluorescein molecules. These results demonstrate the feasibility of co-delivering small 
molecules and genes in one complex. 
Finally, ~CDP-polyplexes were modified with an amomc peptide (GALA) 
conjugated to adamantane. Modification resulted in highly negatively charged particles 
and prevented DNA uptake in cultured cells. The GALA-modified polyplexes were more 
efficient than the PEGylated particles in preventing non-specific uptake, probably due to 
the negative particle zeta potential. In addition, the GALA-adamantane conjugates are 
likely to have a higher polyplex binding constant due to the combination of 
adamantane/cyclodextrin complexations and electrostatic interactions between the 
anionic peptides and cationic polyplexes. 
Thus, this work presents the development of a three component gene delivery 
system by rational design. The system described has clear advantages over other 
currently available synthetic vectors because of its low toxicity and adaptability for in 
vivo delivery. 
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7.2. RECOMMENDATIONS 
The development of a polymeric gene delivery system with low toxicity opens up 
the possibility for systemic administration of gene-based therapeutics. Future 
improvements in the three components may result in a vector matching viral delivery 
efficiency while maintaining the advantages of a synthetic system. In addition, the 
modular self-assembly facilitates the adaptation of the designed system for different 
systems. A proposed vector design is presented here for targeted delivery to hepatocytes. 
There are several genetic diseases that could be treated by gene delivery to the 
liver, including hemophilia, Crigler-Najjar, and phenylkenonuria. In the case of 
hemophilia, the first component (the therapeutic gene-drug) could contain gene coding 
for a clotting factor. The second component would be a cationic, cyclodextrin-based 
polymer such as ~CDP6. 
The third component would consist of a mixture of adamantane conjugates 
assisting in stabilization and cell targeting, endosomal escape, and nuclear localization. 
The desired characteristics for each component will be discussed briefly and a proposed 
structure will be presented. 
Stabilization and cell targeting. The results presented in this work demonstrate that the 
binding constant between a single adamantane molecule and ~-cyclodextrin is too low for 
applications requiring sustained interactions. Thus, the third component should contain a 
small anionic region near the adamantane to increase the binding affinity between the 
polyplex and modifier. Polyethylene glycol should also be incorporated to provide salt 
and serum stability to the particles. For hepatocyte targeting, a ligand such as lactose 
needs to be conjugated to the ends of the PEG. Lactose binds specifically to 
asialoglycoprotein receptors expressed on hepatocytes. After internalization into the 
endosomes, the polypi exes should be released from the receptors. If the compound 
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contained a disulfide bond, reductase enzymes in the endosome would facilitate release 
of the polyplexes. A schematic for this component is shown in Fig 7.1. 
-0- S-S -I PEG5000 kEactos0 
Adamantane Anionic Reducible Stabilizer Targeting Ligand 
Region Link 
Figure 7.1. Stabilization and cell targeting component. 
Endosomal release. As discussed above, the endosomal release component should 
contain a short anionic region near the adamantane. In addition, a pH-sensitive polymer 
or peptide could be used to enhance endosomal release. In this example, the GALA 
peptide (see Chapter 4) that undergoes a conformational change below pH 6.0 to become 
membrane lytic is selected for its water-solubility characteristic at physiological pH. 
Like the targeting component, the endosomal release peptide should be cleaved from the 
polyplex in the endosome to enhance its lytic abilities. Therefore, a disulfide bond 
should also be incorporated in the molecule. 
-D S-S ---i GALA Peptide 
Adamantane Anionic 
Region 
Reducible 
Link 
Figure 7.2. Endosomal release component. 
Endosomal Release Peptide 
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Nuclear localization. The nuclear localization should also contain an anionic region for 
stronger binding to the polyplex. Several authors have published on effective nuclear 
localization sequences (NLS) for gene delivery. For example, Zanta et al. demonstrate 
that incorporation of a single NLS on a reporter gene enhances gene expression by to a 
thousandfold.( 1) However, this component should stay on the polypI ex after endosomal 
release; therefore, no disulfide bond should be incorporated. After release from the 
endosome, the polyplex should be coated with only NLS for efficient DNA translocation 
to the nucleus. 
Adamantane Anionic 
Region 
Figure 7.3. Nuclear localization component. 
Nuclear localization 
Signal 
The final delivery vehicle is depicted in Fig 7.4. The optimal concentration of 
each entity added to the polyplex would have to be determined experimentally. 
However, this example demonstrates the modular approach to assembling a system for a 
specific target. The vehicle could be easily adapted to different targets by substituting 
in the desired ligand for the lactose. Once in vitro cell-specific targeting and delivery is 
achieved, in vivo testing could begin. 
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Figure 7.4. Proposed delivery vehicle for liver targeting. 
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